Conditions: Complicated Urinary Tract Infections
Keywords: Complicated urinary tract infections (cUTIs)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 97
Healthy volunteers: no

Brief summary:
This study will assess the safety, tolerability and efficacy of ceftazidime and avibactam (CAZ-AVI )versus cefepime in children from 3 months to less than 18 years old with complicated urinary tract infections.

Detailed description:
This study will be a single-blind, randomised, multi-centre, active controlled trial. Patients aged from 3 months to less than 18 years with complicated urinary tract infections (cUTIs) will be randomised to 1 of 2 treatment groups (3:1 ratio): Ceftazidime and avibactam (CAZ AVI )or cefepime. Randomisation will be stratified by age cohort.

Patients will receive intravenous (IV) treatment for a minimum of 72 hours (3 full days, ie, 9 doses if given 3 times daily, or 6 doses if given twice daily) before having the option to switch to an oral therapy . The decision to switch to oral therapy is entirely at the Investigator's discretion, if the patient has good or sufficient clinical response, and the patient is tolerating oral fluids or food.

Patients will be assessed for safety and efficacy throughout the study, and blood samples will be taken for pharmacokinetic assessment. The duration of each patient's participation in the study will be a minimum of 27 days to a maximum of 50 days after start of study treatment including (intravenous treatment or oral switch therapy) 7 to 14 days of active treatment. The late follow-up visit (LFU) is to be performed 20 to 36 days after the last dose of any treatment.

The assessments at the test of cure (TOC) visit should be performed in person 8 to 15 days after last dose of any study drug Maximum duration of study drug or oral switch therapy is up to Day 14.

Arms:
arm 1: CAZ-AVI to be administered every 8 hours as a 2-hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function) arm 2: Patients randomised to receive cefepime should receive the dose, schedule and infusion duration as recommended in the local prescribing information or as prescribed by the investigator. The maximum dose of cefepime in any single infusion should not exceed 2000 mg

Interventions: intervention 1: Ceftazidime -avibactam intervention 2: Cefepime
Intervention descriptions: intervention 1: Patients randomised (3:1) to the CAZ-AVI or cefepime treatment intervention 2: Patients randomised (3:1) to the CAZ-AVI or cefepime treatment

Protocol document:
Prot_000.pdf: 
Page 1
Global Revised Clinical Study Protocol
Clinical Study Protocol
Drug Substance
Ceftazidime-avibactam
United States (US) Investigational New Drug (IND) Number: 101,307
European Clinical Trials Database (EudraCT) Number: 2014-003244-13
Pfizer Protocol Number C3591005
AstraZeneca Study Code D4280C00016
Edition Number 3
Date 17 July 2017
A Single Blind, Randomised, Multi-Centre, Active Controlled, Trial To Evaluate 
Safety, Tolerability, Pharmacokinetics And Efficacy Of Ceftazidime And Avibactam 
Compared With Cefepime In Children From 3 Months To Less Than 18 Years Of Age 
With Complicated Urinary Tract Infections (cUTIs)
Title page
Sponsor: Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA (as of 
Version/Amendment 3)
Prior Sponsor: AstraZeneca AB, 151 85 Södertälje, Sweden 
Pfizer site representative
, PhD
Study Leader
PRA
 Netherlands
Date 17 July 
2017
This document and accompanying materials contain confidential information belonging to 
Pfizer.  Except as otherwise agreed to in writing, by accepting or reviewing these documents, 
you agree to hold this information in confidence and not copy or disclose it to others (except 
where required by applicable law) or use it for unauthorized purposes.  In the event of any 
actual or suspected breach of this obligation, Pfizer must be promptly notified.
The following Amendment(s) and Administrative Changes are included in this revised 
protocol: 
PPD
PPD
PP
DPPD
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 2
Amendment 
No.
Date of Amendment
Local Amendment 
No.
Date of local 
Amendment
1
22 September 2015
2
07 March 2017
Administrative 
change No.
Date of 
Administrative 
Change
Local Administrative 
change No.
Date of local 
Administrative 
Change
Document History
Document
Version Date
Summary of Changes and 
Rationale
Amendment 3
17 July 2017
The previous version of the 
protocol (Edition 2, dated 07 
March 2017) has been 
revised to reflect change in 
Sponsorship to Pfizer Inc,
and to include some of the 
latest Pfizer protocol 
template language.  In 
addition, minor text changes 
were made to improve 
protocol clarity.
Amendment [2]
07 March 2017
To include 
Immunosuppressed patients 
in the study per PDCO 
request
Amendment [1]
22 September 2015
To amend the following 
sections of the protocol:
Synopsis, Study sites(s) and 
number of patients planned; 
Synopsis, Pharmacokinetic 
data;
Section 1.4, Study design; 
Section 3.1, Inclusion 
criteria; Section 3.5, Methods 
for assigning
treatment groups; Table 1, 
Study plan detailing study 
procedures; Section 5.3.2, 
Physical
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 3
examination; Section 5.5.1, 
Collection of samples; 
Section 5.9; Volume of 
blood; Table 4,
Volume of blood per patient 
– Cohorts 3 and 4; Section 
8.2, Sample size estimate; 
and
Section 8.5.2.1, 
Pharmacokinetic outcome 
variables
Original protocol
14 January 2015
Not applicable (N/A)
This amendment incorporates all revisions to date, including amendments made at the 
request of country health authorities and institutional review boards (IRBs)/ethics committees 
(ECs).  
The clinical study protocol is publicly registered and the results are disclosed and/or 
published according to the Sponsor publication policy and in compliance with prevailing 
laws and regulations.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


PROTOCOL SYNOPSIS
A Single Blind, Randomised, Multi-Centre, Active Controlled, Trial To Evaluate Safety, 
Tolerability, Pharmacokinetics And Efficacy Of Ceftazidime And Avibactam Compared 
With Cefepime In Children From 3 Months To Less Than 18 Years Of Age With 
Complicated Urinary Tract Infections (cUTIs)
International Co-ordinating Investigator
, MD
United States
Study site(s) and number of patients planned
A sufficient number of patients are to be randomised 3:1 for 80 patients to complete at least 
72 hours (3 full days, ie, 9 doses if given 3 times daily, or 6 doses if given twice daily) of 
study treatment (ie, evaluable patients; at least 60 patients in the ceftazidime and avibactam 
[CAZ-AVI] group and at least 20 patients in the cefepime group).  
Considering patients over all cohorts combined, at least 10% of evaluable patients with 
urological abnormalities in the urinary tract should be included.  Each of the patient cohorts 
is required to have a minimum number of evaluable patients as follows:

Cohort 1: At least 6:2 evaluable patients aged from 12 years to <18 years;

Cohort 2: At least 6:2 evaluable patients aged from 6 years to <12 years;

Cohort 3: At least 9:3 evaluable patients aged from 2 years to <6 years;

Cohort 4: At least 18:6 evaluable patients aged from 3 months to <2 years comprising 
Cohorts 4a and 4b as follows:

Cohort 4a: At least 9:3 evaluable patients aged from 1 year to <2 years.

Cohort 4b: At least 6:2 evaluable patients aged from 3 months to <1 year, with 
a minimum of 3 patients with at least 1 PK sample aged from 3 months to 
<6 months treated with CAZ-AVI
Approximately 65 study centres are planned.
PPD
PPD
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 5
Study period
Phase of development
Estimated date of first patient enrolled
Q3 2015 
2 
Estimated date of last patient completed
Q3 2018
Study Design
This study will be a single-blind, randomised, multi-centre, active controlled trial.  Patients 
aged from 3 months to less than 18 years with complicated urinary tract infections (cUTIs) 
will be randomised to 1 of 2 treatment groups (3:1 ratio): CAZ-AVI or cefepime.  
Randomisation will be stratified as appropriate.  Patients aged from 3 months to <1 year 
(Cohort 4b) must have been born at term (defined as gestational age ≥37 weeks). 
Patients will receive intravenous (IV) treatment for a minimum of 72 hours (3 full days, ie, 
9 doses if given 3 times daily, or 6 doses if given twice daily) before having the option to 
switch to an oral therapy as specified below.  The decision to switch to oral therapy is 
entirely at the Investigator’s discretion, if the patient has good or sufficient clinical response, 
and the patient is tolerating oral fluids or food.
Patients will be assessed for safety and efficacy throughout the study, and blood samples will 
be taken for pharmacokinetic (PK) assessment.  The duration of each patient’s participation 
in the study will be a minimum of 27 days to a maximum of 50 days after start of study 
treatment (defined as the time point at which first dose of study treatment is administered) at 
which time there will be a Late Follow-up (LFU) assessment visit.  The LFU is to be 
performed 20 to 36 days after the last dose of any treatment.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 6
Objectives
Primary (Safety) Objective:
Outcome Measure:
Evaluate the safety and tolerability of 
CAZ-AVI given at the selected dose 
regimen versus cefepime in paediatric 
patients aged ≥3 months to <18 years with 
cUTI

Adverse events (AEs) and serious adverse 
events (SAEs) from the signing of the 
Informed Consent/Assent Form to the LFU 
(27 to 50 days after start of study treatment)

Cephalosporin class effects and additional 
AEs (including, but not limited to, seizures, 
Clostridium difficile-associated diarrhoea, 
allergic reactions, hepatic abnormalities, 
haemolytic anaemia, and changes in renal 
function)

Clinical: vital signs (pulse, blood pressure, 
respiratory rate, temperature), 
electrocardiogram (ECG), and physical 
examinations

Laboratory: complete blood count with 
differential and comprehensive metabolic 
panel

Creatinine clearance (CrCl) 
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 7
Secondary Objective:
Outcome Measure :
Evaluate the descriptive efficacy of 
CAZ-AVI versus cefepime in paediatric 
patients aged ≥3 months to <18 years with 
cUTI

Clinical Outcomes at End of 72 hours’ 
Treatment, End of Intravenous Treatment 
(EOIV) End of Treatment (EOT), and Test 
of Cure (TOC)

Microbiological response at EOIV, EOT, 
TOC and LFU

Clinical relapse at LFU

Emergent infections

Combined response
Evaluate the PK of CAZ-AVI in 
paediatric patients aged ≥3 months to 
<18 years with cUTI

PK data of ceftazidime and avibactam will 
be analysed separately

Plasma concentration will be listed and 
summarised by nominal sampling time 
window using appropriate descriptive 
statistics

PK parameters derived from population PK 
analysis and potential PK/pharmacodynamic 
(PD) relationships will be reported 
separately
Target patient population
Patients aged from 3 months to less than 18 years with cUTI.  
Duration of treatment
Patients will receive IV treatment for a minimum of 72 hours (3 full days, ie, 9 doses if given 
3 times daily, or 6 doses if given twice daily) before having the option to switch to an oral 
therapy as specified below.  The decision to switch to oral therapy is entirely at the 
Investigator’s discretion, if the patient has good or sufficient clinical response, and the 
patient is tolerating oral fluids or food.  Patients can continue to take IV CAZ-AVI up to Day 
14.  The duration of each patient’s participation in the study will be a minimum of 27 days to 
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 8
a maximum of 50 days after start of study treatment including (IV drug or oral switch 
therapy) 7 to 14 days of active treatment.
Investigational product, dosage and mode of administration
The study is single blind, ie, a Blinded Observer will not know the patient’s treatment 
assignment and will conduct clinical assessments (including efficacy and safety).  There is no 
use of placebo to act as a treatment blind.
Intravenous CAZ-AVI infusions will be given at doses based on the age and weight of the 
patient with adjustment according to renal function: 
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 9
Cohort
Age range
Body 
weight
CAZ-AVI dose
CrCl ≥50 mL/min
CAZ-AVI dose
CrCl ≥30 to <50 mL/min
CAZ-AVI must be administered as a 50 to 100 mL infusion (dependent on dose) 
over 2 hours every 8 hours (±30 minutes)
11
12 years to 
<18 years
≥40 kg
2000 mg ceftazidime/500 mg avibactam
1000 mg ceftazidime/250 mg avibactam
11
12 years to 
<18 years
<40 kg
50 mg/kg ceftazidime/12.5 mg/kg 
avibactam
25 mg/kg ceftazidime/6.25 mg/kg 
avibactam
21
6 years to 
<12 years
≥40 kg
2000 mg ceftazidime/500 mg avibactam
1000 mg ceftazidime/250 mg avibactam
21
6 years to 
<12 years
<40 kg
50 mg/kg ceftazidime/12.5 mg/kg 
avibactam
25 mg/kg ceftazidime/6.25 mg/kg 
avibactam
31
2 years to 
<6 years
All
50 mg/kg ceftazidime/12.5 mg/kg 
avibactam
25 mg/kg ceftazidime/6.25 mg/kg 
avibactam
4a2
1 year to 
<2 years
All
50 mg/kg ceftazidime /12.5 mg/kg 
avibactam
25 mg/kg ceftazidime/6.25 mg/kg 
avibactam
4b2
6 months to 
<1 year
All
50 mg/kg ceftazidime/12.5 mg/kg 
avibactam
25 mg/kg ceftazidime/6.25 mg/kg 
avibactam
4b2
3 months to 
<6 months
All
40 mg/kg ceftazidime/10 mg/kg avibactam
20 mg/kg ceftazidime/5 mg/kg avibactam
1
Patients considered for entry into the study will be within the normal range of body mass index (BMI) for their age, (2 to <18).  A healthy weight BMI for 
this age group falls between the 5th percentile and ≤95th percentile according to height, weight, and age.
2
BMI will not be calculated for children <2 years of age as BMI is not considered a screening tool for healthy weight in children under 2 years of age.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 10
Patients whose CrCL drops below 30 mL/min should be withdrawn from study therapy.  
Patients withdrawing from study therapy can be administered alternative therapies at the 
Investigator’s choice, which should be recorded in the Case Report Form.  If possible, 
patients should still be followed for safety.  Because the CrCl determination is only an 
estimate of renal function, in instances where the CrCl is approaching thresholds that would 
require intervention such as a dose change or discontinuation of therapy (ie, CrCL 
approaching 50 or 30 mL/min), the Investigator should use his or her discretion in 
determining (ie, confirming the value by repeat testing, if feasible) whether an immediate 
dose change, a short period of continued observation, or discontinuation of therapy is 
warranted.  If in the opinion of the Investigator there is a clinically significant reduction in a 
patient’s estimated CrCl during the treatment period, then the Investigator should contact the 
Medical Monitor to discuss the above mentioned options (immediate dose change, a short 
period of continued observation, or discontinuation of therapy).  Additionally, in instances of 
rapidly changing renal function, the Investigator should increase the frequency of CrCl 
monitoring, depending on the patient’s clinical status, extent of renal function change and 
Investigator’s clinical evaluation.
An optional switch to oral therapy is permitted on or after Day 4 (ie, after 72 hours of IV 
study drug).  The decision to switch to oral therapy is entirely at the Investigator’s discretion, 
if the patient has good or sufficient clinical response, and the patient is tolerating oral fluids 
or food: 

Oral ciprofloxacin (only in countries where its use for children is permitted; 
according to local guidelines, administered at a dose and formulation per standard of 
care), or

Oral cefixime (only in countries where its use for children is permitted; according to 
local guidelines, administered at a dose and formulation per standard of care), or

Oral amoxicillin/clavulanic acid (only in countries where its use for children is 
permitted; according to local guidelines, administered at a dose and formulation per 
standard of care), or

Oral sulfamethoxazole/trimethoprim (only in countries where its use for children is 
permitted; according to local guidelines, administered at a dose and formulation per 
standard of care), or

Pathogen-based therapy (in discussion with the Medical Monitor).  The choice of oral 
antibacterial agent for pathogen-based therapy will be driven by the results of a 
susceptibility test, which will be provided to the Investigator by either the local or 
central laboratory.  Initiation of pathogen-based therapy is at the Investigator’s 
discretion.  Before administering pathogen-based therapy, the Investigator will 
discuss the results of the susceptibility test and the selected antibacterial drug (which 
should be approved for use in children) with the Medical Monitor.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 11
The patient may continue on IV study drug for the entire duration of the study therapy (7 to 
14 days), at the discretion of the Investigator.
Comparator
Patients randomised to receive cefepime should receive the dose, schedule and infusion 
duration as recommended in the local prescribing information or as prescribed by the 
investigator.  The maximum dose of cefepime in any single infusion should not exceed 
2000 mg. Patients randomised to cefepime treatment may undergo the optional oral switch as 
described above.
Statistical methods
Block randomisation using an interactive voice/web response system, stratified by age 
cohort, will be used to assign patients (3:1) to the CAZ-AVI or cefepime study treatment 
groups.  All study data will be summarised within each age cohort separately and also overall 
(regardless of age cohort).
Safety data
The primary objective will be to assess the safety and tolerability of CAZ-AVI compared 
with comparator (cefepime). Safety data include AEs, clinical laboratory parameters, vital 
signs, ECG parameters, and physical examinations.  For each safety variable, the last 
assessment made prior to the first dose of study drug will be defined as the baseline.  All 
safety data collected from this study will be summarised by the received treatment group (ie, 
for CAZ-AVI versus cefepime, irrespective of switching to oral therapy) for all patients who 
received any amount of study treatment (termed the ‘Safety analysis set’), and key data will 
also be summarised for those patients who received at least 72 hours of study treatment
(termed the ‘Safety evaluable analysis set’) by received treatment group.  Descriptive 
statistics will be produced to summarise the safety data.  Safety data from this study will be 
combined with those from another CAZ-AVI paediatric study for complicated 
intra-abdominal infections (D4280C00015) and will be presented in the same way.
The incidence of AEs and SAEs will be summarised by system organ class and preferred 
term according to the Medical Dictionary for Regulatory Activities vocabulary by treatment 
group.  The summaries will also be produced by relationship to study drug, and by AE 
intensity.  AEs leading to discontinuation from study treatment will also be summarised.  
Summary tables for clinical laboratory tests, vital signs, ECGs, and physical examination 
findings will be produced.
Descriptive efficacy data and patient characteristic/Baseline data
Efficacy will be assessed descriptively in the intent-to-treat (ITT) set (all randomised 
patients), the microbiological ITT (micro-ITT) set (all randomised patients who have a 
baseline pathogen known to cause cUTI), the clinically evaluable (CE) analysis set (patients 
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 12
who meet minimal disease criteria for cUTI and all evaluability criteria, including patients 
who received at least 72 hours of the intended dose and duration of IV study drug, and for 
whom sufficient information regarding the infection is available to determine the patient’s 
outcome), and the microbiologically evaluable (ME) analysis set (patients who meet minimal 
disease criteria for cUTI and all evaluability criteria similar to the CE analysis set, and have 
at least 1 typical UTI bacterial pathogen at Baseline that is susceptible to both study agents, 
ie, CAZ-AVI and cefepime).
Efficacy will be assessed, in the ITT, micro-ITT, CE, and ME analysis sets, with respect to 
the proportion of patients with clinical response outcome of cure (at the end of 72 hours’ 
treatment, at EOIV, EOT, and at the TOC visit) and clinical response outcome of relapse (at 
the LFU visit).  Favourable microbiological response will be assessed in the micro-ITT and 
ME analysis sets, and the number of patients with emergent infections (up to LFU) will be 
assessed in the ME analysis set.  Combined clinical and microbiological response will be 
summarised in the ITT and micro-ITT analysis sets at EOIV and TOC visits.  Patients in the 
ITT, micro-ITT, CE, and ME analysis sets will be summarised according to the randomised 
treatment assignment.
Descriptive statistics (number, mean, standard deviation [SD], median, minimum, and 
maximum) will be provided for continuous variables, and counts and percentages will be 
presented for categorical variables.  All summaries will be presented by treatment group.  
Demographic data and other baseline characteristic data will also be summarised.
Pharmacokinetic data
Pharmacokinetic assessment will be conducted for the PK analysis data set.  The data set will 
consist of all patients who will receive CAZ-AVI treatment, and have at least 1 ceftazidime 
and/or avibactam plasma measurement available. 
A listing of ceftazidime and avibactam concentrations at the nominal sampling windows by 
patient and cohort will be provided.  For Cohorts 1 to 4b, the plasma concentration will be 
summarised by nominal sampling time window using appropriate descriptive statistics (eg, 
number, mean, SD, minimum, median, maximum, geometric mean, lower and upper SD 
bounds [geometric mean ±SD], and coefficient of variation).
In addition, the avibactam and ceftazidime concentration, paediatric patient demographics, 
and disease status data from Cohorts 1 to 4b will be combined with the data from appropriate 
previous clinical studies in paediatric patients and/or adults for a population PK analysis.  
The actual dosing and plasma sampling times will be used for the analysis.  The developed 
population PK model may be used to conduct simulations to determine probability of PK/PD 
target attainment to help to justify the CAZ-AVI dose regimens for paediatric patients with 
cUTI.  A stand-alone population PK modelling and simulation analysis plan will be prepared 
and the results will be reported in a stand-alone report outside of the clinical study report.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 13
TABLE OF CONTENTS
LIST OF TABLES...................................................................................................................18
LIST OF FIGURES .................................................................................................................18
APPENDICES .........................................................................................................................18
1. INTRODUCTION ...............................................................................................................21
1.1. Background And Rationale For Conducting This Study ........................................21
1.2. Rationale for Study Design, Doses And Control Groups........................................22
1.3. Benefit/Risk And Ethical Assessment.....................................................................23
1.4. Study Design ...........................................................................................................27
2. STUDY OBJECTIVES........................................................................................................31
2.1. Primary Objective (safety) ......................................................................................31
2.2. Secondary Objectives..............................................................................................31
2.3. Safety Objectives.....................................................................................................32
2.4. Exploratory Objectives Not Applicable ..................................................................32
3. SUBJECT SELECTION, ENROLMENT, RANDOMISATION, RESTRICTIONS, 
DISCONTINUATION AND WITHDRAWAL .................................................................32
3.1. Inclusion Criteria.....................................................................................................32
3.2. Exclusion Criteria....................................................................................................35
3.3. Subject Enrolment And Randomisation..................................................................37
3.4. Procedures For Handling Incorrectly Enrolled Or Randomised Patients ...............37
3.5. Methods for Assigning Treatment Groups..............................................................38
3.6. Methods for Ensuring Blinding...............................................................................38
3.7. Methods For Unblinding .........................................................................................38
3.8. Restrictions..............................................................................................................39
3.9. Discontinuation Of Investigational Product............................................................39
3.9.1. Procedures For Discontinuation Of A Patient From Investigational 
Product.............................................................................................................40
3.10. Criteria for Withdrawal .........................................................................................40
3.10.1. Screen Failures..........................................................................................40
3.10.2. Withdrawal of the Informed Consent .......................................................41
3.10.3. Lost to Follow-up .....................................................................................41
3.11. Discontinuation of the Study.................................................................................41
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 14
4. STUDY PLAN AND TIMING OF PROCEDURES...........................................................42
4.1. Enrolment/Screening Period ...................................................................................46
4.2. Treatment period .....................................................................................................47
4.2.1. Day 1...........................................................................................................47
4.2.2. Days 2 and 3 ...............................................................................................48
4.2.3. Days 4 to ≤14..............................................................................................48
4.2.4. End of IV treatment ....................................................................................49
4.2.5. End of Treatment (oral switch therapy)......................................................50
4.3. Follow-Up Period....................................................................................................51
4.3.1. Test of Cure ................................................................................................51
4.3.2. Late Follow-up............................................................................................51
5. STUDY ASSESSMENTS ...................................................................................................52
5.1. Efficacy Assessments..............................................................................................53
5.2. Microbiological Assessments..................................................................................53
5.2.1. Urine Samples For Microbiological Analysis And Culture .......................53
5.2.2. Blood Samples For Microbiological Analysis And Culture.......................53
5.3. Safety Assessments .................................................................................................53
5.3.1. Laboratory Safety Assessments..................................................................53
5.3.2. Physical Examination .................................................................................55
5.3.3. Electrocardiogram.......................................................................................56
5.3.4. Vital Signs ..................................................................................................56
5.3.4.1. Pulse and blood pressure...........................................................56
5.3.4.2. Body Temperature.....................................................................56
5.3.4.3. Respiratory Rate........................................................................56
5.3.4.4. Adverse Events..........................................................................56
5.3.5. Cephalosporin Class Effects.......................................................................57
5.4. Other Assessments ..................................................................................................57
5.5. Pharmacokinetics ....................................................................................................57
5.5.1. Collection of Samples.................................................................................57
5.5.2. Determination Of Drug Concentration.......................................................57
5.5.3. Storage and Destruction Of Pharmacokinetic Samples..............................58
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 15
5.6. Pharmacodynamics Not Applicable........................................................................58
5.7. Pharmacogenetics Not Applicable ..........................................................................58
5.8. Biomarker Analysis Not Applicable .......................................................................58
5.9. Volume Of Blood....................................................................................................58
6. ADVERSE EVENT REPORTING AND MEDICAL MANAGEMENT...........................59
6.1. Requirements...........................................................................................................59
6.1.1. Additional Details On Recording Adverse Events on the CRF..................60
6.1.2. Eliciting Adverse Event Information..........................................................60
6.1.3. Withdrawal From the Study Due to Adverse Events..................................61
6.1.4. Time Period for Collecting AE/SAE Information......................................61
6.1.4.1. Reporting SAEs to Pfizer Safety...............................................61
6.1.4.2. Recording Non-serious AEs and SAEs on the CRF .................61
6.1.5. Causality Assessment .................................................................................61
6.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities ..................62
6.2. Definitions...............................................................................................................62
6.2.1. Adverse Events...........................................................................................62
6.2.2. Abnormal Test Findings .............................................................................63
6.2.3. Serious Adverse Events ..............................................................................63
6.2.4. Hospitalization............................................................................................64
6.3. Severity Assessment................................................................................................65
6.3.1. Actions Required In Cases Of Increases In Liver Chemistry Values.........66
6.4. Special Situations ....................................................................................................66
6.4.1. Medication Errors, and Lack of Efficacy ...................................................66
6.4.1.1. Medication Errors......................................................................67
6.4.1.2. Lack of Efficacy........................................................................67
6.5. Overdose..................................................................................................................67
6.5.1. Occupational Exposure...............................................................................68
6.6. Pregnancy................................................................................................................69
6.6.1. Maternal Exposure......................................................................................69
6.6.2. Paternal Exposure .......................................................................................70
6.7. Management of Investigational Product-Related Toxicities...................................70
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 16
6.8. Study Governance And Oversight...........................................................................70
6.8.1. Data and Safety Monitoring Board.............................................................70
7. INVESTIGATIONAL PRODUCT AND OTHER TREATMENTS ..................................71
7.1. Identity of Investigational Product(s)......................................................................71
7.2. Dose And Treatment Regimens ..............................................................................71
7.3. Labelling..................................................................................................................74
7.4. Storage.....................................................................................................................74
7.5. Compliance..............................................................................................................74
7.6. Accountability .........................................................................................................75
7.7. Oral Switch Therapy ...............................................................................................75
7.8. Concomitant And Other Treatments .......................................................................76
7.8.1. Drug-Drug Interactions...............................................................................83
7.8.2. Other Concomitant Treatment ....................................................................83
8. STATISTICAL ANALYSES ..............................................................................................83
8.1. Statistical Considerations ........................................................................................83
8.2. Sample Size Estimate..............................................................................................83
8.3. Definitions of Analysis Sets....................................................................................84
8.3.1. Safety Analysis Set.....................................................................................84
8.3.2. Safety Evaluable Analysis Set....................................................................84
8.3.3. Pharmacokinetic Analysis Set ....................................................................84
8.3.4. Efficacy Analysis Sets................................................................................84
8.3.4.1. Intent-to-Treat Analysis Set ......................................................85
8.3.4.2. Microbiological Intent-To-Treat Analysis Set ..........................85
8.3.4.3. Clinically Evaluable Analysis Set.............................................85
8.3.4.4. Microbiologically Evaluable Analysis Set................................85
8.4. Outcome Measures For Analyses............................................................................86
8.4.1. Primary Outcome Variables .......................................................................86
8.4.2. Secondary Outcome Variables ...................................................................86
8.5. Methods For Statistical Analyses............................................................................87
8.5.1. Analysis Of The Primary Variables............................................................87
8.5.1.1. Adverse Events..........................................................................87
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 17
8.5.1.2. Other Safety Data......................................................................88
8.5.2. Analysis Of The Secondary Variable(s).....................................................89
8.5.2.1. Pharmacokinetic Outcome Variables........................................89
8.5.2.2. Clinical Outcome Definitions....................................................89
8.5.2.3. Microbiological Response Assessments ...................................94
8.5.2.4. Emergent Infections ..................................................................95
8.5.2.5. Combined Response..................................................................95
8.6. Interim Analysis ......................................................................................................96
9. STUDY AND DATA MANAGEMENT.............................................................................96
9.1. Training of Study Site Personnel ............................................................................96
9.2. Monitoring of The Study.........................................................................................96
9.2.1. Source Data.................................................................................................97
9.2.2. Study Agreements.......................................................................................97
9.2.3. Archiving Of Study Documents .................................................................97
9.2.3.1. Data Handling And Record Keeping ........................................98
9.3. Study Timetable And End Of Study .......................................................................98
9.4. Sponsor Discontinuation Criteria............................................................................98
9.5. Data Management ...................................................................................................99
10. ETHICAL AND REGULATORY REQUIREMENTS...................................................100
10.1. Ethical Conduct Of The Study ............................................................................100
10.2. Patient Data Protection........................................................................................100
10.3. Ethics And Regulatory Review...........................................................................100
10.4. Informed Consent................................................................................................101
10.5. Changes To The Protocol And Informed Consent Form ....................................102
10.6. Audits and Inspections ........................................................................................102
10.7. Reporting Of Safety Issues And Serious Breaches Of The Protocol Or ICH 
GCP .........................................................................................................................103
10.8. Publication Of Study Results ..............................................................................103
10.8.1. Communication of Results by the Sponsor ............................................103
10.8.2. Publications by Investigators..................................................................104
11. LIST OF REFERENCES.................................................................................................106
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 18
LIST OF TABLES
Table 1.
Study Plan Detailing The Procedures...................................................................43
Table 2.
Laboratory Safety Parameters...............................................................................54
Table 3.
Volume of Blood Per Patient – Cohorts 1 and 2 ..................................................58
Table 4.
Volume Of Blood Per Patient – Cohorts 3, 4a, and 4b.........................................59
Table 5.
CAZ-AVI Doses By Age, Weight, And Creatinine Clearance ............................73
Table 6.
Contraindications And Drug-Drug interactions....................................................78
Table 7.
Clinical Outcome Assessments At End Of 72 Hours...........................................90
Table 8.
Clinical Outcome Assessments at EOIV ..............................................................91
Table 9.
Clinical Outcome Assessments at EOT................................................................92
Table 10
Clinical Outcome Assessments at TOC................................................................93
Table 11
Clinical Outcome Assessments at LFU ................................................................94
Table 12
Per-Pathogen Microbiological Outcome Categories ............................................95
Table 13
Emergent Infections..............................................................................................95
Table 14
Per-Patient Combined Response...........................................................................96
Table 15.
Classification Of Sexual Maturity States In Girls ..............................................114
LIST OF FIGURES
Figure 1.
Study Flow Chart..................................................................................................30
Figure 2.
Sexual Maturity Ratings (2 To 5) Of Pubic Hair Changes In Adolescent 
Girls. (Courtesy Of 
, MD, 
 
 
 England) ...............................................................................................112
Figure 3.
Sexual Maturity Ratings (1 To 5) Of Breast Changes In Adolescent Girls. 
(Courtesy Of 
, MD, 
 
 England).............113
APPENDICES
Appendix 1. Labelling And Shipment Of Biohazard Samples..............................................107
Appendix 2. Actions Required in Cases of Combined Increase of Aminotransferase and 
Total Bilirubin - Hy’s Law .................................................................................108
Appendix 3. Tanner Staging of Development .......................................................................112
PPD
PPD
PPD
PPD
PPD
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 19
List of abbreviations and definition of terms
The following abbreviations and special terms are used in this study Clinical Study Protocol.
Abbreviation or 
special term
Explanation
AE
Adverse event
AEoSI
Adverse event of special interest
ALT
Alanine aminotransferase
AST
Aspartate aminotransferase
BAT
Best Available Therapy
BMI
Body mass index
CAZ-AVI
Ceftazidime and avibactam
CE
Clinically evaluable
CFU
Colony-forming units
cIAI
Complicated intra-abdominal infections
CrCl
Creatinine clearance
CRF
Case Report Form (electronic/paper)
CRP
C-reactive protein
CSA
Clinical Study Agreement
CSR
Clinical Study Report
CT
Computed tomography 
cUTI
Complicated urinary tract infection
DILI
Drug-induced liver injury
DSMB
Data and Safety Monitoring Board
EDP
Exposure During Pregnancy
ECG
Electrocardiogram
EOIV
End of Intravenous Treatment
EOT
End of Treatment
ESR
Erythrocyte sedimentation rate
EudraCT
European Clinical Trials Database
GCP
Good Clinical Practice
β-hCG
ß-human chorionic gonadotropin
ICF
Informed Consent Form
ICH
International Conference on Harmonisation
IEC
Independent Ethics Committee
IND
Investigational New Drug
INR
International normalised ratio
International 
Co-ordinating 
Investigator
If a study is conducted in several countries the International 
Co-ordinating Investigator is the Investigator co-ordinating the 
Investigators and/or activities internationally. 
IP
Investigational product 
IRB
Institutional Review Board
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 20
Abbreviation or 
special term
Explanation
ITT
Intent-to-treat
IV
Intravenous
IXRS
Interactive voice/web response system
KPC
Klebsiella pneumoniae carbapenemase
LFU
Late Follow-up
ME
Microbiologically evaluable
MedDRA
Medical Dictionary for Regulatory Activities
MIC
Minimum inhibitory concentration
micro-ITT
Microbiological intent-to-treat 
MRI
Magnetic resonance imaging
OAT
Organic anion transporter
PD
Pharmacodynamic
PK
Pharmacokinetic
PRA
PRA Health Sciences
QTcB
QT interval corrected using Bazett’s formula
QTcF
QT interval corrected using Fridericia’s formula
SAE
Serious adverse event 
SAP
Statistical Analysis Plan
SD
Standard deviation
TOC
Test of Cure
ULN
Upper limit of normal
US
United States
WBC
White blood cells
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 21
1. INTRODUCTION
1.1. Background And Rationale For Conducting This Study
Avibactam is a novel, non β-lactam, β-lactamase inhibitor.  Although avibactam itself 
possesses no intrinsic antibacterial activity, it has been shown to restore in vitro activity of 
ceftazidime against Class A, Class C and some Class D β-lactamase-producing pathogens 
including those commonly associated with complicated intra-abdominal infections (cIAIs) 
and complicated urinary tract infections (cUTIs).  Avibactam, when combined with 
ceftazidime, has also been shown to be active against strains that express a combination of 
β-lactamase types, as well as strains that are concomitantly resistant to other antibacterial 
classes such as fluoroquinolones.
Beta-lactamase inhibition by avibactam is effected through the formation of a stable covalent 
carbamoyl linkage to the enzyme complex.  It inhibited Class A and Class C β-lactamases by 
50% at lower concentrations than other currently marketed β-lactamase inhibitors such as 
clavulanic acid, tazobactam, and sulbactam.  In addition, avibactam is a potent inhibitor of 
Class C enzymes whereas clavulanic acid, tazobactam, and sulbactam lack any activity 
against this class of enzymes.  Unlike currently available β-lactamase inhibitors, avibactam 
does not induce β-lactamase production.
Avibactam inhibited Klebsiella pneumoniae carbapenemase (KPC)-2 β-lactamase in vitro 
and restored ceftazidime susceptibility to Enterobacteriaceae-harboring KPC-2 or KPC-3 
β-lactamase (Stachyra et al 2009).4  The potent in vitro activity of the ceftazidime and 
avibactam (CAZ-AVI) combination against Enterobacteriaceae-producing Class A, and 
Class C, β-lactamases has been confirmed in vivo in murine pneumonia, septicaemia, and 
pyelonephritis models.  
Currently the options for the treatment of Gram negative infections, especially multi-drug 
resistant strains including extended-spectrum β-lactamase producers, are extremely limited.  
Until recently, there have been no new investigational compounds under early or late 
development specifically targeted to combat these organisms.  Hence, the availability and 
development of new agents to treat these infections will be a welcome addition to the 
existing treatments.  
Details of the CAZ-AVI clinical development programme to date can be found in 
Section 5.2.2 of the CAZ-AVI Investigator’s Brochure. 
The purpose of this study is to assess the safety, tolerability and descriptive efficacy of 
CAZ-AVI versus cefepime in patients aged from 3 months to less than 18 years with cUTI.  
Data from this study will be compared to similar data generated in adult patients so as to be 
able to extrapolate efficacy and tolerability to children.  The dosing regimen(s) has been 
chosen based on the paediatric pharmacokinetic (PK) study and PK/pharmacodynamic (PD) 
modelling of the exposure required for the successful treatment of infections used in Phase 3 
adult studies.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 22
1.2. Rationale for Study Design, Doses And Control Groups
This study will be a single blind, randomised, multi-centre, active controlled trial. 
A single blind study observer is a well-accepted study design in a paediatric population.  
Children are a vulnerable population and need close clinical monitoring by un-blinded 
observers to interject when needed whilst the blind observer will assess the safety and the
clinical cure without bias.  Given the risk to patients and severity of disease, a 
placebo-controlled trial would not be ethically appropriate.
The study is designed to include patients <1 year of age who are born at term only (defined 
as a gestational age ≥37 weeks).  Maturation during foetal life and after birth is a process 
involving all organs and functions of the growing human.  As such, all the main steps of drug 
disposition (absorption, distribution, metabolism, catabolism, elimination/excretion) may be 
under the influence of still incomplete morphological stages.  An incompletely absorbed 
compound may be less effective whereas a poorly metabolized and/or excreted compound 
may result in an increased risk of toxicity.  Both risks will have to be evaluated.  Better 
understanding of the maturing kidney should help to anticipate possible early and late 
adverse effects of drugs in neonatal populations.  Nephrogenesis is completed by the end of 
34th week of gestation and the kidney of a full-term neonate (ie, between 37 and 41 weeks of 
gestation) possesses a full set of nephrons and adult levels of glomerular filtration rate are 
reached between 1 and 2 years of age.  Therefore, patients <1 year of age who were born 
pre-term are excluded from this study.
This study will be conducted in hospitalised paediatric patients with cUTI requiring treatment 
with intravenous (IV) antibiotics.  The CAZ-AVI doses in this trial have been selected to 
achieve similar exposures reached in the Phase 3 adult studies (D4280C00001 and 
D4280C00005), with the intention of reaching the same level of efficacy (for further details 
regarding the dose selection rationale, please refer to the CAZ-AVI Investigator’s Brochure).  
The active comparator chosen for this study is IV cefepime.  Cefepime has been widely used 
for the safe treatment of pyelonephritis and cUTIs in children.  Details of the dosing regimen 
can be found in Section 7.2.
Complicated UTIs are defined as a clinical syndrome characterised by pyuria and a 
documented microbial pathogen on culture of urine or blood accompanied by local and 
systemic signs and symptoms, including fever (ie, oral or tympanic temperature greater than 
38 degrees Celsius), chills, malaise, flank pain, back pain, and/or costo-vertebral angle pain 
or tenderness, that occur in the presence of a functional or anatomical abnormality of the 
urinary tract or in the presence of catheterisation. Patients with pyelonephritis, regardless of 
underlying abnormalities of the urinary tract, are considered a subset of patients with cUTIs.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 23
Complicated UTIs are frequently managed initially with IV antibacterial therapy, with 
subsequent conversion to oral antibacterial therapy after an improvement in clinical 
symptoms.  In clinical practice, the oral agent chosen is dependent upon the results of culture, 
susceptibility testing and regional common practice.  The oral step-down antimicrobial of 
choice is described in Section 7.
The reference document for definition of expectedness/listedness is the Investigator’s 
Brochure for CAZ-AVI and the EU Summary of Product Characteristics for the active 
comparator product.
1.3. Benefit/Risk And Ethical Assessment
This study is the first study with therapeutic intent for CAZ-AVI in children with cUTIs;
however, the doses of CAZ-AVI have previously shown to achieve similar exposures in 
adults and children, so efficacy of CAZ-AVI in children is likely.  
Cohort 4 (≥3 months to <2 years) includes very young patients (aged from 3 months to 
<6 months) who are particularly vulnerable in terms of lack of a physiological reserve and 
rapid maturation of organs.  Therefore, in order to ensure that exposure (maximum 
concentration and area under the curve) was minimised in this group, while also still assuring 
robust predictions of sufficient exposure above the PK/PD target, Cohort 4 was divided into 
2 parts for further analysis for dose selection: Cohort 4a (from 1 year to <2 years) and Cohort 
4b (≥3 to <1 year).  This analysis indicated that a lower dose of 40 mg/kg 
ceftazidime/10 mg/kg avibactam reduces exposure in Cohort 4b, while still providing very 
high predictions of sufficient exposure above the PK/PD target (≥98% probability of target 
attainment) in patients with normal renal function and patients with mild renal impairment. 
Thus, for the purposes of dosing in this study, Cohort 4 is split into Cohort 4a, who will 
receive the same dose as Cohort 2 (50 mg/kg ceftazidime/12.5 mg/kg avibactam, every 
8 hours), and Cohort 4b, who will receive 50 mg/kg ceftazidime/12.5 mg/kg avibactam, 
every 8 hours for patients from 6 months to <1 year of age, and 40 mg/kg 
ceftazidime/10 mg/kg avibactam for patients from 3 months to <6 months of age.
The doses for use in patients with renal impairment have been chosen on the basis of 
modelling and simulation to achieve similar exposures of both ceftazidime and avibactam to 
those in adults with normal or mild renal impairment and predictions of sufficient exposure 
above the PK/PD target.
Patients enrolled into this clinical study will have cUTIs that are of sufficient severity to 
require hospitalisation and treatment with IV antibiotics.  The potential benefit to patients 
participating in this study is that they will receive effective antibiotic therapy for their 
infection.  The potential benefit of the study, in general, is the identification of a novel 
antibiotic combination product that is an effective treatment for cUTIs in the paediatric
population, in the face of the changing pattern of antibiotic resistance.  The safety and 
tolerability of CAZ-AVI was established in a Phase 1 study in children from 3 months to 
<18 years, during which the exposures were similar to those observed in adults.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 24
It is possible that CAZ-AVI may not be as effective a treatment as the comparator for 
treatment for cUTIs.  This risk is mitigated in that the patients are closely monitored and will 
be managed with appropriate therapies as determined by the Investigator who is providing 
treatment.  Furthermore, studies have indicated that there are no drug interactions between 
ceftazidime and avibactam when co-administered, and also that there are no safety 
implications.
A Phase 3, randomised, multicentre, double-blind, double-dummy, parallel-group, 
comparative study to determine the efficacy, safety, and tolerability of CAZ-AVI plus 
metronidazole versus meropenem was conducted in the treatment of cIAIs in hospitalised 
adults, aged 18 to 90 years. Treatment duration was 5 to 15 days (RECAIM study).  The 
doses administered were IV CAZ-AVI (500 mg avibactam and 2000 mg ceftazidime), 
immediately followed by 500 mg IV metronidazole, or 1000 mg IV meropenem, and 
529 patients in each treatment arm received study treatment.   Study treatments were
administered every 8 hours. CAZ-AVI was non-inferior compared with meropenem. 
CAZ-AVI plus metronidazole was effective in treating infections due to Gram-negative 
pathogens resistant to ceftazidime with response rates similar to that seen with
ceftazidime-susceptible isolates.  The adverse events (AEs) were generally mild or moderate in 
severity and the overall frequency and pattern of AEs were comparable between the treatment
groups. Analysis of the safety topics of interest did not reveal any new safety concerns.
Another Phase 3 study was an open-label, randomised, multicentre, study of CAZ-AVI and 
Best Available Therapy (BAT) for the treatment of infections due to ceftazidime-resistant 
Gram-negative pathogens, which was conducted in 333 adults aged 18 to 90 years diagnosed 
with cIAI or cUTI.  The dose administered was 2000 mg ceftazidime/500 mg avibactam 
IV over 2 hours. Those patients diagnosed with cIAI received an additional dose of 500 mg 
metronidazole IV. Study treatments were repeated every 8 hours and the treatment duration 
was 5 to 21 days. In terms of the primary objective to estimate the per-patient clinical 
response to CAZ-AVI and BAT at the Test of Cure (TOC) visit, the estimated clinical cure 
rate at the TOC visit was 90.9% for CAZ-AVI and 91.2% for BAT. In the mMITT analysis
set, the per-patient favourable microbiological response rate for patients with cUTI at the 
TOC visit was higher in the CAZ-AVI group than in the BAT group (81.9% versus 64.2%, 
respectively). 
There were no definitive conclusions of any treatment-related trends in patients with cIAI, 
and there were no obvious safety concerns identified from the data available. In the patients 
with cUTI, the proportion who experienced an AE up to the Late Follow-up (LFU) visit was 
28.3% in the CAZ-AVI group and 35.3% in the BAT group.  For patients with cUTI and 
cIAI, the majority of AEs were mild or moderate in intensity. Up to the LFU visit, the 
incidence of serious adverse events (SAEs) was low and balanced across treatment groups
(5.5% in the CAZ-AVI group and 6.0% in the BAT group).  All SAEs were assessed as not 
causally related to the study treatment by the Investigator. The number of patients with AEs 
of special interest (AEoSI) was generally low and balanced across treatment groups, with the 
exception of diarrhoea in patients with cUTI, which was higher in the BAT group (5.9% and 
2.0%, for BAT and CAZ-AVI, respectively).  No new safety concerns were identified from 
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 25
the safety topics of interest. The frequency of potentially clinically significant changes in 
clinical laboratory tests was also low and balanced across treatment groups.
There were no 
Hy’s Law cases.
A Phase 2 study (NXL104/2001) examining the safety of CAZ-AVI versus imipenem 
cilastatin followed by appropriate oral therapy as a comparator was conducted in 137 patients 
aged 18 to 90 years with cUTIs.  In this study patients were randomised 1:1 and given 
500 mg ceftazidime and 125 mg avibactam IV every 8 hours or 500 mg imipenem cilastatin 
IV every 6 hours.  Approximately 35% of patients in the CAZ-AVI group and 42% of 
patients in the imipenem cilastin group experienced a local reaction at the IV infusion site.  
The majority of the infusion site reactions were mild or moderate in intensity.  One patient in 
the imipenem cilastatin group experienced a severe local reaction (induration, swelling).  The 
most common infusion-related events across the treatment arms were erythema, pain and 
tenderness.  Of note, patients in the CAZ-AVI group received 3 infusions per day, while 
patients in the imipenem cilastatin group received 4 infusions per day.
In the Phase 2 study (NXL104/2002) examining CAZ-AVI plus metronidazole versus 
meropenem as a comparator in patients with cIAIs, approximately 30% of participants in 
both the CAZ-AVI and meropenem comparator treatment groups experienced at least 
1 symptom of local intolerability, with pain, erythema, swelling and tenderness reported most 
frequently across both groups.  The majority of infusion site events were mild.  There was a 
somewhat greater percentage of patients with infusion site events of moderate/severe 
intensity in the CAZ-AVI group, who also received IV metronidazole (17/101 patients 
[16.8%]) versus the meropenem group (11/102 patients [10.8%]).  Of note, patients in the 
CAZ-AVI plus metronidazole group received an infusion of 3 different agents per dose, 
whilst patients in the meropenem group received an infusion with 1 study drug per dose.
A Phase 1, open-label, single-dose study to characterise the pharmacokinetics (PK) of
CAZ-AVI and assess its safety and tolerability following a single IV dose was conducted in 
hospitalised paediatric patients aged 3 months to <18 years, receiving systemic antibiotic 
therapy for suspected or confirmed infection. The patients in this study were stratified by age 
and patients were enrolled in each cohort as follows: Cohort 1, patients aged ≥12 to 
<18 years; Cohort 2, patients aged ≥6 to <12 years; Cohort 3, patients aged ≥2 to <6 years; 
and Cohort 4, patients aged ≥3 months to <2 years (split into 2 groups of at least 4 patients 
each, ≥3 months to <1 year and ≥1 year to <2 years).  
Patients in Cohort 1 and any patients in Cohort 2 weighing ≥40 kg received a single IV dose
of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) administered as a single infusion 
over a 2-hour period on Day 1.  Patients in Cohort 2 weighing <40 kg received a single IV 
dose of CAZ-AVI (50 mg/kg ceftazidime and 12.5 mg/kg avibactam) administered as a 
single infusion over a 2-hour period on Day 1.  These doses were applicable for patients with 
normal renal function and mild renal insufficiency (creatinine clearance [CrCl] >50 to 
80 mL/min).
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 26
In Cohorts 3 and 4, patients with normal renal function or mild renal insufficiency received a 
single IV dose of CAZ-AVI (50 mg/kg ceftazidime and 12.5 mg/kg avibactam) on Day 1. 
Each patient in the study received a single IV dose of CAZ-AVI administered as a 
continuous infusion over a 2-hour period.  There were 32 patients in the safety analysis set 
and 32 patients in the PK analysis set.
Concentration versus time overlay plots suggest that the plasma ceftazidime and avibactam 
concentration profiles were similar in all 4 cohorts across sampling time points.  
Review of the haematology, coagulation, clinical chemistry, and urinalysis laboratory values 
did not reveal any unexpected findings within patients or any trends across patients; there 
were no potentially clinically significant haematology, clinical chemistry, or liver function 
test values reported.  No patients met Potential Hy’s Law criteria.  Review of vital signs 
values and physical examination findings did not identify any new safety concerns.  There 
were no clinically significant changes in electrocardiograms (ECGs) reported.  The single IV 
dose of CAZ-AVI was well tolerated, with no new safety concerns identified in hospitalised 
paediatric patients.
The risk considerations for this study should encompass the known and potential risks for the 
development product CAZ-AVI and its component products ceftazidime and avibactam, as 
well as the risks associated with other treatments that might be administered as described in 
this protocol.  Other possible treatments include the marketed product cefepime.  As the risk 
profile for the marketed product is widely available in the respective prescribing information, 
such risks will not be discussed in this section.  
The risks for CAZ-AVI have not been fully elucidated; however, it is assumed that known or 
potential risks for CAZ-AVI should include those identified in the clinical study experience 
with CAZ-AVI, avibactam alone, and for ceftazidime alone.  Additional risk information for 
avibactam and CAZ-AVI is located in the CAZ-AVI Investigator’s Brochure.  
The full risk profile for ceftazidime is described in the prescribing information for the 
product (refer to local ceftazidime product labelling).  Important risks as laid out in the 
warnings and precautions in product labelling for ceftazidime include:

Hypersensitivity reactions.  Though patients with hypersensitivity and serious allergic 
reactions to cephalosporins carbapenem or other β-lactam antibiotics are excluded 
from the trial, first-time episodes of such reactions could occur;

Antibiotic-associated diarrhoea, Clostridium difficile diarrhoea, colitis, and 
pseudomembranous colitis;

Bacterial overgrowth with non-susceptible organisms;

Distal necrosis as a result of inadvertent intra-arterial administration of ceftazidime;
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 27

Elevated levels of ceftazidime used in patients with renal impairment have been 
associated with neurological sequelae, such as tremors, myoclonus, seizures, 
encephalopathy, and coma.
Potential risks for CAZ-AVI include the occurrence of events seen with ceftazidime alone 
but that go beyond the frequency and/or severity of those seen with ceftazidime.  Local 
intolerance has been seen in the pre-clinical studies and has been monitored in the clinical 
programme.  In the Phase 1 studies, erythema and haematoma at the administration site were 
reported.  
In regard to hypersensitivity reactions, of those reported, there was 1 report in the CAZ-AVI 
clinical trials for which the clinical Investigator considered the events of skin rash and 
elevated liver function tests to be a possible hypersensitivity reaction because of the temporal 
relationship of the events to study therapy administration.  In the CAZ-AVI development 
programme, rashes have been reported.  Elevations of liver enzymes, independent of skin 
rashes or other potential signs of hypersensitivity, have also been reported.
In summary, the known and potential risks of receiving the developmental antibiotic 
combination CAZ-AVI are expected to be similar to those seen with ceftazidime and 
cephalosporins in general.  Side effects for the avibactam part of CAZ-AVI include injection 
site redness and injection site bruising.  The risks of the marketed antibiotics are considered 
acceptable.  While it is anticipated that CAZ-AVI will have similar efficacy for the treatment 
of cUTIs, it is possible that efficacy will not be demonstrated.  For each patient in the trial, 
appropriate treatment of the cUTI is determined by the clinical Investigator, based on the 
clinical response of the patient.
1.4. Study Design 
This study will be a single-blind, randomised, multi-centre, active controlled trial.  Patients 
aged from 3 months to less than 18 years with cUTIs will be randomised to 1 of 2 treatment 
groups (3:1 ratio): CAZ-AVI or cefepime.  Patients aged from 3 months to <1 year 
(Cohort 4b) must have been born at term (defined as gestational age ≥37 weeks).
A sufficient number of patients are to be randomised 3:1 for 80 patients to complete at least 
72 hours (3 full days, ie, 9 doses if given 3 times daily, or 6 doses if given twice daily) of 
study treatment (ie, evaluable patients; at least 60 patients in the CAZ-AVI group and at least 
20 patients in the cefepime group).
Patients will be allocated to 1 of 4 cohorts based on age.  Each cohort is required to have a 
minimum number of evaluable patients, and randomisation will be stratified as follows: 

Cohort 1: At least 6:2 evaluable patients aged from 12 years to <18 years;

Cohort 2: At least 6:2 evaluable patients aged from 6 years to <12 years;

Cohort 3: At least 9:3 evaluable patients aged from 2 years to <6 years;
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 28

Cohort 4: At least 18:6 evaluable patients aged from 3 months to <2 years comprising 
Cohorts 4a and 4b as follows: 

Cohort 4a: At least 9:3 evaluable patients aged from 1 year to <2 years;

Cohort 4b: At least 6:2 evaluable patients aged from 3 months to <1 year, with 
a minimum of 3 patients with at least 1 PK sample aged from 3 months to 
<6 months treated with CAZ-AVI.
Intravenous CAZ-AVI infusions will be given at doses based on age and weight with 
adjustment according to renal function as detailed in Table 5.
Patients whose CrCl drops below 30 mL/min should be withdrawn from study therapy.  
Patients withdrawing from study therapy can be administered alternative therapies at the 
Investigator’s choice, which should be recorded in the Case Report Form (CRF).  If possible, 
patients should still be followed for safety (see Section 3.9.1).  Because the CrCl 
determination is only an estimate of renal function, in instances where the CrCl is 
approaching thresholds that would require intervention such as a dose change or 
discontinuation of therapy (ie CrCL approaching 50 or 30 mL/min), the Investigator should 
use his or her discretion in determining (ie confirming the value by repeat testing, if feasible) 
whether an immediate dose change, a short period of continued observation, or 
discontinuation of therapy is warranted. If in the opinion of the Investigator there is a 
clinically significant reduction in a patient’s estimated CrCl during the treatment period, then 
the Investigator should contact the Medical Monitor to discuss the above mentioned options 
(immediate dose change, a short period of continued observation, or discontinuation of 
therapy).  Additionally, in instances of rapidly changing renal function, the Investigator 
should increase the frequency of CrCl monitoring, depending on the patient’s clinical status, 
extent of renal function change and Investigator’s clinical evaluation.
Patients randomised to receive cefepime should receive the dose, schedule and infusion 
duration as recommended in the local prescribing information or as prescribed by the 
investigator.  The maximum dose of cefepime in any single infusion should not exceed 
2000 mg.
Patients will receive IV treatment for a minimum of 72 hours (3 full days, ie, 9 doses if given 
3 times daily, or 6 doses if given twice daily) before having the option to switch to an oral 
therapy as specified in Section 7.7 below.  The decision to switch to oral therapy is entirely at 
the Investigator’s discretion, if the patient has good or sufficient clinical response, and the 
patient is tolerating oral fluids or food.  Patients can continue to take IV CAZ-AVI up to 
Day 14.  Patients requiring systemic prophylactic antibiotic medication for any reason at 
Screening are allowed to enter the study provided that they discontinue this medication prior 
to first dose of randomised study treatment (see Section 7.8 for further details).  
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 29
Patients will be assessed for safety and efficacy throughout the study, and blood samples will 
be taken for PK assessment.  The duration of each patient’s participation in the study will be 
a minimum of 27 days to a maximum of 50 days after start of study treatment (including 7 to 
14 days of active treatment), at which time there will be a LFU assessment visit.  The LFU is 
to be performed 20 to 36 days after the last dose of any treatment. 
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 30
Figure 1.
Study Flow Chart
*Optional switch to oral therapy permitted on or after Study Day 4 (ie, after 72 hours [3 full days, ie, 9 doses if given 3 times daily, or 6 doses if given 
twice daily] of IV study drug).  Assessment should be performed no later than 8 hours after the 72-hour time point.  The decision to switch to oral therapy 
is entirely at the Investigator’s discretion, if the patient has good or sufficient clinical response, and the patient is tolerating oral fluids or food:
Oral ciprofloxacin (only in countries where its use for children is permitted; according to local guidelines, administered at a dose and formulation per 
standard of care), or oral cefixime (only in countries where its use for children is permitted; according to local guidelines, administered at a dose and 
formulation per standard of care), or oral amoxicillin/clavulanic acid (only in countries where its use for children is permitted; according to local 
guidelines, administered at a dose and formulation per standard of care), or oral sulfamethoxazole/trimethoprim (only in countries where its use for 
children is permitted; according to local guidelines, administered at a dose and formulation per standard of care), or pathogen-based therapy (in discussion
with the Medical Monitor), see Section 7.7.
The patient may continue on IV study drug for the entire duration of the study therapy (7 to 14 days), at the discretion of the Investigator.
** Visit performed within 24 hours of completion of last infusion or within 48 hours after the last dose of oral switch therapy.
Screening
Treatment
Follow Up
Last Follow-up 
visit
27 to 50 days 
after start of 
study treatment
Test of Cure 
visit
8 to 15 days 
after last dose of 
study drug (IV 
or oral)
Patients with 
cUTI
Patients 
randomised 
(3:1) to the 
CAZ-AVI or 
cefepime 
treatment
End of IV drug 
or oral switch 
therapy visit**
Cefepime per local 
prescribing 
information/as 
prescribed by 
Investigator, but not 
exceeding 2000 mg*
IV CAZ-AVI
Infused over 
2 hours*
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 31
2. STUDY OBJECTIVES
2.1. Primary Objective (safety)
Primary Safety Objective:
Outcome Measure:
Evaluate the safety and tolerability of 
CAZ-AVI given at the selected dose 
regimen versus cefepime in paediatric 
patients aged ≥3 months to <18 years with 
cUTI

AEs and SAEs from the signing of the 
Informed Consent Form (ICF)/Assent Form 
to the LFU visit (27 to 50 days after start of 
study treatment) 

Cephalosporin class effects and additional 
AEs (including, but not limited to, seizures, 
C. difficile-associated diarrhoea, allergic 
reactions, hepatic abnormalities, haemolytic 
anaemia, and changes in renal function)

Clinical: vital signs (pulse, blood pressure, 
respiratory rate, temperature), ECG, and 
physical examinations

Laboratory: complete blood count with 
differential and comprehensive metabolic 
panel

CrCl 
2.2. Secondary Objectives
Secondary Objective:
Outcome Measure:
Evaluate the descriptive efficacy of 
CAZ-AVI versus cefepime in paediatric 
patients aged ≥3 months to <18 years with 
cUTI

Clinical outcomes at End of 72 hours’ 
Treatment, End of Intravenous Treatment 
(EOIV) End of treatment (EOT), and TOC

Microbiological response at EOIV, EOT, 
TOC and LFU

Clinical relapse at LFU

Emergent infections

Combined response
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 32
Evaluate the PK of CAZ-AVI in 
paediatric patients aged ≥3 months to 
<18 years with cUTI

PK data of ceftazidime and avibactam will 
be analysed separately

Plasma concentration will be listed and 
summarised by nominal sampling time 
window using appropriate descriptive 
statistics

PK parameters derived from population PK 
analysis and potential PK/PD relationships 
will be reported separately
2.3. Safety Objectives 
Safety is the primary objective.
2.4. Exploratory Objectives Not Applicable
3. SUBJECT SELECTION, ENROLMENT, RANDOMISATION, RESTRICTIONS, 
DISCONTINUATION AND WITHDRAWAL 
This study can fulfill its objectives only if appropriate subjects are enrolled.  The following 
eligibility criteria are designed to select subjects for whom participation in the study is 
considered appropriate.  All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular subject is suitable for this protocol.
Subject eligibility should be reviewed and documented by an appropriate member of the 
investigator’s study team before subjects are included in the study.  Each patient should meet 
all of the inclusion criteria and none of the exclusion criteria for this study.  Under no 
circumstances can there be exceptions to this rule.
3.1. Inclusion Criteria
For inclusion in the study patients should fulfil the following criteria:
1. Must be ≥3 calendar months to <18 years of age.  Patients aged ≥3 calendar months to 
<1 year must have been born at term (defined as gestational age ≥37 weeks).
2. Written informed consent from parent(s) or other legally acceptable representative(s), and 
informed assent from patient (if age appropriate according to local regulations)
3. If female and has reached menarche, or has reached Tanner stage 3 development (even if 
not having reached menarche) (refer to Appendix E for further details on Tanner staging), 
the patient is authorised to participate in this clinical study if the following criteria are 
met:
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 33
At screening

(a) Patient reports sexual abstinence for the prior 3 months or reports use of at least 
1 of the acceptable methods of contraception, including an intrauterine device (with 
copper banded coil), levonorgestrel intrauterine system (eg, Mirena®), or regular 
medroxyprogesterone injections (Depo-Provera®); or (b) Patient agrees to initiate 
sexual abstinence from the time of screening until 7 days after end of treatment with 
study drug; and

Patient is advised to avoid conception from the time of screening until 7 days after
receipt of study drug and agrees not to attempt pregnancy from the time of screening 
until 7 days after end of treatment with study drug; and

Patient is provided guidelines regarding continuation of abstinence, initiation of 
abstinence, or about allowed contraception; and

Patient has a negative serum β-human chorionic gonadotropin (β-hCG) test just prior 
to study entry.  Since serum tests may miss an early pregnancy, relevant menstrual 
history and sexual history, including methods of contraception, should be considered.  
Note: if the result of the serum β-hCG test cannot be obtained prior to dosing of 
investigational product, a patient may be enrolled on the basis of a negative urine 
pregnancy test, though a serum β-hCG test result must still be obtained.
Note 1: Hormonal contraceptives delivered orally, as patches, or via vaginal devices should 
not be used as a method of birth control because the effect of CAZ-AVI on the efficacy of 
these types of contraceptives has not yet been established.  
Note 2: Barrier methods (such as male condom) can be used as a means of preventing 
sexually transmitted disease but are not acceptable as a means of contraception for this 
clinical trial.  
4. Patient has a clinically suspected and/or bacteriologically documented cUTI or acute 
pyelonephritis judged by the Investigator to be serious and requires the patient to be 
hospitalised for treatment with IV therapy.
5. Patient has pyuria: 

Cohorts 1 to 3 as determined by a midstream clean catch or clean urethral 
catheterisation urine specimen with ≥10 white blood cells (WBCs) per high-power 
field on standard examination of urine sediment or ≥10 WBCs/mm3 in unspun urine;
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 34

Cohorts 4a and 4b as determined by a midstream clean catch or clean urethral 
catheterisation urine specimen, or urine specimen obtained using urine collection 
pads (or supra-pubic collection if standard procedure in the assigned sites) ≥5 WBCs 
per high-power field on standard examination of urine sediment or ≥5 WBCs/mm3 in 
unspun urine.
6. Patient has a positive urine culture: 1 midstream clean catch or clean urethral 
catheterisation urine specimen taken within 48 hours of randomisation containing 
≥105 colony-forming units (CFU)/mL of a recognised uropathogen known to be 
susceptible to the IV study therapy (CAZ-AVI and cefepime).
Note: If patients meet all of entry criteria except for positive urine culture as outlined above, 
the patients may be enrolled before urine culture results are available if the results are likely 
(based on urinalysis and clinical findings) to be positive and study drugs are considered 
appropriate empiric therapy.  If a patient urine culture is negative after 24 or 48 hours of 
treatment but the patient is improving, the Investigator can keep the patient on treatment.  If 
the urine culture is negative and the patient is not improving, study treatment will be 
stopped, and the patient will be followed for the rest of the study including undergoing all 
safety assessments until LFU. 
7. Demonstrates either acute pyelonephritis or complicated lower UTI as defined by the 
following criteria:
a.
Qualifying criteria: patients must have at least 1 of the following signs/symptoms 
(signs/symptoms must have onset or have worsened within 7 days of enrolment) in 
addition to pyuria:

Dysuria (including perceived dysuria as referred by parent/caregiver);

Urgency;

Frequency;

Abdominal pain;

Fever defined as oral temperature >38.5°C (or equivalent by other methods) with 
or without patient symptoms of rigor, chills, warmth;

Nausea;

Vomiting;

Irritability;

Loss of appetite;
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 35

Flank pain.
b. Or patients considered to have complicated UTI as indicated by 2 of the previous 
qualifying signs/symptoms in (a) plus at least 1 complicating factor from the 
following:

Recurrent UTI (2 or more within 12 months period);

Obstructive uropathy that is scheduled to be surgically relieved during IV study 
therapy and before the EOT;

Functional or anatomical abnormality of the urogenital tract, including anatomic 
malformations or neurogenic bladder;

Vesicoureteral reflux;

Use of intermittent bladder catheterisation or presence of an indwelling bladder 
catheter for >48 hours prior to the diagnosis of Cuti;

Urogenital procedure (eg, cystoscopy or urogenital surgery) within the 7 days 
prior to study entry;
3.2. Exclusion Criteria
Patients should not enter the study if any of the following exclusion criteria are fulfilled:
1. Involvement in the planning and/or conduct of the study (applies to both Sponsor staff 
and/or staff at the study site).
2. Previous enrolment or randomisation in the present study.
3. Participation in another clinical study with an investigational product (IP) during the last 
30 days before the first dose of IV study drug or have previously participated in the 
current study or in another study of CAZ-AVI (in which an active agent was received).
4. History of hypersensitivity reactions to carbapenems, cephalosporins, penicillins or other 
β-lactam antibiotics.
5. Concurrent infection, including, but not limited to, central nervous system infection 
requiring systemic antibiotics in addition to the IV study drug therapy at the time of 
randomization.
6. Receipt of more than 24 hours of any systemic antibiotics after culture and before study 
drug therapy.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 36
7. Receipt of systemic antibiotics within 24 hours before obtaining the study-qualifying 
pre-treatment baseline urine sample and before study drug therapy.
8. The child is suspected or documented to have an infection caused by organisms resistant 
to the prophylactic antibiotics.
9. A permanent indwelling bladder catheter or instrumentation including nephrostomy or 
current urinary catheter that will not be removed or anticipation of urinary catheter 
placement that will not be removed during the course of IV study drug therapy 
administration.
10. Patient has suspected or known complete obstruction of any portion of the urinary tract, 
perinephric abscess, or ileal loops.
11. Patient has had trauma to the pelvis or urinary tract.
12. Patient has undergone renal transplantation.
13. Patient has a condition or history of any illness that, in the opinion of the Investigator, 
would make the patient unsuitable for the study (eg, may confound the results of the 
study or pose additional risk in administering the study therapy to the patient).
14. Patient is considered unlikely to survive the 6 to 8 week study period or have a rapidly 
progressive illness, including septic shock that is associated with a high risk of mortality.
15. At the time of randomisation, patient is known to have a cUTI caused by pathogens 
resistant to the antimicrobials planned to be used in the study.
16. Presence of any of the following clinically significant laboratory abnormalities: 
a.
Haematocrit <25% or haemoglobin <8 g/dL (<80 g/L, <4.9 mmol/L);
b. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3×the 
age-specific upper limit of normal (ULN), or total bilirubin >2×ULN (except known 
Gilbert’s disease).  
For a) and b): unless if these values are acute and directly related to the infectious process 
being treated.
17. Creatinine clearance <30 mL/min/1.73 m2 calculated using the child’s measured height 
(length) and serum creatinine within the updated “bedside” Schwartz formula (Schwartz 
et al 2009)3: 
CrCl (mL/min/1.73m2)=0.413×height (length) (cm)/serum creatinine (mg/dL).
18. History of seizures, excluding well-documented febrile seizure of childhood.d
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 37
19. If female, currently pregnant or breast feeding.
See Section 3.4 for procedures for withdrawal of incorrectly enrolled patients.
3.3. Subject Enrolment And Randomisation
Investigator(s) should keep a record, the patient screening log, of patients who entered 
pre-study screening.  Patients will be enrolled if they meet all the inclusion criteria, including 
informed consent and assent in writing from parent(s) or other legally-acceptable 
representative(s)/patient as applicable, and none of the exclusion criteria.  The Blinded 
Observer may perform screening and enrolment; however, the Investigator must perform 
randomisation.
The Blinded Observer/Investigator will:
1. Obtain signed informed consent from the parent or guardian/legally acceptable 
representative(s) of the potential patient and informed assent from the potential patient (if 
age appropriate according to local regulations) before any study specific procedures are 
performed
2. Assign potential patient a unique enrolment number, beginning with 
3. Determine patient eligibility (see Section 3.1 and Section 3.2.
4. Investigator only: Assign eligible patient unique randomisation code (via an interactive 
voice/web response system [IXRS] not available for access by the Blinded Observer)
If a patient withdraws from participation in the study, then his/her enrolment/randomisation 
code cannot be reused.
Randomisation codes will be assigned strictly sequentially as potential patients become 
eligible for randomisation.
3.4. Procedures For Handling Incorrectly Enrolled Or Randomised Patients
Patients who fail to meet the eligibility criteria should not, under any circumstances, be 
enrolled or receive study medication.  There can be no exceptions to this rule.  Patients who 
are enrolled, but subsequently found not to meet all the eligibility criteria, must not be 
randomised or initiated on treatment, and must be withdrawn from the study.
Where a patient does not meet all the eligibility criteria but is randomised in error, or 
incorrectly started on treatment, the Investigator should inform the Medical Monitor
immediately, and a discussion should occur between the Medical Monitor and the 
Investigator regarding whether to continue or discontinue the patient from treatment. The 
Medical Monitor must ensure all decisions are appropriately documented.
PPD
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 38
3.5. Methods for Assigning Treatment Groups
Block randomisation using an IXRS will be used to assign patients in a ratio of 3:1 to the 
study treatment groups of CAZ-AVI or cefepime respectively in each of the cohorts for the 
age groups (see Section 8.2 for a description of the sample size).
A representative of Sponsor, under the supervision of Sponsor statistical personnel, will 
perform this randomisation. 
3.6. Methods for Ensuring Blinding
This study will be observer-blinded.  Each investigational site will be required to have a 
site-specific Blinding Plan that describes site-specific precautions being taken to ensure that 
the study is observer-blinded, taking into account the specific patient care procedures, 
equipment, and information accessibility at that site.
At each investigational site, at least 1 blinded investigator (referred to as “Blinded Observer”
hereafter) will not know the patient’s treatment assignment and will conduct clinical 
assessments related to safety and efficacy.  The Blinded Observer may perform screening and 
enrolment activities but will not be responsible for randomising patients (the Blinded 
Observer will not have access to the IXRS).  The Blinded Observer will not ask other 
members of the study team, the patient, or the patient’s parent(s)/legally acceptable 
representative(s) which study treatment is being given, and will avoid all attempts to uncover 
treatment assignment.  The Blinded Observer should arrange to see the patient during times 
when study drug is NOT being administered, and not when assessments are being performed 
that could possibly unblind the Blinded Observer, in order to maintain the blind.  If possible, 
the same Blinded Observer should complete all clinical assessments for a patient. The 
Blinded Observer should perform all causality assessments for all AEs and SAEs.
At each investigational site, an unblinded Investigator (referred to as “Investigator” 
hereafter), Pharmacist or designee, study centre personnel, patient, and parent(s)/legally 
acceptable representative(s) may be aware of which IV study drug therapy is being 
administered and shall be instructed not to reveal to the Blinded Observer which drug the 
patient is receiving. Refer to Section 3.7 if the Blinded Observer learns of the treatment 
assignment.
3.7. Methods For Unblinding 
Individual treatment codes, indicating the treatment randomisation for each randomised 
patient, will be available to the Investigator(s) or pharmacists from the IXRS.  Routines for 
this will be described in the IXRS user manual that will be provided to each centre.
This study has an observer-blinded design.  During the study, the Blinded Observer(s) will 
not make any effort to determine which IV study drug is being administered.  The details of 
blinding will be described in the Blinding Plan.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Only in the case of an emergency, when knowledge of the study drug is essential for the 
immediate clinical management or welfare of a specific patient and the Investigator or 
designee is not available to provide or cannot provide appropriate medical care to the patient, 
may the Blinded Observer be unblinded to the patient’s treatment assignment.
Before any unblinding of the Blinded Observer, it is strongly advised to discuss options with 
the Medical Monitor or appropriate study personnel. As soon as possible, and without 
revealing the patient’s study treatment assignment (unless important to the safety of patients 
remaining in the study), the Blinded Observer or designee must notify PRA Health Sciences 
(PRA) if the observer blind is broken for any reason and the Blinded Observer was unable to 
contact PRA before unblinding. PRA Health Sciences is a contract research organization that 
manages various aspects of this study on behalf of the Sponsor.  PRA will inform Sponsor of 
the incident.
3.8. Restrictions
Hormonal contraceptives which are potentially subject to drug-to-drug interaction, such as 
pills, patches, and intravaginal devices, are not acceptable methods of birth control during 
this study based on potential for antibiotics to alter gut flora, hormone absorption, and 
hormone effectiveness.  If an adolescent female study participant was previously using 
hormonal contraceptives such as pills, patches, and intravaginal devices, she should follow 
her health care provider’s specific recommendations for effective use of these methods after 
completing IV study therapy.  Such recommendations may address the need for a second 
method of contraception until the hormonal method becomes fully effective.
3.9. Discontinuation Of Investigational Product
Patients may be discontinued from IP in the following situations:

Patient or patient’s parent(s)/legally acceptable representative(s) decision.  The 
patient or the patient’s parent(s) or other legally acceptable representative(s) is at any 
time free to decide to discontinue treatment, without prejudice to further treatment

AE (eg, risk to patients, as judged by the Investigator)

Positive pregnancy test at any time during the study treatment period

In the absence of any alternative explanation for an increase in the following 
abnormalities, individual patients should be withdrawn if the following hepatic/liver 
criteria are met:

ALT or AST >8×ULN;

ALT or AST ≥3×ULN and either total bilirubin ≥2×ULN or evidence of 
coagulopathy.  Evidence of coagulopathy should be discussed with the PRA 
physician where possible;
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 40

ALT or AST ≥3×ULN and with appearance of symptoms suggestive of new 
or progressive liver disease.  Symptoms suggestive of new or progressive liver 
disease should be discussed with the PRA physician where possible.

Significant reduction in CrCl measurements as judged by the investigator;

CrCl value <30 mL/min;

Severe non-compliance with the study protocol as judged by the Investigator;

In the opinion of the Investigator, it is not in the best interest of the patient to continue 
study therapy and/or lack of efficacy.
3.9.1. Procedures For Discontinuation Of A Patient From Investigational Product 
At any time, patients or the patient’s parent(s) or other legally acceptable representative(s) 
are free to decide to discontinue the child’s use of IP or withdraw from the study (ie, IP and 
assessments – see Section 3.10), without prejudice to further treatment.  A patient or the 
patient’s parent(s) or other legally acceptable representative(s) who decides to discontinue IP 
will always be asked about the reason(s) and the presence of any AEs.  If possible, they will 
be seen and assessed by an Investigator(s) at the time of discontinuation from the IP and at 
the LFU visit.  
Adverse events and SAEs will be followed up (See Section 6).  For patients who discontinue 
IP early, their follow-up assessments should be collected (see Section 3.10.3 for follow-up of 
unresolved AEs).  Liver CRF modules should be completed for patients discontinued after 
meeting hepatic/liver criteria.  The patient should be scheduled for the EOIV visit within 
24 hours after IV study therapy discontinuation, ideally before starting any new antibiotic 
treatment.
If a patient is withdrawn from study, see Section 3.10.
3.10. Criteria for Withdrawal 
Subjects may withdraw from the study at any time at their own request, or they may be 
withdrawn at any time at the discretion of the investigator or Sponsor for safety (see also the 
Withdrawal From the Study Due to Adverse Events section) or behavioral reasons, or the 
inability of the subject to comply with the protocol-required schedule of study visits or 
procedures at a given study site. 
3.10.1. Screen Failures 
Screen failures are patients who have provided informed consent/assent and subsequently do 
not fulfil the eligibility criteria for the study, and therefore must not be randomised.  These 
patients should have the reason for study withdrawal recorded as ‘Failed Eligibility Criteria’ 
(ie, patient does not meet the required inclusion/exclusion criteria).  This reason for study 
withdrawal is only valid for screen failures (not randomised patients).  For details on the 
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 41
procedures to follow regarding negative urine culture results after the test at Baseline, see 
Section 3.1. 
3.10.2. Withdrawal of the Informed Consent
Patients or the patient’s parent(s) or other legally acceptable representative(s) are free to 
withdraw the child from the study at any time (IP and assessments), without prejudice to 
further treatment.
A patient or the patient’s parent(s) or other legally acceptable representative(s) who 
withdraws consent will always be asked about the reason(s) and the presence of any AEs.  
The Investigator will follow up AEs outside of the clinical study. If the 
parent/legally-acceptable representative withdraws consent for disclosure of future 
information, no further evaluations should be performed, and no additional data should be 
collected.  The Sponsor may retain and continue to use any data collected before such 
withdrawal of consent.
If a patient withdraws from participation in the study, then his/her enrolment/randomisation 
code cannot be reused. 
3.10.3. Lost to Follow-up
If a patient does not return for a scheduled visit, every effort should be made to contact the 
patient.  All attempts to contact the patient and information received during contact attempts 
must be documented in the patient’s source documentation.  In any circumstance, every 
effort should be made to document patient outcome, if possible.  The investigator should 
inquire about the reason for withdrawal, request that the patient return for a final visit, if 
applicable, and follow up with the patient regarding any unresolved adverse events (AEs).
3.11. Discontinuation of the Study
The study may be stopped if, in the judgment of Sponsor, trial patients are placed at undue 
risk because of clinically significant findings that:

Meet individual stopping criteria or are otherwise considered significant 

Are assessed as causally related to study drug 

Are not considered to be consistent with continuation of the study
Regardless of the reason for termination, all data available for the patients at the time of 
discontinuation of follow-up must be recorded in the CRF.  All reasons for discontinuation of 
treatment must be documented.
In terminating the study, the Sponsor will ensure that adequate consideration is given to the 
protection of the patients’ interests.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 42
4. STUDY PLAN AND TIMING OF PROCEDURES 
Table 1 provides an overview of the protocol visits and procedures.  Refer to the Study 
assessments section of the protocol for detailed information on each procedure and 
assessment required for compliance with the protocol. 
The investigator may schedule visits (unplanned visits) in addition to those listed on the 
schedule of activities table, in order to conduct evaluations or assessments required to protect 
the well-being of the subject.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 43
Study plan detailing the procedures
Table 1.
Study Plan Detailing The Procedures
Assessment or Procedure
Baseline1
Treatment
Follow-up
Day 12
Days 2 
and 3
Days
4 to ≤143
EOIV4
EOT5
(Oral 
only)
TOC6
LFU7
ICF (and Assent Form, if 
applicable)8
X
Verify inclusion/exclusion criteria
X
Clinical
Medical and surgical history
X
Complete physical examination9
X
X After 72 hours’ 
treatment only
X
X
X
X10
Prior and concomitant medications 
(including lactating mother)11
X
X
X
X
X
X
X
X
Vital signs12
X
X
X
X
X
X
X
X10
ECG13
X
X
X
Record adjunctive therapeutic 
procedures (if performed)
X
X
X
X
X
X
X
Record radiological 
examinations14
X
Clinical outcome
X15 After 72 hours’ 
treatment only
X15
X15
X15
X16
AEs and SAEs17
X
X
X
X
X
X
X
X
Laboratory
Complete blood count with 
differential, chemistry panel, CrCl 
calculation, ESR, and optional 
CRP18
X
If clinically indicated
X19
X20
If 
clinically 
indicated
X21
If clinically 
indicated
Urine or serum pregnancy test22
X
X
Urine sample routine analysis23
X
If clinically indicated
Micr
o
Urine culture24
X
X
X
X
X
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Assessment or Procedure
Baseline1
Treatment
Follow-up
Day 12
Days 2 
and 3
Days
4 to ≤143
EOIV4
EOT5
(Oral 
only)
TOC6
LFU7
Blood sample for culture25
Blood cultures should be performed as clinically indicated
PK
Blood for PK analyses26
X
Randomisation27
X
Study drug administration
X
X
X
X
Oral switch therapy administration
X
ESR=erythrocyte sedimentation rate
1.
Perform baseline assessments within 24 hours before first dose of IV study drug.
2.
Day 1 is the first day of IV study drug administration; subsequent study days are consecutive days. Perform Day 1 assessments after administration of at least 1 dose of IV 
study drug.
3.
On Days 4 to ≤14, study drug administration applies to all patients and daily assessments are to be performed only for patients on IV study drug.
4.
Perform EOIV assessments in person by the Blinded Observer within 24 hours after completion of the last infusion of study drug or at time of premature discontinuation of 
study drug or early withdrawal from study (if on IV study drug).  Conduct the EOIV assessments in place of the regular study visit (eg, Days 4 to ≤14) assessments that would 
have been performed the day of that visit.  A patient may be eligible to switch to oral therapy on or after Day 4 (Section 7.2); EOIV assessments must occur before starting 
oral switch therapy.
5.
Perform EOT assessments in person within 48 hours after the last dose of oral switch therapy or at time of premature discontinuation of study drug or early withdrawal from 
study (if on oral switch therapy). 
6.
Perform TOC assessments in person 8 to 15 days after last dose of any study drug (IV or oral).
7.
Perform LFU assessments 20 to 36 days after last dose of any study drug (IV or oral).  Conduct LFU via telephone for any patient who has not experienced clinical relapse, 
did not have ongoing AEs or SAEs at TOC, or did not develop AEs or SAEs since TOC.  If symptoms of relapse or new AEs or SAEs are noted, or at the discretion of the 
Blinded Observer or Investigator, the patient should be immediately scheduled for an in-person visit.
8.
Obtain informed consent from parent(s) (or other legally acceptable representative[s]) in writing and informed assent from patient (if age appropriate according to local 
requirements) before initiating any study assessments or procedures.  
9.
Height measured at Baseline only.  Weight measured at Baseline only, but should be measured at subsequent time points if clinically indicated and feasible.  Physical 
examination to be performed after completion of 72 hours’ treatment (either Day 3 or Day 4, depending on timing of treatment administration).  Assessment should be 
performed no later than 8 hours after the 72-hour time point.
10. Not applicable if visit conducted by telephone.
11. For patients who are breast fed, all medications taken by the lactating mother in the previous 2 weeks prior to the first dose of study therapy until LFU will also be recorded.
12. Temperature, respiratory rate, pulse and blood pressure, by the appropriate method for the patient’s age.  To be performed before ECG on days when both assessments are 
indicated.
13. Baseline ECG to be performed prior to obtaining blood samples for laboratory testing.  Day 1 ECG to be performed within 30 minutes following the end of the first study 
treatment infusion.  Electrocardiograms will be taken after the patient has been resting in a recumbent position for at least 10 minutes.
14. Radiological examinations are not required for the study, but the results should be recorded if done as part of the diagnosis.  Radiological examinations include WBC scans, 
plain abdominal radiographs, computed tomography (CT) scans, voiding cystourethrogram, ultrasound and/or MRI scans with or without contrast. 
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 45
15. Blinded Observer: Assess clinical outcome per protocol, after 72 hours’ treatment. Assessment should be performed no later than 8 hours after the 72-hour time point (no 
assessment required on Day 2).
16. Blinded Observer: Assess patients for clinical relapse per protocol.  Emergent infections will be assessed up to LFU.
17. Investigator or Blinded Observer: Collect and report AEs and SAEs from signing of the ICF (and Assent Form if applicable) until at least 30 days after any dose of study drug 
(IV or oral) (or LFU, whichever is later); site staff are to follow unresolved AEs and SAEs at LFU until resolution or stabilisation.  The causality assessment should be done 
by the Blinded Observer (not the Investigator) for all AEs and SAEs.
18. Laboratory tests indicated at Baseline do not need to be repeated if they were performed within 24 hours of the Baseline visit, unless clinically indicated.  Perform local safety 
laboratory tests at additional time points as clinically indicated.  Erythrocyte sedimentation rate to be performed if clinically indicated or if required per standard of care.  
C-reactive protein is an optional test and may be included if part of standard of care.  C-reactive protein and CrCl calculation may be repeated at additional time points if 
clinically indicated.  Additionally, in instances of rapidly changing renal function, the Investigator should increase the frequency of CrCl monitoring, depending on the 
patient’s clinical status, extent of renal function change and the Investigator’s clinical evaluation.  Direct Coombs test at Baseline and TOC only. Test results of any samples 
taken as standard of care should be recorded in the CRF.
19. Conduct on Day 7 if patient is still on IV study drug at that time.
20. If EOIV occurs within 48 hours after these assessments are performed on Study Day 7, do not repeat these assessments.
21. Perform at TOC only if patient had an abnormal (high/low flag) result on or after EOIV.
22. Perform test if patient is a female who has reached menarche or has reached Tanner stage 3 development (even if not having reached menarche). If a pregnancy test is positive 
post-baseline, follow reporting requirements in Section 6.5.1.  Note: if the result of the serum β-hCG test cannot be obtained prior to dosing of investigational product, a 
patient may be enrolled on the basis of a negative urine pregnancy test, though a serum β-hCG test result must still be obtained.  At TOC, a serum pregnancy test is required.
23. At Baseline, before any antibiotics are administered. Subsequent additional time points if clinically indicated.
24. At Baseline, before any antibiotics administered. 
25. If clinically indicated and not already collected per standard of care.
26. Blood samples for PK (1 mL per sample for Cohorts 1 and 2, and 0.5 mL per sample for Cohorts 3, 4a, and 4b) will be collected from patients randomised to CAZ-AVI 
treatment on Day 3 following a dose administration that is convenient for the plasma sample collections at the following time points: anytime within 15 minutes prior to or 
after stopping CAZ-AVI infusion, anytime between 30 minutes and 90 minutes after stopping CAZ-AVI infusion, and anytime between 300 minutes (5 hours) and 360 
minutes (6 hours) after stopping CAZ-AVI infusion.  Every attempt should be made to obtain at least 1 sample from each of the 3 time windows for each patient.  Blood 
samples should be taken in a manner such that the Blinded Observer remains blinded.
27. Verify that the patient meets all study inclusion and no exclusion criteria before randomisation.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 46
4.1. Enrolment/Screening Period
Procedures will be performed according to the Study Plan (Table 1). Details of study 
assessments are provided in Section 5.
At screening, consenting/assenting patients will be assessed to ensure that they meet 
eligibility criteria. Patients who do not meet these criteria must not be enrolled in the study.  
Baseline assessments must be performed within 24 hours of administration of the first dose 
of IV study drug.  The following assessments will be performed at Baseline: 

Provision of informed consent/assent and verification of inclusion and exclusion 
criteria.  Informed consent should be obtained from the parent(s) (or other legally 
acceptable representative[s]) in writing and informed assent from the patient (if age 
appropriate according to local requirements) before initiating any study assessments 
or procedures;

Medical and surgical history;

Complete physical examination, including height and weight;

Prior and concomitant medication recording, including medications taken by the 
mother if the infant is breast feeding.  Prior medications include all prescription and 
over-the-counter medications being taken by the patient (and lactating mother, if 
patient is breast fed) for the 2 weeks prior to study entry;

Vital signs (temperature, respiratory rate, pulse and blood pressure, by the appropriate 
method for the patient’s age).  To be performed before the ECG;

ECG (to be performed prior to obtaining blood samples for laboratory testing);

Record radiologic examinations;

AEs and SAEs to be collected from the time of provision of informed consent/assent;

Complete blood count with differential, Direct Coombs test, chemistry panel, CrCl 
calculation, ESR (if clinically indicated or if required per standard of care), and 
optional CRP.  Note: Laboratory tests indicated at Baseline do not need to be repeated 
if they were performed within 24 hours of the Baseline visit, unless clinically 
indicated.  C-reactive protein is an optional test and may be included if part of 
standard of care.  C-reactive protein and CrCl calculation may be repeated at 
additional time points if clinically indicated. Additionally, in instances of rapidly 
changing renal function, the Investigator should increase the frequency of CrCl 
monitoring, depending on the patient’s clinical status, extent of renal function change
and the Investigator’s clinical evaluation.  Test results of any samples taken as 
standard of care should be recorded in the CRF;
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 47

Urine or serum pregnancy test applicable only to female patients who have reached 
menarche or have reached Tanner stage 3 development (even if not having reached 
menarche).  If a pregnancy test is positive post-baseline, follow reporting 
requirements in Section 6.5.1.  Note: if the result of the serum β-hCG test cannot be 
obtained prior to dosing of IP, a patient may be enrolled on the basis of a negative 
urine pregnancy test, though a serum β-hCG test result must still be obtained;

Urine sample for routine analysis before administration of any antibiotics;

Urine culture (before administration of any antibiotics);

Blood sample for culture (if clinically indicated and not already collected per standard 
of care);

Randomisation via IXRS only after verification of all inclusion and exclusion criteria.
4.2. Treatment period
The procedures for this period are listed in the Study Plan (Table 1). Details of study 
assessments are provided in Section 5.  
4.2.1. Day 1
Day 1 is the first day of IV study drug administration; subsequent study days are consecutive 
days.  Day 1 assessments should be performed after administration of at least 1 dose of IV 
study drug.  The following will be performed: 

IV study drug administration: CAZ-AVI or cefepime; see Section 7.2 for dosing and 
treatment regimens;

Recording of concomitant medications, including mother if patient is breast fed;

Vital signs (to be performed before the ECG);

ECG within 30 minutes following the end of the first study treatment infusion;

Recording of any adjunctive therapeutic procedures performed;

If clinically indicated: CrCl calculation, urine sample for routine analysis, blood 
sample for culture, ESR, CRP (optional), weight (if feasible). Additionally, in 
instances of rapidly changing renal function, the Investigator should increase the 
frequency of CrCl monitoring, depending on the patient’s clinical status, extent of 
renal function change and the Investigator’s clinical evaluation.  Test results of any 
samples taken as standard of care should be recorded in the CRF;

Recording of any AEs/SAEs.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 48
4.2.2. Days 2 and 3
The following will be performed: 

IV study drug administration;

Complete physical examination after completion of 72 hours’ treatment only.  This 
assessment may be performed on Day 4, depending on the timing of treatment 
administration.  Assessment should be performed no later than 8 hours after the 
72-hour time point;

Recording of concomitant medications, including mother if patient is breast fed;

Vital signs;

Recording of any adjunctive therapeutic procedures performed;

Assessment of clinical outcome after 72 hours’ treatment. Assessment should be 
performed no later than 8 hours after the 72-hour time point (assessment is not 
required on Day 2).  See Section 8.5.2.2 for definitions of clinical outcomes;

Recording of any AEs/SAEs;

If clinically indicated: CrCl calculation, urine sample for routine analysis, blood 
sample for culture, ESR, CRP (optional), weight (if feasible). Additionally, in 
instances of rapidly changing renal function, the Investigator should increase the 
frequency of CrCl monitoring, depending on the patient’s clinical status, extent of 
renal function change and the Investigator’s clinical evaluation.  Test results of any 
samples taken as standard of care should be recorded in the CRF;

Blood sampling for PK analysis from patients randomised to CAZ-AVI treatment on 
Day 3 only.  To be performed following a dose administration that is convenient for 
the plasma sample collections at the following time points: anytime within 15 minutes 
prior to or after stopping CAZ-AVI infusion, anytime between 30 minutes and 
90 minutes after stopping CAZ-AVI infusion, and anytime between 300 minutes 
(5 hours) and 360 minutes (6 hours) after stopping CAZ-AVI infusion.  Every attempt 
should be made to obtain at least 1 sample from each of the 3 time windows for each 
patient.
4.2.3. Days 4 to ≤14
On Days 4 to ≤14, study drug administration applies to all patients and daily assessments are 
to be performed only for patients on IV study drug.  Patients will receive IV treatment for a 
minimum of 72 hours (3 full days, ie, 9 doses if given 3 times daily, or 6 doses if given twice 
daily) before having the option to switch to an oral therapy as specified in Section 7.7 below.  
The decision to switch to oral therapy is entirely at the Investigator’s discretion, if the patient 
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 49
has good or sufficient clinical response, and the patient is tolerating oral fluids or food.  
Patients can continue to take IV CAZ-AVI up to Day 14.  The following will be performed: 

IV study drug or oral switch therapy administration;

Complete physical examination after completion of 72 hours’ treatment only.  This 
assessment may be performed on Day 3, depending on the timing of treatment 
administration.  Assessment should be performed no later than 8 hours after the 
72-hour time point;

Recording of concomitant medications, including mother if patient is breast fed;

Vital signs;

Recording of any adjunctive therapeutic procedures performed;

Recording of any AEs/SAEs;

Complete blood count with differential, chemistry panel, and CrCl calculation to be 
conducted on Day 7 if the patient is still receiving IV study drug at that time;  

If clinically indicated: urine sample for routine analysis, blood sample for culture, 
ESR, CRP (optional), weight (if feasible). Additionally, in instances of rapidly 
changing renal function, the Investigator should increase the frequency of CrCl 
monitoring, depending on the patient’s clinical status, extent of renal function change
and the Investigator’s clinical evaluation.  Test results of any samples taken as 
standard of care should be recorded in the CRF.
4.2.4. End of IV treatment 
EOIV assessments should be performed in person by the Blinded Observer within 24 hours 
after completion of the last infusion of study drug or at the time of premature discontinuation 
of study drug or early withdrawal from study (if on IV study drug).  The EOIV assessments 
should be conducted in place of the regular study visit (eg, Days 4 to ≤14) assessments that 
would have been performed the day of that visit.  A patient may be eligible to switch to oral 
therapy on or after Day 4 (Section 7.2); EOIV assessments must occur before starting oral 
switch therapy.  The following will be performed: 

Complete physical examination;

Recording of concomitant medications, including mother if patient is breast fed;

Vital signs;

Recording of any adjunctive therapeutic procedures performed;
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017

If clinically indicated: urine sample for routine analysis, blood sample for culture, 
ESR, CRP (optional), weight (if feasible).  Additionally, in instances of rapidly 
changing renal function, the Investigator should increase the frequency of CrCl 
monitoring, depending on the patient’s clinical status, extent of renal function change
and the Investigator’s clinical evaluation.  Test results of any samples taken as 
standard of care should be recorded in the CRF;

Assessment of clinical outcome;

Recording of any AEs/SAEs;

Complete blood count with differential, chemistry panel, and CrCl calculation.  If 
EOIV occurs within 48 hours after these assessments are performed on Study Day 7, 
these assessments should not be repeated;

Urine culture;

Oral switch therapy administration.
4.2.5. End of Treatment (oral switch therapy)
The assessments at EOT should be performed in person within 48 hours after the last dose of 
oral switch therapy or at the time of premature discontinuation of oral switch therapy or early 
withdrawal from study (if on oral switch therapy).  If a patient does not switch to oral 
therapy, the EOIV assessments should be conducted instead of the EOT assessments.  For 
patients receiving oral switch therapy only, the following will be performed: 

Complete physical examination;

Recording of concomitant medications, including mother if patient is breast fed;

Vital signs;

Recording of any adjunctive therapeutic procedures performed;

If clinically indicated: CrCl calculation, urine sample for routine analysis, blood 
sample for culture, ESR, CRP (optional), weight (if feasible). Additionally, in 
instances of rapidly changing renal function, the Investigator should increase the 
frequency of CrCl monitoring, depending on the patient’s clinical status, extent of 
renal function change and the Investigator’s clinical evaluation.  Test results of any 
samples taken as standard of care should be recorded in the CRF;

Assessment of clinical outcome;

Recording of any AEs/SAEs.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 51

Urine culture
4.3. Follow-Up Period
The procedures for this period are listed in the Study Plan (Table 1).  Details of study 
assessments are provided in Section 5.
4.3.1. Test of Cure
The assessments at the TOC visit should be performed in person 8 to 15 days after last dose 
of any study drug (IV or oral).  The following will be performed:

Complete physical examination;

Recording of concomitant medications, including mother if patient is breast fed;

Vital signs;

ECG (to be performed after the vital signs);

Recording of any adjunctive therapeutic procedures performed;

If clinically indicated: urine sample for routine analysis, blood sample for culture, 
ESR, CRP (optional), weight (if feasible). Additionally, in instances of rapidly 
changing renal function, the Investigator should increase the frequency of CrCl 
monitoring, depending on the patient’s clinical status, extent of renal function change
and the Investigator’s clinical evaluation.  Test results of any samples taken as 
standard of care should be recorded in the CRF;

Assessment of clinical outcome;

Recording of any AEs/SAEs;

Complete blood count with differential, chemistry panel, and CrCl calculation to be 
performed only if the patient had an abnormal (high or low) result at or after EOIV;  

Direct Coombs test;

Serum pregnancy test;

Urine culture.
4.3.2. Late Follow-up
Assessments at LFU should be performed 20 to 36 days after last dose of any study drug (IV 
or oral).  The LFU visit may be conducted via telephone for any patient who has not 
experienced clinical relapse, did not have ongoing AEs or SAEs at TOC, or did not develop 
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 52
AEs or SAEs since TOC.  If symptoms of relapse or new AEs or SAEs are noted, or at the 
discretion of the Blinded Observer or Investigator, the patient should be immediately 
scheduled for an in-person visit.  The following will be assessed at LFU: 

Complete physical examination (not applicable if visit conducted by telephone);

Recording of concomitant medications, including mother if patient is breast fed;

Vital signs (not applicable if visit conducted by telephone);

Recording of any adjunctive therapeutic procedures performed;

If clinically indicated: CrCl calculation, urine sample for routine analysis, blood 
sample for culture, ESR, CRP (optional), weight (if feasible). Additionally, in 
instances of rapidly changing renal function, the Investigator should increase the 
frequency of CrCl monitoring, depending on the patient’s clinical status, extent of 
renal function change and the Investigator’s clinical evaluation.  Test results of any 
samples taken as standard of care should be recorded in the CRF;

Assessment of clinical relapse;

Recording of any AEs/SAEs;

Urine culture.
5. STUDY ASSESSMENTS  
Every effort should be made to ensure that the protocol-required tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may be 
circumstances outside of the control of the investigator that may make it unfeasible to 
perform the test.  In these cases the investigator will take all steps necessary to ensure the 
safety and well-being of the subject.  When a protocol-required test cannot be performed, the 
investigator will document the reason for this and any corrective and preventive actions that 
he or she has taken to ensure that normal processes are adhered to as soon as possible.  The 
study team will be informed of these incidents in a timely manner.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 53
5.1. Efficacy Assessments
Clinical outcome, relapse, and emergent infections will be assessed by the Blinded Observer 
at the time points specified in Table 1.  The Blinded Observer will assess clinical outcome, 
(including at LFU, assessment of patients for clinical relapse) and collection and reporting of 
AEs and SAEs from signing of the ICF (and Assent Form if applicable) until at least 30 days 
after any dose of study drug (IV or oral) or LFU. 
5.2. Microbiological Assessments
Culture and organism identification should be performed at the local or regional laboratory, 
as applicable.  Susceptibility testing should be done at the local or regional laboratory to 
support patient care.  All isolates should be sent to the central laboratory for organism 
identification and susceptibility testing.
Refer to the study-specific clinical and microbiology laboratory manual for specific 
procedures pertaining to the collection, processing, storage, and shipment of blood and urine 
culture samples or isolates.
5.2.1. Urine Samples For Microbiological Analysis And Culture
Urine samples should be obtained for culture and routine quantitative analysis (including 
microscopic examination) at Baseline (before any antibiotics are administered) and at EOIV, 
EOT, TOC, and LFU.  Cultures should be repeated per standard of care upon knowledge of a 
positive result until sterilisation is confirmed.  
5.2.2. Blood Samples For Microbiological Analysis And Culture
If clinically indicated, blood samples (1 mL) may be obtained for culture and routine analysis 
(including microscopic examination) at Baseline (before any antibiotics are administered) 
and at any time until LFU.  
This protocol complies with European Union’s recommendations for blood loss associated 
with paediatric research (European Commission 2008)1 and the World Health Organisation 
guidelines “Blood Sample Volumes in Child Health Research: Review of Safe Limits” 
(Howie 2011).2  To minimise risk from blood loss associated with this study, standard of care 
laboratory results will be used whenever possible.  In addition, paediatric blood collection 
tubes will be used and capillary methods of blood draw will be implemented whenever 
feasible.  PK samples will be collected from patients unless deemed unsafe due to the risk 
from additional blood loss (per the Investigator’s judgment).
5.3. Safety Assessments
5.3.1. Laboratory Safety Assessments
Blood and urine samples for determination of clinical chemistry, haematology, and urinalysis 
will be taken at the times indicated in Table 1.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 54
The following laboratory variables will be measured:
Table 2.
Laboratory Safety Parameters
Comprehensive Metabolic 
Panel 
Haematology
Urinalysis
Magnesium
Haematocrita
Urinalysis (routine and 
microscopy) will be 
performed according to the 
study centre’s standard 
procedures
Bicarbonate
Haemoglobin
Sodium
Erythrocyte count
Potassium
Mean cell volume
Phosphorus
Leukocyte count (WBC)
Chloride
Neutrophils
Calcium
Lymphocytes
Alkaline phosphatase
Monocytes
Gamma glutamyltransferase
Eosinophils
ALT
Basophils
AST
Platelets
Creatine kinase
Immunohaematology
Lactate dehydrogenase
Coombs test (direct)
Total bilirubin
Pregnancy testing
Indirect bilirubin
Serum β-hCG (females only)
Glucose, non-fasting
Inflammation index
Creatinine
CRP (optional)
Blood urea nitrogen
Erythrocyte sedimentation 
rateb
Note: any other laboratory parameter that is deemed to be important as per local practices can be assessed if 
considered necessary, but will not be part of the required laboratory parameters as per protocol.  Assessment of 
any additional laboratory parameters should not impact the blood volume to be drawn.
a.
If a patient’s haemoglobin or haematocrit decreases significantly (in the Investigator’s judgment) after 
administration of the CAZ-AVI infusion, a workup for haemolytic anaemia should be performed per standard of 
care.   
b.
To be collected if clinically indicated or if required per standard of care.
Additional safety samples may be collected if clinically indicated at the discretion of the 
Investigator.  The date, time of collection and results (values, units and reference ranges) will 
be recorded on the appropriate CRF.
The clinical chemistry, haematology and urinalysis will be performed at a local laboratory at 
or near to the Investigator site.  Sample tubes and sample sizes may vary depending on 
laboratory method used and routine practice at the site.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 55
The Direct Coombs test is required at Baseline and TOC only. 
The Investigator should make an assessment of the available results with regard to clinically 
relevant abnormalities.  The laboratory results should be signed and dated and retained at 
centre as source data for laboratory variables.  For information on how AEs based on 
laboratory tests should be recorded and reported, see Section 6.1.1.
NB. If a patient shows an AST or ALT ≥3×ULN or total bilirubin ≥2×ULN please refer to 
Appendix D for further instructions.
Creatinine clearance will be measured at Baseline and at each time that serum creatinine is 
being assessed as part of the clinical chemistry panel using the child’s measured height 
(length) and serum creatinine within the updated “bedside” Schwartz formula (Schwartz et al 
2009).3 It is recommended that serum creatinine, and therefore CrCl obtained using the 
Schwartz bedside formula, are assessed at additional time points if the Investigator deems 
that the test is required for the safety of the patient, based on previous results and the 
patient’s clinical condition, and if the additional test(s) does not exceed the maximum 
volume of blood allowed per protocol.  The Investigator should also consider the balance of 
the risk and benefit of taking additional samples when making the decision.  If a 
biochemistry panel is requested and serum creatinine can be added and evaluated without 
increasing the volume of blood allowed per protocol, the site should record the result in the 
CRF.  Note: measurement of height is not required at each point that CrCl is estimated: 
CrCl (mL/min/1.73m2)=0.413×height (length) (cm)/serum creatinine (mg/dL)
If there is a significant reduction (according to the Investigator) in a patient’s estimated CrCl 
during the treatment period, the Investigator should contact the Medical Monitor for 
discussion.
5.3.2. Physical Examination
A complete physical examination will be performed and will include an assessment of the 
following: general appearance, skin, head and neck  (including ears, eyes, nose and throat), 
lymph nodes, thyroid, respiratory, cardiovascular, abdomen, musculoskeletal (including 
spine and extremities) and neurological systems. Height and weight will be measured at 
Baseline only.  Weight may be measured at subsequent time points if clinically indicated and 
feasible.  Body mass index (BMI) (kg/m2) will be calculated as the ratio of weight in 
kg/(height in cm/100)2.  BMI will only be calculated at Baseline (Day -1/Day 1).  BMI will 
not be calculated for children <2 years of age (Cohorts 4a and 4b) as BMI is not considered a 
screening tool for healthy weight in children <2 years of age.  Tanner staging of development 
(refer to Appendix E for further details on Tanner staging) will be assessed at screening only 
(Day 1/Day1) for females who have not reached menarche but may reasonably have the 
potential to become pregnant.  
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 56
5.3.3. Electrocardiogram
A single 12-lead (or as appropriate per Investigator decision) ECG recording will be 
performed at the times indicated in Table 1.  At Baseline, the ECG will be performed prior to 
obtaining blood samples for laboratory testing.  The Day 1 ECG will be performed within 
30 minutes following the end of the first study treatment infusion.  Electrocardiograms will 
be taken after the patient has been resting in a recumbent position for at least 10 minutes.  
The results for the ECG will be paper reports provided locally for safety review by the 
Investigator.  
Each ECG will be interpreted as appropriate for the patient’s age.
5.3.4. Vital Signs
Vital signs will be measured as required as well as at the time intervals indicated in Table 1
before the ECG on the days when both assessments are indicated.  On days when more than 
1 vital signs assessment is performed as part of the standard of care for the patient, the first 
set of vital sign measurements for the day and the highest temperature of the day should be 
recorded in the CRF. 
5.3.4.1. Pulse and blood pressure
Supine blood pressure and pulse rate will be measured.  The patients will be required to rest 
in the supine position for at least 10 minutes prior to heart rate and blood pressure 
measurements.  For timings of vital signs assessments refer to Table 1.
5.3.4.2. Body Temperature
Body temperature will be measured in degrees Celsius using an automated thermometer at 
the times indicated in Table 1 and the actual time of body temperature collection will be 
recorded.  For each individual patient, the method of temperature measurement (oral, rectal, 
temporal, axillary, or tympanic, as appropriate) ideally should be consistent for the duration 
of the study.  
5.3.4.3. Respiratory Rate
Respiratory rate will be measured in breaths per minute at the times indicated in Table 1.
5.3.4.4. Adverse Events
Adverse events will be collected at Baseline, throughout the Treatment Period, and at EOT, 
TOC and LFU.  AEs and SAEs are defined in Sections Section 6.1.4 and Section 6.1.4.1 and, 
respectively.  AEs will be collected and reported as described in Section 6.1.4.2.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 57
5.3.5. Cephalosporin Class Effects
In addition to AE and SAE monitoring as described in Section 6, cephalosporin class effects 
and additional AEs will also be closely monitored (including, but not limited to seizures, 
C. difficile-associated diarrhoea, allergic reactions, hepatic abnormalities, haemolytic 
anaemia and changes in renal function).
5.4. Other Assessments
Medical and surgical history and prior and concomitant medications will be recorded at 
Baseline and, if applicable, during the study according to Table 1.  See Section 7.8 for further 
details on concomitant medications. Serum β-hCG pregnancy tests will be performed at 
Baseline and TOC in female patients who have reached menarche or have reached Tanner 
stage 3 development.  If the result of the serum β-hCG test cannot be obtained prior to dosing 
of investigational product, a urine pregnancy test may be done at Baseline though a serum 
β-hCG test result must still be obtained.
If performed, adjunctive therapeutic procedures will be recorded throughout the treatment 
period until TOC. 
Radiological examinations are not required for the study, but the results should be recorded if 
done as part of the diagnosis.  Radiological examinations include WBC scans, plain 
abdominal radiographs, CT scans, voiding cystourethrogram, ultrasound and/or MRI scans 
with or without contrast.    
5.5. Pharmacokinetics
5.5.1. Collection of Samples
Blood samples (1 mL per sample for Cohorts 1 and 2, and 0.5 mL per sample for Cohorts 3, 
4a, and 4b) for determination of ceftazidime and avibactam in plasma will be taken at the 
times presented in Table 1 in a manner such that the Blinded Observer remains blinded (ie, 
the Investigator should collect the samples).  The date and time of sample collection will be 
recorded, as well as the date and time of the dose of IV study therapy immediately preceding 
the sample collection.
Samples will be collected, labelled, stored and shipped as detailed in the Laboratory Manual. 
5.5.2. Determination Of Drug Concentration
Samples for determination of ceftazidime and avibactam concentration in plasma will be 
analysed by Covance on behalf of Sponsor, using an appropriate bioanalytical method.  Full 
details of the analytical method used will be described in a separate bioanalytical report.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 58
5.5.3. Storage and Destruction Of Pharmacokinetic Samples
Pharmacokinetic samples will be disposed of after the Bioanalytical Report finalisation 
or 6 months after issuance of the draft Bioanalytical Report (whichever is earlier), unless 
requested for future analyses.
Pharmacokinetic samples may be disposed of or destroyed or anonymised by pooling.
Additional analyses may be conducted on the anonymised, pooled PK samples to further 
evaluate and validate the analytical method. Any results from such analyses may be reported 
separately from the Clinical Study Report (CSR).
Incurred sample reproducibility analysis, if any, will be performed alongside the bioanalysis 
of the test samples.  The results from the evaluation will not be reported in the CSR but 
separately in a Bioanalytical Report.
5.6. Pharmacodynamics Not Applicable
5.7. Pharmacogenetics Not Applicable
5.8. Biomarker Analysis Not Applicable
5.9. Volume Of Blood
The minimum total volume of blood that will be drawn from each patient in the study is 
displayed in Table 3 for Cohorts 1 and 2, Table 4 for Cohorts 3, 4a, and 4b.  Assessments 
that are to be performed if clinically indicated and are not mandated by the protocol are not 
included in the tables below.  The combined volume of all blood samples taken from a 
subject by the end of the study for investigational laboratory tests (ie, complete blood count 
with differential, chemistry panel, Direct Coombs test, pregnancy testing, and PK analyses) is 
to be no more than 2.4 cc/kg. Any deviation from this should be clinically justified.
Table 3.
Volume of Blood Per Patient – Cohorts 1 and 2
Blood 
Volume 
(mL)
Day
Baseline
Day 3
EOIV
TOC
Totals 
(minimum 
blood 
volume)
Chemistry
2
2
2
6
Haematology
0.75
0.75
0.75
2.25
Direct
Coombs
1.5
1.5
3
Serum 
pregnancy
2
2
4
PK
3
3
Totals
6.25
3
2.75
6.25
18.25
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 59
Table 4.
Volume Of Blood Per Patient – Cohorts 3, 4a, and 4b
Blood 
Volum
e (mL)
Day
Baseline
Day 3
EOIV
TOC
Totals 
(minimum 
blood 
volume)
Chemistry
2
2
2
6
Haematology
0.75
0.75
0.75
2.25
Direct
Coombs
1.5
1.5
3
Serum 
pregnancy
0
PK
1.5
1.5
Totals
4.25
1.5
2.75
4.25
12.75
6. ADVERSE EVENT REPORTING AND MEDICAL MANAGEMENT
The Principal Investigator is responsible for ensuring that all staff involved in the study are 
familiar with the content of this section.
6.1. Requirements
The table below summarizes the requirements for recording safety events on the CRF and for 
reporting safety events on the Clinical Trial (CT) Serious Adverse Event (SAE) Report Form 
to Pfizer Safety.  These requirements are delineated for 3 types of events: (1) SAEs; (2) 
non-serious adverse events (AEs); and (3) exposure to the investigational product under 
study during pregnancy or breastfeeding, and occupational exposure.  
Safety Event
Recorded on the CRF
Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours of 
Awareness
SAE
All
All
Non-serious AE
All
None
Exposure to the 
investigational product 
under study during 
pregnancy or 
breastfeeding, and 
occupational exposure
All (regardless of whether 
associated with an AE), 
except occupational 
exposure
Exposure during pregnancy, 
exposure via breastfeeding, 
occupational exposure 
(regardless of whether 
associated with an AE)
All observed or volunteered events regardless of suspected causal relationship to the 
investigational product(s) will be reported as described in the following paragraphs.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 60
Events listed in the table above that require reporting to Pfizer Safety on the CT SAE Report 
Form within 24 hours of awareness of the event by the investigator are to be reported 
regardless of whether the event is determined by the investigator to be related to an 
investigational product under study.  In particular, if the SAE is fatal or life-threatening, 
notification to Pfizer Safety must be made immediately, irrespective of the extent of available 
event information.  This time frame also applies to additional new (follow-up) information on 
previously forwarded reports.  In the rare situation that the investigator does not become 
immediately aware of the occurrence of an event, the investigator must report the event 
within 24 hours after learning of it and document the time of his/her first awareness of the 
event.
For each event, the investigator must pursue and obtain adequate information both to 
determine the outcome and to assess whether it meets the criteria for classification as an SAE 
(see the Serious Adverse Events section below).  In addition, the investigator may be 
requested by Pfizer Safety to obtain specific follow-up information in an expedited fashion.  
This information is more detailed than that recorded on the CRF.  In general, this will include 
a description of the event in sufficient detail to allow for a complete medical assessment of 
the case and independent determination of possible causality.  Any information relevant to 
the event, such as concomitant medications and illnesses, must be provided.  In the case of a 
subject death, a summary of available autopsy findings must be submitted as soon as possible 
to Pfizer Safety.  Any pertinent additional information must be reported on the CT SAE 
Report Form; additional source documents (eg, medical records, CRF, laboratory data) are to 
be sent to Pfizer Safety ONLY upon request.
As part of ongoing safety reviews conducted by the Sponsor, any non-serious AE that is 
determined by the Sponsor to be serious will be reported by the Sponsor as an SAE.  To 
assist in the determination of case seriousness, further information may be requested from the 
investigator to provide clarity and understanding of the event in the context of the clinical 
study.
6.1.1. Additional Details On Recording Adverse Events on the CRF
All events detailed in the table above will be recorded on the AE page(s) of the CRF.  It 
should be noted that the CT SAE Report Form for reporting of SAE information is not the 
same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical 
terminology and the same AE term should be used on both the CRF and the CT SAE Report 
Form for reporting of SAE information.
6.1.2. Eliciting Adverse Event Information
The investigator is to record on the CRF all directly observed AEs and all AEs spontaneously 
reported by the parent(s)/legal guardian/legally acceptable representative.  In addition, each 
parent(s)/legal guardian/legally acceptable representative will be questioned about the 
occurrence of AEs in a non-leading manner.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 61
6.1.3. Withdrawal From the Study Due to Adverse Events 
Withdrawal due to AEs should be distinguished from withdrawal due to other causes, 
according to the definition of AE noted below, and recorded on the CRF.  
When a subject withdraws from the study because of an SAE, the SAE must be recorded on 
the CRF and reported, as appropriate, on the CT SAE Report Form, in accordance with the 
Requirements section above.
6.1.4. Time Period for Collecting AE/SAE Information
The time period for actively eliciting and collecting AEs and SAEs (“active collection 
period”) for each subject begins from the time the subject provides informed consent, which 
is obtained before the subject’s participation in the study (ie, before undergoing any 
study-related procedure and/or receiving investigational product), through and including the 
LFU visit.
For subjects who are screen failures, the active collection period ends when screen failure 
status is determined.
6.1.4.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a subject during the active collection period are reported to Pfizer 
Safety on the CT SAE Report Form.
SAEs occurring in a subject after the active collection period has ended are reported to Pfizer 
Safety if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility of being related to investigational 
product must be reported to Pfizer Safety.
Follow up by the investigator continues throughout and after the active collection period and 
until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and 
Pfizer concurs with that assessment.
6.1.4.2. Recording Non-serious AEs and SAEs on the CRF
During the active collection period, both non-serious AEs and SAEs are recorded on the 
CRF.
Follow-up by the investigator may be required until the event or its sequelae resolve or 
stabilize at a level acceptable to the investigator, and Pfizer concurs with that assessment.
6.1.5. Causality Assessment
The investigator’s assessment of causality must be provided for all AEs (serious and 
non-serious); the investigator must record the causal relationship on the CRF, and report such 
an assessment in accordance with the SAE reporting requirements, if applicable.  An 
investigator’s causality assessment is the determination of whether there exists a reasonable 
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
possibility that the investigational product caused or contributed to an AE; generally the facts 
(evidence) or arguments to suggest a causal relationship should be provided.  If the 
investigator does not know whether or not the investigational product caused the event, then 
the event will be handled as “related to investigational product” for reporting purposes, as 
defined by the Sponsor.  If the investigator's causality assessment is “unknown but not 
related” to investigational product, this should be clearly documented on study records.  
In addition, if the investigator determines that an SAE is associated with study procedures, 
the investigator must record this causal relationship in the source documents and CRF, and 
report such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
6.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities
AE reporting, including suspected unexpected serious adverse reactions, will be carried out 
in accordance with applicable local regulations.
6.2. Definitions
6.2.1. Adverse Events
An AE is any untoward medical occurrence in a study subject administered a product or 
medical device; the event need not necessarily have a causal relationship with the treatment 
or usage.  Examples of AEs include, but are not limited to: 

Abnormal test findings;

Clinically significant signs and symptoms;

Changes in physical examination findings;

Hypersensitivity;

Progression/worsening of underlying disease;

Drug abuse;

Drug dependency.
Additionally, AEs may include signs and symptoms resulting from:

Drug overdose;

Drug withdrawal;

Drug misuse; 
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 63

Drug interactions;

Extravasation;

Exposure during pregnancy (EDP);

Exposure via breastfeeding;

Medication error;

Occupational exposure.
6.2.2. Abnormal Test Findings
Abnormal objective test findings should be recorded as AEs when any of the following 
conditions are met: 

Test result is associated with accompanying symptoms; and/or

Test result requires additional diagnostic testing or medical/surgical intervention; 
and/or

Test result leads to a change in study dosing (outside of any protocol-specified dose 
adjustments) or discontinuation from the study, significant additional concomitant 
drug treatment, or other therapy; and/or

Test result is considered to be an AE by the investigator or Sponsor.
Merely repeating an abnormal test, in the absence of any of the above conditions, does not 
constitute an AE.  Any abnormal test result that is determined to be an error does not require 
recording as an AE.
6.2.3. Serious Adverse Events
A serious adverse event is any untoward medical occurrence at any dose that:

Results in death;

Is life-threatening (immediate risk of death);
a.
Requires inpatient hospitalization or prolongation of existing hospitalization.
note: patients will be hospitalised at study entry.  The initial hospitalisation that 
made the patient eligible for the study will not be considered an SAE but if the 
hospitalisation is prolonged due to an AE, the hospitalisation becomes an SAE).

Results in persistent or significant disability/incapacity (substantial disruption of the 
ability to conduct normal life functions);
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 64

Results in congenital anomaly/birth defect.
Or that is considered to be:

An important medical event.
Medical and scientific judgment is exercised in determining whether an event is an important 
medical event.  An important medical event may not be immediately life-threatening and/or 
result in death or hospitalization.  However, if it is determined that the event may jeopardize 
the subject or may require intervention to prevent one of the other AE outcomes, the 
important medical event should be reported as serious.
Examples of such events are intensive treatment in an emergency room or at home for 
allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; 
or development of drug dependency or drug abuse.
6.2.4. Hospitalization
Hospitalization is defined as any initial admission (even less than 24 hours) in a hospital or 
equivalent healthcare facility, or any prolongation of an existing admission.  Admission also 
includes transfer within the hospital to an acute/intensive care unit (eg, from the psychiatric 
wing to a medical floor, medical floor to a coronary care unit, or neurological floor to a 
tuberculosis unit).  An emergency room visit does not necessarily constitute a hospitalization; 
however, the event leading to the emergency room visit is assessed for medical importance.
Note: patients will be hospitalised at study entry.  The initial hospitalisation that made the 
patient eligible for the study will not be considered an SAE but if the hospitalisation is 
prolonged due to an AE, the hospitalisation becomes an SAE)
Hospitalization does not include the following:

Rehabilitation facilities;

Hospice facilities;

Respite care (eg, caregiver relief);

Skilled nursing facilities;

Nursing homes;

Same-day surgeries (as outpatient/same-day/ambulatory procedures).
Hospitalization or prolongation of hospitalization in the absence of a precipitating clinical 
AE is not in itself an SAE.  Examples include:
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017

Admission for treatment of a preexisting condition not associated with the 
development of a new AE or with a worsening of the preexisting condition (eg, for 
workup of a persistent pretreatment laboratory abnormality);

Social admission (eg, subject has no place to sleep);

Administrative admission (eg, for yearly physical examination);

Protocol-specified admission during a study (eg, for a procedure required by the study 
protocol);

Optional admission not associated with a precipitating clinical AE (eg, for elective 
cosmetic surgery);

Hospitalization for observation without a medical AE;

Preplanned treatments or surgical procedures.  These should be noted in the baseline 
documentation for the entire protocol and/or for the individual subject;
Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery, should not 
be reported as SAEs.  However, the medical condition for which the procedure was 
performed should be reported if it meets the definition of an SAE.  For example, an acute 
appendicitis that begins during the reporting period should be reported if the SAE 
requirements are met, and the resulting appendectomy should be recorded as treatment of the 
AE.
6.3. Severity Assessment
The investigator will use the adjectives MILD, MODERATE, or SEVERE to describe the 
maximum intensity of the AE.  For purposes of consistency, these intensity grades are 
defined as follows:
MILD
Does not interfere with subject's usual function.
MODERATE
Interferes to some extent with subject's usual function.
SEVERE
Interferes significantly with subject's usual function.
Note the distinction between the severity and the seriousness of an AE.  A severe event is not 
necessarily an SAE.  For example, a headache may be severe (interferes significantly with 
the subject's usual function) but would not be classified as serious unless it met one of the 
criteria for SAEs, listed above.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 66
6.3.1. Actions Required In Cases Of Increases In Liver Chemistry Values
The Investigator is responsible for, without delay, determining whether the patient meets 
potential Hy’s law criteria; AST or ALT ≥3×ULN and total bilirubin ≥2×ULN irrespective 
of the value of the patient’s alkaline phosphatase, at any point during the study following the 
start of study medication.  
A Hy’s Law case is defined as study patient with an increase in serum AST or ALT ≥3×ULN 
together with total bilirubin ≥2×ULN, where no other reason can be found to explain the 
combination of increases, eg, elevated serum ALP indicating cholestasis, viral hepatitis, or 
another drug.
For potential Hy’s Law and Hy’s Law the elevation in transaminases must precede or be 
coincident with (ie, on the same day) the elevation in total bilirubin, but there is no specified 
timeframe within which the elevations in transaminases and total bilirubin must occur.  
Details regarding the actions required in the cases of increases in ALT, AST, and total 
bilirubin can be found in Appendix D.  
If a patient reaches an ALT or AST=5×ULN, the patient may continue with the IP as planned 
unless discontinuation criteria as described in Section 3.9 are met.  The patient should be 
seen within 48 hours to instigate enhanced follow-up and monitoring.  Enhanced follow-up 
should include collection of clinical and historical information to determine the cause of ALT 
and/or AST elevations.  Additional testing for liver laboratory test results must be done every 
48 hours until the peak value has been reached as documented by a decline in the values 
and/or until the patient is feeling better.  The frequency of retesting can decrease to once per 
week or less if abnormalities stabilise or study drug has been discontinued and the patient is 
asymptomatic.  The patient should be followed until resolution (including laboratory testing).
6.4. Special Situations
There are no protocol-specified SAEs in this study.  All SAEs will be reported to Pfizer 
Safety by the investigator as described in previous sections, and will be handled as SAEs in 
the safety database. 
6.4.1. Medication Errors, and Lack of Efficacy
Other exposures to the investigational product under study may occur in clinical trial settings, 
such as medication errors and lack of efficacy.
Safety Event
Recorded on the CRF
Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours of 
Awareness
Medication errors and lack of 
efficacy
If associated with an AE
Only if associated with an 
SAE
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 67
6.4.1.1. Medication Errors
Medication errors may result from the administration or consumption of the investigational 
product by the wrong subject, or at the wrong time, or at the wrong dosage strength, or at the 
wrong infusion rate.  
Medication errors include:

Medication errors involving subject exposure to the investigational product;

Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the participating subject.
In the event of a medication dosing error, the Sponsor should be notified immediately.
When the medication error is accompanied by an AE, as determined by the investigator, the
associated AE(s), serious and non-serious, are recorded on an AE page of the CRF.
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE.
6.4.1.2. Lack of Efficacy
Lack of efficacy is reportable to Pfizer Safety only if associated with an SAE.
6.5. Overdose
Overdose is defined as a dose administered to a patient in excess of that specified in this 
protocol. Overdose does not automatically make an AE serious but if the consequences of 
the overdose are serious for example death or hospitalisation, the event is serious and should 
be reported as such.
Recording an overdose will be done according to the following:

An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE modules in the CRF and on the Overdose CRF module.

An overdose without associated symptoms is only reported on the Overdose CRF 
module.

If an overdose on an Pfizer IV study therapy occurs in the course of the study, then 
Investigators or other study centre personnel will inform appropriate Pfizer
representatives within 1 day, ie, immediately but no later than the end of the next 
business day from when he or she becomes aware of it.

The designated Pfizer representative works with the Investigator to ensure that all 
relevant information is provided to the Pfizer patient safety data entry site.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017

For overdoses associated with an SAE, standard reporting time lines apply, see 
Section. For other overdoses, reporting should be done within 30 days.
6.5.1. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact with the 
product, which may or may not lead to the occurrence of an AE.
An occupational exposure is reported to Pfizer Safety within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertain to a subject enrolled in the study, the 
information is not recorded on a CRF; however, a copy of the completed CT SAE Report 
Form is maintained in the investigator site file.
Occupational exposure also includes an exposure during pregnancy if:

A female becomes, or is found to be, pregnant while having been exposed (because of  
environmental exposure) to the investigational product; or the female becomes or is 
found to be pregnant after being exposed to the investigational product;

An example of environmental exposure would be a case involving direct contact 
with a Pfizer product in a pregnant woman (eg, a nurse reports that she is pregnant 
and has been exposed to chemotherapeutic products).

A male has been exposed (eg, environmental exposure) to the investigational product 
prior to or around the time of conception and/or is exposed during his partner’s 
pregnancy. 
The investigator must submit information regarding environmental exposure to a Pfizer 
product in a pregnant woman (eg, a subject reports that she is pregnant and has been exposed 
to a cytotoxic product by inhalation or spillage) to Pfizer Safety using the Exposure During 
Pregnancy (EDP) supplemental form.  This must be done irrespective of whether an AE has 
occurred and within 24 hours of awareness of the exposure.  The information submitted 
should include the anticipated date of delivery (see below for information related to 
termination of pregnancy).
Follow-up is conducted to obtain general information on the pregnancy and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy until 
completion (or until pregnancy termination) and notify Pfizer Safety of the outcome as a 
follow-up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrity of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clinically possible, the structural 
integrity of the terminated fetus should be assessed by gross visual inspection (unless 
pre-procedure test findings are conclusive for a congenital anomaly and the findings are 
reported).
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 69
Additional information regarding the EDP may be requested by the sponsor.  Further 
follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on 
preterm infants to identify developmental delays).  In the case of paternal exposure, the 
investigator will provide the subject with the Pregnant Partner Release of Information Form 
to deliver to his partner.  The investigator must document in the source documents that the
subject was given the Pregnant Partner Release of Information Form to provide to his 
partner.
6.6. Pregnancy
All pregnancies and outcomes of pregnancy should be reported to the Pfizer Drug Safety 
Department.
6.6.1. Maternal Exposure
If a patient becomes pregnant during the course of the study, IP should be discontinued 
immediately.
Pregnancy itself is not regarded as an AE unless there is a suspicion that the IP under study 
may have interfered with the effectiveness of a contraceptive medication.  Congenital 
abnormalities/birth defects and spontaneous miscarriages should be reported and handled as 
SAEs.  Elective abortions without complications should not be handled as AEs.  The 
outcome of all pregnancies (spontaneous miscarriage, elective termination, ectopic 
pregnancy, normal birth or congenital abnormality) should be followed up and documented 
even if the patient was discontinued from the study.
If any pregnancy occurs in the course of the study, then the Investigator or other site 
personnel informs the Pfizer Drug Safety Department immediately but no later than 
24 hours of when he or she becomes aware of it.
PRA works with the Investigator to ensure that all relevant information is provided to the 
Pfizer Drug Safety Department within 1 or 3 calendar days for SAEs (see Section 6.6) and 
within 30 days for all other pregnancies.
The same timelines apply when outcome information is available.
All outcomes of pregnancy should be reported to the Pfizer Drug Safety Department.  Any 
patient who becomes pregnant during the course of the study will be followed so that 
pregnancy outcome can be determined and reported to Pfizer and the regulatory authorities.
A pregnancy report form (electronic copy of the PREGREP form) will be used to report the 
pregnancy to the Pfizer Drug Safety Department. The outcome of the pregnancy will be 
reported on the pregnancy report form (paper copy of the PREGOUT form) and provided by 
site staff to the Pfizer Drug Safety Department, but the outcome of the pregnancy will not be 
documented in the clinical database.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 70
6.6.2. Paternal Exposure 
There is no restriction on fathering children or donating sperm during the study.  Pregnancy 
of the patient’s partner is not considered to be an AE.  However, the outcome of all 
pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, 
or congenital abnormality) should if possible be followed up and documented.  The outcome 
of any conception occurring from the date of the first IP administration until 7 days after the 
last IP administration should be followed up and documented.
6.7. Management of Investigational Product-Related Toxicities 
Clostridium difficile-associated diarrhoea has been reported with ceftazidime as with nearly 
all antibacterial agents, and may range in severity from mild diarrhoea to fatal colitis.  This is 
as a result of alteration of the normal flora of the colon by ceftazidime leading to overgrowth 
of C. difficile. If C. difficile-associated diarrhoea is suspected or confirmed, ongoing 
antibiotic use not directed against C. difficile may need to be discontinued.  Appropriate fluid 
and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and 
surgical evaluation should be instituted as clinically indicated.
Ceftazidime overdosage has occurred in patients with renal failure.  Reactions have included 
tremors, myoclonus, seizures, encephalopathy, and coma.  Patients who receive an acute 
overdosage should be carefully observed and given supportive treatment.  In the presence of 
renal insufficiency, haemodialysis or peritoneal dialysis may aid in the removal of 
ceftazidime from the body.  Continued dosage should be determined by degree of renal 
impairment, severity of infection, and susceptibility of the causative organisms. 
Cephalosporins may be associated with a fall in prothrombin activity.  Those at risk include 
patients with renal and hepatic impairment, or poor nutritional state, as well as patients 
receiving a protracted course of antimicrobial therapy.  Prothrombin time should be 
monitored in patients at risk and exogenous vitamin K administered as indicated.
6.8. Study Governance And Oversight
The safety of all Pfizer clinical studies is closely monitored on an on-going basis by the 
Sponsor representatives in consultation with Patient Safety.  Issues identified will be 
addressed; for instance this could involve amendments to the study protocol and letters to 
Investigators.
6.8.1. Data and Safety Monitoring Board
As this study is descriptive in nature, no interim or final inferential analyses will be 
performed for either efficacy or safety.  A Data and Safety Monitoring Board (DSMB) is 
deemed necessary since the trial has a long period of enrolment, is multicentre and 
multi-national, and represents one of the first safety and efficacy trials of CAZ-AVI in 
children.  
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 71
The DSMB is charged with reviewing and evaluating the study safety (AEs, SAEs, and 
potentially clinically significant laboratory results) at periodic intervals.  The DSMB
members will be familiarised with AEs and SAEs likely to occur in this patient population, 
based on experience in adults and adolescents, as well as with this class of drugs 
(cephalosporins).  The DSMB will conduct pre-planned and possibly ad hoc reviews of 
accumulating data.
Based on the findings of these reviews, the DSMB may make recommendations to Sponsor
regarding the study, including, but not limited to: continue the study without modification, 
modify the protocol or informed consent/assent document(s), or temporarily stop enrolment 
in all or some of the study centres.  The recommendations made by the DSMB to alter the 
conduct of the study will be forwarded to the Sponsor for final decision.  The Sponsor will 
forward such decisions, which may include summaries of aggregate analyses of endpoint 
events and of safety data that are not endpoints, to regulatory authorities, as appropriate. The 
Sponsor will be responsible for discussing and, if considered appropriate, implementing the 
DSMB recommendations.  Further details can be found in the DSMB charter.
7. INVESTIGATIONAL PRODUCT AND OTHER TREATMENTS
For the purposes of this study, and per International Conference on Harmonisation (ICH) 
guidelines, investigational product is defined as a pharmaceutical form of an active
ingredient or placebo being tested or used as a reference/comparator in a clinical trial, 
including a product with a marketing authorization when used or assembled (formulated or 
packaged) in a way different from the approved form, or when used for an unapproved 
indication, or when used to gain further information about an approved use (ICH E6 1.33).  
7.1. Identity of Investigational Product(s)
Investigational product
Dosage form and strength
CAZ-AVI
Ceftazidime avibactam powder for concentrate for solution 
for infusion 2000 mg/500 mg
Cefepime
Cefepime hydrochloride powder for solution for infusion 
1000 mg and 2000 mg to 50 mg/kg IV every 12 hours
CAZ-AVI and cefepime will be supplied centrally by Sponsor.  Kits containing the labelled 
vials will be provided to the study centre as an open label supply for reconstitution and 
dilution in accordance with the handling instructions.
Consult the product package insert, label, and local dosing guidelines for further information 
regarding dosage, administration, storage, maximum doses, contraindications, warnings, 
precautions, and AEs reported.
7.2. Dose And Treatment Regimens
The study is single blind, ie, a Blinded Observer will not know the patient’s treatment 
assignment and will conduct clinical assessments (including efficacy and safety).  There is no 
use of placebo to act as a treatment blind.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 72
The doses of CAZ-AVI are based on age and weight with adjustment according to renal 
function as detailed in Table 5.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 73
Table 5.
CAZ-AVI Doses By Age, Weight, And Creatinine Clearance
Cohort
Age range
Body 
weight
CAZ-AVI dose
CrCl ≥50 mL/min
CAZ-AVI dose
CrCl ≥30 to <50 mL/min
CAZ-AVI must be administered as a 50 to 100 mL infusion (dependent on dose) 
over 2 hours every 8 hours (±30 minutes)
11
12 years to 
<18 years
≥40 kg
2000 mg ceftazidime/500 mg avibactam
1000 mg ceftazidime/250 mg avibactam
11
12 years to 
<18 years
<40 kg
50 mg/kg ceftazidime/12.5 mg/kg 
avibactam
25 mg/kg ceftazidime/6.25 mg/kg 
avibactam
21
6 years to 
<12 years
≥40 kg
2000 mg ceftazidime/500 mg avibactam
1000 mg ceftazidime/250 mg avibactam
21
6 years to 
<12 years
<40 kg
50 mg/kg ceftazidime/12.5 mg/kg 
avibactam
25 mg/kg ceftazidime/6.25 mg/kg 
avibactam
31
2 years to 
<6 years
All
50 mg/kg ceftazidime/12.5 mg/kg 
avibactam
25 mg/kg ceftazidime/6.25 mg/kg 
avibactam
4a2
1 year to 
<2 years
All
50 mg/kg ceftazidime /12.5 mg/kg 
avibactam
25 mg/kg ceftazidime/6.25 mg/kg 
avibactam
4b2
6 months to 
<1 year
All
50 mg/kg ceftazidime/12.5 mg/kg 
avibactam
25 mg/kg ceftazidime/6.25 mg/kg 
avibactam
4b2
3 months to 
<6 months
All
40 mg/kg ceftazidime/10 mg/kg avibactam
20 mg/kg ceftazidime/5 mg/kg avibactam
1.
Patients considered for entry into the study will be within the normal range of BMI for their age, (2 to <18).  A healthy weight BMI for this age group falls between the 5th 
percentile and ≤95th percentile according to height, weight, and age.
2.
BMI will not be calculated for children <2 years of age as BMI is not considered a screening tool for healthy weight in children under 2 years of age.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 74
Full details of infusion preparation are given in the Pharmacy Manual.
Patients whose CrCl changes during treatment should receive the appropriate dose reduction 
or increase according to Table 5.
Patients whose CrCL drops below 30 mL/min should be withdrawn from study therapy.  
Patients withdrawing from study therapy can be administered alternative therapies at the 
Investigator’s choice, which should be recorded in the CRF.  If possible, patients should still 
be followed for safety (see Section 3.9.1).  Because the CrCl determination is only an 
estimate of renal function, in instances where the CrCl is approaching thresholds that would 
require intervention such as a dose change or discontinuation of therapy (ie CrCL 
approaching 50 or 30 mL/min), the Investigator should use his or her discretion in 
determining (ie confirming the value by repeat testing, if feasible) whether an immediate 
dose change, a short period of continued observation, or discontinuation of therapy is 
warranted. If in the opinion of the Investigator there is a clinically significant reduction in a 
patient’s estimated CrCl during the treatment period, then the Investigator should contact the 
Medical Monitor to discuss the above mentioned options (immediate dose change, a short 
period of continued observation, or discontinuation of therapy).  Additionally, in instances of 
rapidly changing renal function, the Investigator should increase the frequency of CrCl 
monitoring, depending on the patient’s clinical status, extent of renal function change and 
Investigator’s clinical evaluation.
Patients randomised to receive cefepime should receive the dose, schedule and infusion 
duration as recommended in the local prescribing information or as prescribed by the 
investigator.  The maximum dose of cefepime in any single infusion should not exceed 
2000 mg.
7.3. Labelling
Labels will be prepared in accordance with Good Manufacturing Practice and local 
regulatory guidelines.  Label text will be translated into the local language.
Personnel at the study centre will prepare and label the individual IV infusions as assigned by 
the IXRS, and according to the handling instructions.
7.4. Storage
All study drugs should be kept in a secure place under appropriate storage conditions.  The 
storage conditions will be stated on the study drug labelling and in the handling instructions.
7.5. Compliance
To ensure that the patient is compliant with administration of study drug, oral switch therapy, 
and study procedures, the date and dose of the medication should be recorded in the 
appropriate sections of the CRF.  The site will monitor patient compliance, which will be 
documented in the patient’s source documents, and relevant data will be reported in the CRF.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 75
7.6. Accountability
The study drug provided for this study will be used only as directed in the study protocol.
The study personnel will account for all study drugs dispensed to and returned from the 
patient.
The investigator site must maintain adequate records documenting the receipt, use, loss, or 
other disposition of the investigational product supplies.  Study site personnel, if applicable, 
or the PRA monitor will account for all study drugs received at the site, unused study drugs 
and for appropriate destruction.  Certificates of delivery, destruction, and return should be 
signed.  For general drug destruction (eg, left over drug at site), the investigator must ensure 
that the materials are destroyed in compliance with applicable environmental regulations, 
institutional policy, and any special instructions provided by the Sponsor, and all destruction 
must be adequately documented...  Therefore, where at all possible the IP should be 
destroyed locally at site and a third party supplier for return and destruction should only be 
used where specific country regulations or local procedures state this is not possible.  
Documentation should be provided by PRA or Sponsor identifying that this is the case. IP 
associated with a recall, Sponsor or its representative will determine what is to be destroyed, 
but PRA will manage the execution of destruction using standards acceptable to Sponsor or 
its representative.
7.7. Oral Switch Therapy
The choice of oral switch therapy, among the options listed below, should be in line with the 
approved and marketed drugs in the respective country, and should observe the local specific
regulations and local therapeutic guidelines (if existent), regarding posology.  The decision to 
switch to oral therapy is entirely at the Investigator’s discretion, if the patient has good or 
sufficient clinical response, and the patient is tolerating oral fluids or food.  For the optional 
oral switch therapy, the following should be given: 

Oral ciprofloxacin (only in countries where its use for children is permitted; 
according to local guidelines, administered at a dose and formulation per standard of 
care), or

Oral cefixime (only in countries where its use for children is permitted; according to 
local guidelines, administered at a dose and formulation per standard of care), or

Oral amoxicillin/clavulanic acid (only in countries where its use for children is 
permitted; according to local guidelines, administered at a dose and formulation per 
standard of care), or

Oral sulfamethoxazole/trimethoprim (only in countries where its use for children is 
permitted; according to local guidelines, administered at a dose and formulation per 
standard of care), or
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 76

Pathogen-based therapy (in discussion with the Medical Monitor).  The choice of oral 
antibacterial agent for pathogen-based therapy will be driven by the results of a 
susceptibility test, which will be provided to the Investigator by either the local or 
central laboratory.  Initiation of pathogen-based therapy is at the Investigator’s 
discretion.  Before administering pathogen-based therapy, the Investigator will 
discuss the results of the susceptibility test and the selected antibacterial drug (which 
should be approved for use in children) with the Medical Monitor.
The optional oral switch therapies will be sourced locally by the study centres or sourced as 
agreed between the study centres and PRA.
Consult the Summary of Product Characteristics or product package insert, label, and local 
dosing guidelines for further information regarding dosage, administration, storage, 
maximum doses, contraindications, warnings, precautions, and AEs reported.
7.8. Concomitant And Other Treatments
All prescription and over-the-counter medications being taken by the patients for the 2 weeks 
prior to study entry (considered prior treatment) and from enrolment through the LFU visit 
(considered concomitant treatment) must be documented on the appropriate pages of the 
CRF.  Systemic antibiotics should be documented for the entire duration of the study (from 
2 weeks prior to study entry through the LFU visit).  For patients who are being breast fed, 
all medications taken by the lactating mother in the previous 2 weeks before the first dose of 
study therapy until LFU will also be recorded.
Patients requiring systemic prophylactic antibiotic medication for any reason at Screening are 
allowed to enter the study provided that they discontinue this medication prior to first dose of 
randomised study treatment.  Prophylactic use is prohibited between the time point of first 
dose of study treatment and the EOT assessment.  Any violations of this will result in the
patient being assigned an “indeterminate” clinical response at all future clinical outcome 
assessments.  
Prophylactic use is permitted after EOT until study end and will not result in a change to the 
patient’s clinical outcome, provided that the patient had not previously violated the 
aforementioned prophylactic use criterion between first dose of study treatment and the EOT 
assessment.
In vitro, avibactam is a substrate of organic anion transporter (OAT) 1 and OAT3, which 
might contribute to the active uptake from the blood compartment and, thereby its excretion.
Probenecid (a potent OAT inhibitor) inhibits this uptake by 55% to 70% in vitro and, 
therefore, has the potential to alter the elimination of avibactam when co-dosed.  Since a 
clinical interaction study of avibactam and probenecid has not been conducted, co-dosing of 
avibactam with probenecid is not recommended.  Patients who meet protocol-specific criteria 
may be switched to oral ciprofloxacin (only in countries where its use for children is 
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 77
permitted, according to local guidelines) or cefixime after a minimum of 72 hours IV 
infusion of study therapy. 
No other oral, intramuscular, or IV concomitant antibacterial treatments are permitted while 
receiving study therapy at any time up to the LFU visit.  A patient requiring such 
antibacterial treatments other than the allowed study therapy for the treatment of the cUTI 
will be considered a treatment failure.
Other medication, which is considered necessary for the patient’s safety and well-being, may 
be given at the discretion of the Investigator and recorded in the appropriate sections of the 
CRF.  If analgesic medications are needed for pain, the use of analgesic medications without 
antipyretic properties is preferred.  Should a patient require immunosuppressive agents or 
chemotherapy after being randomised to IV study therapy, the Investigator should contact the 
PRA Medical monitor (as an Sponsor delegate) before initiating therapy.  Continued patient 
study participation will be determined based upon assessment of the safety risk to the patient 
if he or she was to continue in the study. Patients who have completed study therapy and are 
in the Follow-up Period should remain in the study, as they are not actively on study therapy 
but are being followed for outcomes.
A number of unfavourable reactions with other drugs are known for ceftazidime and 
ciprofloxacin.  Contraindications for these agents and known drug interactions are 
summarised in Table 6.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 78
Table 6.
Contraindications And Drug-Drug interactions
Ciprofloxacin
Administration in pregnant or lactating women is contraindicated.
Concurrent administration with tizanidine is contraindicated.
Concurrent administration with methotrexate is not recommended; methotrexate may inhibit renal tubular 
transport of ciprofloxacin, potentially leading to increased plasma levels of methotrexate and increased risk of
methotrexate-associated toxic reactions.
Concurrent administration with theophylline decreases theophylline clearance, resulting in elevated serum
theophylline levels and increased risk of a patient developing central nervous system or other adverse 
reactions.
Concurrent administration with caffeine or pentoxifylline (oxpentifylline) may raise serum concentrations of 
these xanthine derivatives.
Concurrent administration with antacids containing magnesium hydroxide or aluminium hydroxide may 
reduce the bioavailability of ciprofloxacin by as much as 90%.
Concurrent administration with probenecid interferes with renal secretion of ciprofloxacin and increases 
ciprofloxacin serum concentrations.
Concurrent administration with phenytoin may result in increased or reduced serum levels of phenytoin; 
monitoring of drug levels is recommended.
Concurrent administration with warfarin may augment its anticoagulant effects.  The risk may vary with the 
underlying infection, age, and general status of the patient so that the contribution of a fluoroquinolone to an 
increased INR is difficult to assess.  It is recommended that INR be monitored frequently during and shortly 
after co-administration of ciprofloxacin with an oral anticoagulant agent.
Concurrent administration with ropinirole increases the maximum plasma concentration of ropinirole by as 
much as 60%.  Monitoring of ropinirole-related side effects and dose adjustment as appropriate is 
recommended during and shortly after co-administration with ciprofloxacin.
Concurrent administration with clozapine increases serum concentrations of clozapine and 
N-desmethylclozapine, a metabolite, by as much as 29% and 31%, respectively.  Clinical surveillance and 
appropriate adjustment of clozapine dosage during and shortly after co-administration with ciprofloxacin are 
recommended.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 79
Ceftazidime
Concurrent administration with chloramphenicol should be avoided.  Chloramphenicol has been shown to be 
antagonistic to β-lactam antibiotics, including ceftazidime.
Concurrent administration with aminoglycoside antibiotics or potent diuretics such as furosemide may result 
in nephrotoxicity.  Because of potential nephrotoxicity and ototoxicity of aminoglycosidic antibiotics, renal 
function should be carefully monitored, especially if higher dosages of aminoglycosides are to be 
administered or if therapy is prolonged.
Concurrent administration with combined oral oestrogen/progesterone contraceptives may result in lower 
oestrogen reabsorption and reduced efficacy of these contraceptives secondary to the effects of ceftazidime on 
gut flora.
Cefixime
Administration in pregnant or lactating women is not recommended unless clearly indicated.
Concurrent administration with carbamazepine may result in increased plasma levels of carbamazepine; 
monitoring of drug levels is recommended. 
Concurrent administration with warfarin and anticoagulants may increase prothrombin time, with or without 
clinical bleeding.  It is recommended that international normalised ratio (INR) be monitored frequently during 
and shortly after co-administration of cefixime with an oral anticoagulant agent. 
Administration of cefixime may result in a false positive reaction for ketones in the urine with tests using 
nitroprusside but not with those using nitroferricyanide. 
Administration of cefixime may result in a false positive reaction for glucose in the urine using Clinitest®, 
Benedict’s solution, or Fehling’s solution.  It is recommended that glucose tests based on enzymatic glucose 
oxidase reactions (such as Clinistix or TesTape) be used.  A false positive direct Coombs test has been 
reported during treatment with other cephalosporins; therefore, it should be recognised that a positive Coombs 
test may be due to the drug.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 80
Amoxicillin-clavul
anic acid
Concurrent administration with probenecid decreases the renal tubular secretion of amoxicillin but does not 
delay renal excretion of clavulanic acid.  Concurrent use with amoxicillin-clavulanic acid may result in 
increased and prolonged blood concentrations of amoxicillin.  Co-administration of probenecid is not 
recommended.
Concurrent administration of amoxicillin with oral anticoagulants may result in abnormal prolongation of 
prothrombin time (increased INR).  Appropriate monitoring should be undertaken when anticoagulants are 
prescribed concurrently with amoxicillin-clavulanic acid.  Adjustments in the dose of oral anticoagulants may 
be necessary to maintain the desired level of anticoagulation.
Concurrent administration of allopurinol and amoxicillin increases the incidence of rashes in patients 
receiving both drugs as compared to patients receiving amoxicillin alone.
Concurrent administration of oral contraceptives and amoxicillin-clavulanic acid may affect intestinal flora, 
leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone 
contraceptives.
High urine concentrations of amoxicillin may result in false-positive reactions when testing for the presence 
of glucose in urine using Clinitest®, Benedict's solution, or Fehling's solution.  Since this effect may also 
occur with amoxicillin-clavulanic acid, it is recommended that glucose tests based on enzymatic glucose 
oxidase reactions be used.
Following administration of amoxicillin to pregnant women, a transient decrease in plasma concentration of 
total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted.
Sulfamethoxazole 
–
trimethoprim
Concurrent administration with ACE inhibitors may result in hyperkalaemia, possibly with cardiac 
arrhythmias or cardiac arrest.  Monitoring of serum potassium concentrations is recommended.
Concurrent administration with amantadine may cause toxic delirium. Monitoring patients for CNS adverse 
reactions is recommended.  If an interaction is suspected, it may be necessary to discontinue 1 or both drugs.
Concurrent administration with dofetilide is contraindicated.
Concurrent administration with cyclosporine may cause decreased therapeutic effect of cyclosporine and 
increased risk of nephrotoxicity.  Monitoring of cyclosporine blood or plasma concentrations, and serum 
creatinine concentrations is recommended. 
Concomitant administration with digoxin may increase plasma concentrations, especially in elderly patients. 
Monitoring of digoxin concentrations and dose adjustment as appropriate is recommended.
Concurrent administration with diuretics (eg, thiazides) may result in increased incidence of 
thrombocytopenia with purpura.  Monitoring of platelet count is recommended. If an interaction is suspected, 
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 81
it may be necessary to discontinue 1 or both agents.
Concurrent administration with alcohol may produce an alcohol intolerance reaction.  Patients receiving 
trimethoprim/sulfamethoxazole may be advised to avoid drinking alcohol and taking alcohol-containing 
medications.
Concurrent administration with Indomethacin may result in elevated sulfamethoxazole blood levels, 
increasing the pharmacologic effects and risk of adverse reactions. 
Concurrent administration with meglitinide may elevate meglitinide plasma concentrations, increasing the 
risk of hypoglycaemia.  Close monitoring of blood glucose after starting or stopping trimethoprim dose 
adjustment as appropriate is recommended. 
Methenamine is contraindicated for use with sulfonamides.
Concurrent administration with methotrexate may increase toxicity of methotrexate.  Trimethoprim may 
increase the risk of methotrexate-induced bone marrow suppression and megaloblastic anaemia. Monitoring 
hematologic status is recommended and lowering dose of methotrexate or higher leucovorin rescue dose may 
be needed. 
Concurrent administration with phenytoin may increase the pharmacologic effects and risk of toxicity.  
Monitoring of phenytoin concentrations and toxicity and dose adjustment as appropriate is recommended.
Concurrent administration with procainamide may increase the pharmacologic effects and risk of toxicity. 
Monitoring of procainamide and its metabolite, N-acetylprocainamide and cardiac function and dose 
adjustment as appropriate is recommended.
Concurrent administration with pyrimethamine may increase the risk of megaloblastic anaemia.  Assessment 
for haematologic and neurologic manifestations of megaloblastic anaemia, if an interaction is suspected, 
corrective treatment (eg, folic acid if indicated) and if necessary discontinuation of 1 or both drugs is 
recommended.
Concurrent administration with sulfones (eg, dapsone) may increase the pharmacologic effects and toxicity of 
both agents.  Monitoring plasma concentrations of both agents and patients for sulfone toxicity (eg, 
methemoglobinaemia) is recommended.  Adjust doses or discontinue therapy as necessary.
Concurrent administration with sulfonylureas may increase hypoglycaemic response.  Monitoring of blood 
glucose and dose adjustment as appropriate as needed is recommended.
Concomitant administration of thiazolidinediones (eg, pioglitazone) may increase the risk of hypoglycaemia 
and other adverse reactions.  Monitoring of blood glucose and for other adverse reactions, dose adjustment as 
appropriate is recommended.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
PFIZER CONFIDENTIAL
Page 82
Concurrent administration with tretinoin may augment phototoxicity, hence co-administration should be 
avoided. 
Concomitant tricyclic antidepressants (eg, amitriptyline) may decrease the efficacy of tricyclic 
antidepressants. Monitoring the response of the patient and dose adjustment as appropriate is recommended.
Concurrent administration with live vaccines is not recommended.
Concurrent administration with warfarin may increase anticoagulant effect of warfarin.  Monitoring of 
coagulation parameters and dose adjustment as appropriate is recommended.
Trimethoprim can interfere with serum methotrexate assay.  Trimethoprim/sulfamethoxazole may interfere 
with Jaffe alkaline picrate reaction assay for creatinine, resulting in overestimations.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 83
7.8.1. Drug-Drug Interactions
Drug-antibiotic interactions occur with many medications commonly prescribed in children, 
particularly those drugs with a narrow therapeutic index.  Therefore, extra caution is advised 
in the event that concomitant medications need to be changed or added for children.
7.8.2. Other Concomitant Treatment
Other medication other than that described above, which is considered necessary for the 
patient’s safety and well-being, may be given at the discretion of the Investigator and 
recorded in the appropriate sections of the CRF.
8. STATISTICAL ANALYSES
8.1. Statistical Considerations
All personnel involved with the analysis of the study will remain blinded until database-lock.  
Analyses will be performed by Sponsor or its representatives.  
A comprehensive Statistical Analysis Plan (SAP) will be prepared prior to the randomisation 
of the first patient to the study.  Any subsequent amendments to the SAP will be documented, 
with final amendments completed prior to unblinding of the data for the analysis.
8.2. Sample Size Estimate
Patients will continue to be recruited into this study until 80 patients complete at least 
72 hours (3 full days, ie, 9 doses if given 3 times daily, or 6 doses if given twice daily) of
study treatment (deemed to be evaluable patients).  Patients will be randomised 3:1 to the 
CAZ-AVI or cefepime study treatment groups.  At least 60 and 20 evaluable patients, 
respectively, are required in the CAZ-AVI and cefepime groups.
The proposed sample size is based on the probability of observing a ‘rare’ safety event.  
Safety data from this study and from Study D4280C00015 for cIAI will be combined for 
analysis.  As a total of at least 120 patients will be treated with CAZ-AVI in both studies 
combined, when assuming an underlying incidence rate of 3% for a specific ‘rare’ event, this 
will ensure that the probability of observing such an event in at least 1 patient treated with 
CAZ-AVI exceeds 95%.
In addition, each of the patient cohorts is required to have a minimum number of evaluable 
patients as follows:

Cohort 1: At least 6:2 evaluable patients aged from 12 years to <18 years;

Cohort 2: At least 6:2 evaluable patients aged from 6 years to <12 years;

Cohort 3: At least 9:3 evaluable patients aged from 2 years to <6 years;
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 84

Cohort 4: At least 18:6 evaluable patients aged from 3 months to <2 years comprising 
Cohorts 4a and 4b as follows: 

Cohort 4a: At least 9:3 evaluable patients aged from 1 year to <2 years;

Cohort 4b: At least 6:2 evaluable patients aged from 3 months to <1 year, with 
a minimum of 3 patients with at least 1 PK sample aged from 3 months to 
<6 months treated with CAZ-AVI.
The inclusion of more patients in the younger age cohorts (Cohorts 3, 4a, and 4b) compared 
to Cohorts 1 and 2 was based on epidemiological data.
Considering patients over all cohorts combined, at least 10% of evaluable patients with 
urological abnormalities in the urinary tract should be included.
8.3. Definitions of Analysis Sets
The analysis of data will be based on different analysis sets according to the purpose of 
analysis, ie, for safety and efficacy.  The decision regarding validity of data for each of the 
analysis sets will be based on a blinded review of data, which will occur prior to declaring 
database lock.
8.3.1. Safety Analysis Set
The Safety analysis set will include all randomised patients who received any amount of IV 
study therapy (ie, CAZ-AVI or cefepime).  For the Safety analysis set, patients will be 
included in all outputs according to the study treatment they actually received.
8.3.2. Safety Evaluable Analysis Set
The safety evaluable analysis set will be a subset of the patients in the Safety analysis set that 
received at least 9 doses of study treatment if given 3 times daily, or at least 6 doses if given 
twice daily.  Each subject’s dosing profile will be reviewed by the evaluability review 
committee to confirm whether the scheduling and number of doses received is acceptable for 
inclusion in the safety evaluable analysis set.
8.3.3. Pharmacokinetic Analysis Set
The PK analysis set will be a subset of the patients in the Safety analysis set who have at 
least 1 ceftazidime and/or avibactam plasma measurement available.
8.3.4. Efficacy Analysis Sets
The efficacy analysis of data in this study will be based on 4 analysis sets of patients 
(intent-to-treat [ITT], microbiological ITT [micro-ITT], clinically evaluable [CE], and 
microbiologically evaluable [ME] analysis sets) as defined in Section 8.3.4.1 to Section 
8.3.4.4.  Each of these analysis sets will be defined separately for each of the visits at which 
efficacy is assessed.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 85
Patients who receive both study therapies will be excluded from the CE and ME analysis 
sets.  Patients in the ITT, micro-ITT, CE, and ME analysis sets will be summarised according 
to the randomised treatment assignment.
8.3.4.1. Intent-to-Treat Analysis Set 
The ITT analysis set will include all patients who have been assigned a randomised 
treatment.
8.3.4.2. Microbiological Intent-To-Treat Analysis Set
The micro-ITT analysis set will include all randomised patients who have at least 
1 Gram-negative typical pathogen at baseline known to cause cUTI and no Gram-positive 
pathogen at baseline.
8.3.4.3. Clinically Evaluable Analysis Set
The CE analysis set is defined separately at the end of 72 hours of study treatment, and at 
each of the EOIV, EOT, TOC and LFU visits.  The CE analysis set is a subset of all patients 
randomised and will include all randomised patients who receive any amount of IV study 
drug and have a confirmed diagnosis of cUTI; patients must also meet the following specific 
conditions:

Have received at least 48 hours of IV study drug in order to be considered an 
evaluable clinical failure, unless deemed a clinical failure based on a 
treatment-limiting AE

Have received at least 72 hours of IV study drug in order to be considered an 
evaluable clinical cure

Have been evaluated at the End of 72 hours and at the specific visits of EOIV, EOT, 
and TOC with a clinical response of cure or failure (or have assessed as a clinical 
failure before the planned assessment visit), or for LFU, have been evaluated with a 
clinical response of sustained cure or relapse

Had no Gram-positive pathogen identified at baseline,

Had no important protocol deviations that would affect assessment of efficacy
8.3.4.4. Microbiologically Evaluable Analysis Set
The ME analysis set will be defined separately at the end of 72 hours of study treatment, and 
at each of the EOIV, EOT, TOC and LFU visits. It includes all patients meeting the 
following criteria:

Are a subset of all randomised patients who have received any amount of IV study 
drug and have a confirmed diagnosis of cUTI;
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 86

Have received at least 48 hours of IV study drug in order to be considered an 
evaluable clinical failure, unless deemed a clinical failure based on a 
treatment-limiting AE;

Have received at least 72 hours of IV study drug in order to be considered an 
evaluable clinical cure;

At the specific visit had a microbiological response which was not indeterminate;

Had no Gram-positive pathogen identified at baseline;

Had no important protocol deviations that would affect assessment of efficacy;

Have at least 1 typical UTI bacterial pathogen which has been isolated from an 
adequate microbiological specimen at Baseline that is susceptible to both study agents
(CAZ-AVI and cefepime).
8.4. Outcome Measures For Analyses
8.4.1. Primary Outcome Variables
The primary outcome variables are for safety and tolerability as assessed by:

AEs and SAEs;

Cephalosporin class effects and additional AEs;

Vital signs (pulse, blood pressure, respiratory rate, temperature);

Physical examination;

Laboratory parameters;

ECG;

CrCl.
8.4.2. Secondary Outcome Variables

Plasma concentrations of CAZ and AVI will be listed and summarised by nominal 
sampling time window using appropriate descriptive statistics

Clinical response at End of 72 hours’ treatment, EOIV, EOT, and TOC;

Microbiological response at EOIV, EOT, TOC, and LFU;

Clinical relapse at LFU;
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017

Emergent infections;

Combined response.
8.5. Methods For Statistical Analyses
8.5.1. Analysis Of The Primary Variables
The primary variables are for safety and tolerability.  No inferential statistical tests will be 
performed for any safety variables.  All data will be presented by treatment group and by 
cohort (and also by summed cohorts).  Descriptive statistics (number, mean, standard 
deviation [SD], median, minimum, and maximum) will be provided for continuous variables, 
and counts and percentages will be presented for categorical variables.  Demographic data,
other baseline characteristic data, and concomitant medications will also be summarised.
Safety assessments will be based on AE reports and the results of vital sign measurements, 
physical examinations, ECGs and clinical laboratory tests.  For each safety variable, the last 
assessment made prior to the first dose of study drug will be defined as the baseline.  All 
safety data collected from this study up to the LFU visit will be presented within the Safety 
analysis set (as defined in Section 8.3.1) by the received study treatment group (ie, for 
CAZ-AVI or cefepime), irrespective of whether the patient switched to oral therapy. Key 
safety data reported up to the LFU visit will also be summarised for the Safety evaluable 
analysis set (ie, those who received at least 72 hours of study treatment as defined in Section 
8.3.2) by received treatment group.
Safety data from this study and from Study D4280C00015 for cIAI will be combined for
analysis.  This analysis of combined safety data will be reported separately of the data from 
this study, and will include the summaries of top-line data using the same formats as 
presented for this study.
8.5.1.1. Adverse Events
The incidence of AEs will be tabulated and reviewed for potential significance and clinical 
importance.  AEs occurring before the start of study treatment will be reported separately 
from all other AEs.  AEs occurring from the start of the first infusion of IV study therapy will 
be summarised by preferred term and system organ class using the latest version of Medical 
Dictionary for Regulatory Activities (MedDRA) vocabulary.
All recorded AEs will be listed and tabulated by system organ class, preferred term and for 
each cohort.  
Summaries and listings of AEs leading to death, SAEs and AEs leading to discontinuation of 
study treatment will also be presented.  Summaries will also be presented by relationship to 
IV study therapy and by AE intensity.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 88
The number of patients reporting AEs among the following topic groups of AEoSI, for which 
prior review has identified groupings of specific AE preferred terms from the MedDRA 
vocabulary, will also be tabulated by cohort:

Liver disorder;

Diarrhoea;

Hypersensitivity/anaphylaxis;

Haematological disorder;

Renal disorder.
The number of patients with at least 1 AE within each AEoSI topic group will be presented 
by study treatment group, together with a further presentation of the AE incidence rates for 
each PT within each AEoSI topic group.
8.5.1.2. Other Safety Data
Summaries and listings of data for vital signs, clinical laboratory and urinalysis laboratory 
tests, ECGs and physical examination findings will be presented.  Appropriate data will be 
summarised for the observed value at each scheduled assessment and for the corresponding 
change from Baseline.  
For clinical laboratory tests, listings of patient data will also flag up any abnormal or 
out-of-range values.  Potentially clinically significant changes in the laboratory test 
parameters will also be identified, listed, and summarised at scheduled visits.  This summary 
will present data for patients meeting the criteria at any time during the study up to the EOT 
visit, and separately at any time up to the LFU visit.  Clinical laboratory data will be reported 
in Système International units.
The following number of patients meeting the following criteria at any time during the study 
up to the LFU visit will be assessed: (maximum ALT ≥3×ULN or maximum AST ≥3×ULN) 
and (maximum total bilirubin ≥2×ULN).  The AST, ALT, total bilirubin elevations can occur 
at any time in the specific review period and do not need to occur simultaneously.
For ECG variables, the QT correction factor will be based on both the Bazett and Fridericia 
formulae (QTcB and QTcF).  Categorical summaries of absolute QT, QTcB and QTcF values 
(≥450 ms, ≥480 ms, ≥500 ms) and change from Day 1 (Baseline) values in QT, QTcB and 
QTcF values (≥30 ms, ≥60 ms), and additionally the number and percentage of patients who 
have a post-baseline value of ≥500 ms with a change from Day 1 of ≥60 ms will be presented 
by treatment, visit and cohort.  The number of patients meeting these criteria at any time after 
the start of study treatment until the LFU visit will also be summarised by treatment and 
cohort.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
The number and percentage of patients with CrCl in the following ranges <30 mL/min, 30 to 
50 mL/min, >50 mL/min will be tabulated at each of the TOC and LFU visits for each 
treatment group.
8.5.2. Analysis Of The Secondary Variable(s)
No inferential statistical tests will be performed for any secondary variables.
8.5.2.1. Pharmacokinetic Outcome Variables
A listing of ceftazidime and avibactam concentrations at the nominal sampling windows by 
patient and cohort will be provided.  For Cohorts 1 to 4b, the plasma concentration will be 
summarised by nominal sampling time window using appropriate descriptive statistics (eg, 
number, mean, SD, minimum, median, maximum, geometric mean, lower and upper SD 
bounds [geometric mean ±SD], and coefficient of variation).
In addition, the avibactam and ceftazidime concentration, paediatric patient demographics, 
and disease status data from Cohorts 1 to 4b will be combined with the data from appropriate 
previous clinical studies in paediatric patients and/or adults for a population PK analysis.  
The actual dosing and plasma sampling times will be used for the analysis.  The developed 
population PK model may be used to conduct simulations to determine probability of PK/PD 
target attainment to help to justify the CAZ-AVI dose regimens for paediatric patient with 
cUTI.  A stand-alone population PK modelling and simulation analysis plan will be prepared 
and the results will be reported in a stand-alone report outside of the CSR.
Avibactam and ceftazidime PK parameters derived from population PK analysis and 
potential PK/PD relationships will be reported separately. 
8.5.2.2. Clinical Outcome Definitions
Clinical response outcomes will be summarised by visit, treatment, and cohort in each of the 
CE and ME analysis sets at End of 72 hours’ treatment, EOIV, EOT, TOC, and LFU, as well 
as the ITT and micro-ITT analysis sets.  A clinical failure occurring at the EOIV timepoint or 
later will always be carried forward to any subsequent assessment time.  The Blinded 
Observer will make the assessment of clinical outcome.
For each baseline pathogen identified with sufficient frequency, the number and percentage 
of patients in each treatment group and cohort classified as having a favourable clinical 
outcome for the particular pathogen will also be summarised.
Clinical Outcome At End Of 72 Hours 
The clinical outcome categories at the End of 72 hours are defined in Table 7.  Favourable 
clinical outcomes are clinical improvement and clinical cure. 
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 90
Table 7.
Clinical Outcome Assessments At End Of 72 Hours
Outcome
Definition
Clinical Cure
Resolution of all acute signs and symptoms of cUTI or improvement to such an 
extent that no further antimicrobial therapy is required
Clinical Improvement
Patients who are improving but not enough to switch to oral therapy and are 
still on IV study drug at End of 72 hours and meet the following criterion:

Absence of new signs and symptoms, and improvement in at least 
1 symptom or sign (ie, fever, pain, tenderness, elevated WBCs, elevated 
CRP) from Baseline, and with no worsening of any symptom or sign
Clinical Failure
Patients who meet any of the following criteria:
Discontinuation of study drug due to insufficient therapeutic effect, including 
persistence, incomplete clinical resolution, or worsening in signs and symptoms 
of cUTI that requires alternative non-study antimicrobial therapy

Discontinuation of study drug due to an AE and requirement for alternative 
non-study antimicrobial therapy for cUTI

Death in which cUTI is contributory

Patients who are improving but not enough to switch to oral therapy and 
are still on IV study drug at End of 72 hours and who fail to meet the 
following criterion:

Absence of new signs and symptoms, and improvement in at least 
1 symptom or sign (ie, fever, pain, tenderness, elevated WBCs, elevated 
CRP) from Baseline, and with no worsening of any symptom or sign
Indeterminatea
Study data are not available for evaluation of efficacy for any reason, 
including:

Death in which cUTI is clearly non-contributory

Extenuating circumstances precluding classification as a cure or failure or 
improvement (eg, patient lost to follow-up)
CRP = C-reactive protein
a Any prophylactic systemic prophylactic antibiotic medication use after first dose until the End of 72 hours 
assessment will result in a clinical outcome of Indeterminate. See Section 7.8 for further details.
Within each analysis set, the proportion of patients with a favourable outcome is defined 
using the following formula: 
Number of patients with Clinical cure or Improvement
(Number of patients in the analysis set)
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 91
Clinical Outcome at EOIV
The clinical outcome categories at EOIV are defined in Table 8.  Favourable clinical 
outcomes are clinical improvement and clinical cure.  A clinical failure at EOIV will be 
carried forward to the EOT and TOC visits.
Table 8.
Clinical Outcome Assessments at EOIV
Outcome
Definition
Clinical Cure
Resolution of all acute signs and symptoms of cUTI or improvement to such an 
extent that no further antimicrobial therapy is required
Clinical Improvement
Patients who switch to oral therapy and meet all of the following criteria at 
EOIV:

Afebrile (temperature ≤38.0°C) for at least 24 hours

Absence of new and improvement in at least 1 symptom or sign (ie, fever, 
pain, tenderness, elevated WBCs, elevated CRP) from Baseline and 
worsening of none.
Clinical Failurea
Patients who meet any of the following criteria:

Discontinuation of study drug due to insufficient therapeutic effect, 
including persistence, incomplete clinical resolution, or worsening in signs 
and symptoms of cUTI that requires alternative non-study antimicrobial 
therapy

Discontinuation of study drug due to an AE and requirement for alternative 
non-study antimicrobial therapy for cUTI

Death in which cUTI is contributory
Indeterminateb
Study data are not available for evaluation of efficacy for any reason, 
including:

Death in which cUTI is clearly non-contributory

Extenuating circumstances precluding classification as a cure or failure 
(eg, patient lost to follow-up)
a A clinical failure at EOIV will be carried forward to EOT and TOC.
b Any prophylactic systemic prophylactic antibiotic medication use after first dose until the EOIV assessment 
will result in a clinical outcome of Indeterminate. See Section 7.8 for further details.
Within each analysis set, the proportion of patients with a favourable outcome is defined 
using the following formula: 
Number of patients with Clinical cure or Improvement
(Number of patients in the analysis set)
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 92
Clinical Outcome at EOT
The clinical outcome categories at EOT are defined in Table 9.  A favourable clinical 
outcome is clinical cure.  A clinical failure at EOT will be carried forward to the TOC visit.
Table 9.
Clinical Outcome Assessments at EOT
Outcome
Definition
Clinical Cure
Resolution of all acute signs and symptoms of cUTI or improvement to such an 
extent that no further antimicrobial therapy is required
Clinical Failurea
Patients who meet any of the following criteria:

Discontinuation of study drug due to insufficient therapeutic effect, 
including persistence, incomplete clinical resolution, or worsening in signs 
and symptoms of cUTI that requires alternative non-study antimicrobial 
therapy

Discontinuation of study drug due to an AE and requirement for alternative 
non-study antimicrobial therapy for cUTI

Death in which cUTI is contributory
Indeterminateb
Study data are not available for evaluation of efficacy for any reason, 
including:

Death in which cUTI is clearly non-contributory

Extenuating circumstances precluding classification as a cure or failure 
(eg, patient lost to follow-up)
a A clinical failure at EOT will be carried forward to TOC.
b Any prophylactic systemic prophylactic antibiotic medication use after first dose until the EOT assessment 
will result in a clinical outcome of Indeterminate. See Section 7.8 for further details.
Within each analysis set, the proportion of patients with a favourable outcome is defined 
using the following formula:
Number of patients with Clinical cure
(Number of patients in the analysis set)
Clinical Outcome at TOC
The clinical outcome categories at TOC are defined in Table 10.  A favourable clinical 
outcome is clinical cure. Clinical response by pathogen at TOC will also be determined for 
each pathogen isolated at Baseline.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 93
Table 10
Clinical Outcome Assessments at TOC
Outcome
Definition
Clinical Cure
Resolution of all acute signs and symptoms of cUTI or improvement to such an 
extent that no further antimicrobial therapy is required
Clinical Failure
Patients who meet either of the following criteria:

Incomplete resolution or worsening of cUTI signs or symptoms or 
development of new signs or symptoms requiring alternative non-study 
antimicrobial therapy

Death in which cUTI is contributory
Indeterminate
Study data are not available for evaluation of efficacy for any reason, 
including:

Death in which cUTI is clearly non-contributory

Extenuating circumstances precluding classification as a cure or failure 
(eg, patient lost to follow-up)
Any prophylactic systemic prophylactic antibiotic medication use after the EOT assessment will not impact 
clinical outcome at TOC. See Section 7.8 for further details.
Within each analysis set, the proportion of patients with a favourable outcome is defined 
using the following formula: 
Number of patients with Clinical cure
(Number of patients in the analysis set)
8.5.2.2.1. Clinical Outcome at LFU
Each patient who was considered clinically cured at TOC will be reassessed at LFU by the 
Blinded Observer for evidence of clinical relapse of cUTI symptoms.  The clinical outcome 
categories at LFU are defined in Table 11.  A favourable clinical outcome at LFU is 
sustained clinical cure.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Table 11
Clinical Outcome Assessments at LFU
Outcome
Definition
Sustained Clinical Cure
Continued favourable response, defined as resolution of all acute signs and 
symptoms of cUTI and no further antimicrobial therapy is required
Clinical Relapse
Patients who meet either of the following criteria:

Reappearance or worsening of signs and symptoms of cUTI that requires 
further antimicrobial therapy and/or surgery

Death after TOC in which cUTI is contributory
Indeterminate
Study data are not available for evaluation of efficacy for any reason, 
including:

Death in which cUTI is clearly non-contributory

Extenuating circumstances precluding classification as sustained clinical 
cure or clinical relapse (eg, patient lost to follow-up)
Note: Clinical outcome at LFU will only be assessed in patients who were considered clinically cured at TOC.
Any prophylactic systemic prophylactic antibiotic medication use after the EOT assessment will not impact 
clinical outcome at LFU. See Section 7.8 for further details.
The proportion of patients with clinical relapse at the LFU visit will be summarised by 
treatment and cohort in both the CE and ME analysis sets.
Within each analysis set, the proportion of patients with a clinical relapse is defined using the 
following formula: 
Number of patients with Clinical Relapse
(Number of patients in the analysis set)
8.5.2.3. Microbiological Response Assessments
The proportion of patients with a favourable per-patient microbiological response (ie, 
eradication) will be summarised by treatment and cohort in the micro-ITT and ME analysis 
sets at the EOIV, EOT, TOC and LFU visits. 
The per-pathogen microbiological outcome categories are defined in Table 12.  Favourable 
microbiological outcomes are eradication.  Baseline pathogens will be determined based on 
central laboratory data (see Section 5.2.1 for details on culture and organism identification).  
Rules for determination of pathogens will be described in the SAP.
In order for a patient to have a favourable microbiological response, the outcome for each 
baseline pathogen must be favourable (eradicated).  If the outcome for any pathogen is 
persistence, the patient will be considered to have an unfavourable microbiological response.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 95
Table 12
Per-Pathogen Microbiological Outcome Categories
Outcome
Definition
Eradication
Source specimen demonstrates absence of the original baseline pathogen
Persistence
Source specimen demonstrates continued presence of the original baseline 
pathogen
Persistence with increasing 
MICa
Source specimen demonstrates continued presence of the original baseline 
pathogen with a minimum inhibitory concentration (MIC) value ≥4-fold larger 
than that observed for the baseline pathogen
Indeterminate
Source specimen was not available to culture
a Persistence with increasing MIC is a subset of the Persistence outcome.
For patients who have a microbiological outcome of persistence at the EOIV timepoint or 
later, this outcome will be carried forward to subsequent visits.
8.5.2.4. Emergent Infections
Pathogens first appearing after Baseline (“emergent infections”) until the LFU in patients 
with a baseline pathogen are categorised in Table 13 and these will be summarised separately 
by treatment and cohort.
Table 13
Emergent Infections
Emergent infections
Definition
Superinfection
A urine culture identified pathogen other than a baseline pathogen during 
the course of active treatment with IV study therapy along with worsening 
signs and symptoms of infection requiring alternative antimicrobial 
therapy.
New infection
A urine culture identified pathogen other than a baseline pathogen at any 
time after IV study treatment has finished along with worsening signs and 
symptoms of infection requiring alternative antimicrobial therapy.
The proportion of patients with an emergent infection (and by infection category) will be 
summarised by treatment and cohort in both the CE and ME analysis sets.
8.5.2.5. Combined Response
Combined clinical and microbiological response will be summarised in the ITT and the 
micro-ITT analysis sets at EOIV and TOC visits.  The number and percentage of patients for 
combined response outcome at each visit will be summarised by response categories, cohort, 
and treatment group.
At the EOIV and TOC assessments, the clinical and per-patient microbiological responses 
will be used to create a combined response. If either clinical or microbiological response is 
unfavourable, then the combined response will be unfavourable. Otherwise, in the absence 
of unfavourable responses, if either clinical or microbiological response is indeterminate or 
missing, then the response will be indeterminate. Finally, if both clinical and microbiological 
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
responses are favourable, then the outcome will be favourable. This is all summarised in 
cross-tabulation form in Table 14.
Table 14
Per-Patient Combined Response
Clinical Outcome
Microbiological Outcome
Favourable
Indeterminate
Unfavourable
Favourable
Favourable
Indeterminate
Unfavourable
Indeterminate
Indeterminate
Indeterminate
Unfavourable
Unfavourable
Unfavourable
Unfavourable
Unfavourable
8.6. Interim Analysis
No formal interim analysis will be conducted for this study.
9. STUDY AND DATA MANAGEMENT 
9.1. Training of Study Site Personnel
Before the first patient is entered into the study, a PRA representative will review and discuss 
the requirements of the Clinical Study Protocol and related documents with the 
investigational staff and also train them in any study specific procedures and the PRA 
Datalabs data capture system.
The Principal Investigator will ensure that appropriate training relevant to the study is given 
to all of these staff, and that any new information relevant to the performance of this study is 
forwarded to the staff involved.
The Principal Investigator will maintain a record of all individuals involved in the study 
(medical, nursing and other staff).
9.2. Monitoring of The Study
During the study, an Sponsor representative will have regular contacts with the study site, 
including visits to:

Provide information and support to the Investigator(s);

Confirm that facilities remain acceptable;

Confirm that the investigational team is adhering to the protocol, that data are being 
accurately and timely recorded in the CRFs, that biological samples are handled in 
accordance with the Laboratory Manual and that study drug accountability checks are 
being performed;

Perform source data verification (a comparison of the data in the CRFs with the 
patient’s medical records at the hospital or practice, and other records relevant to the 
study) including verification of informed consent/assent of participating patients.  
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
This will require direct access to all original records for each patient (eg, clinic 
charts);

Ensure withdrawal of informed consent/assent to the use of the patient’s biological 
samples is reported and biological samples are identified and disposed of/destroyed 
accordingly, and the action is documented, and reported to the patient.
The Sponsor representative will be available between visits if the Investigator(s) or other 
staff at the centre needs information and advice about the study conduct.
9.2.1. Source Data
Refer to the Clinical Study Agreement (CSA) for location of source data.   In most cases, the 
source documents are the hospital or the physician subject chart.  In these cases, data 
collected on the CRFs must match the data in those charts. 
In some cases, the CRF may also serve as the source document.  In these cases, a document 
should be available at the investigator site and at the Sponsor that clearly identifies those data 
that will be recorded on the CRF, and for which the CRF will stand as the source document.
9.2.2. Study Agreements
The Principal Investigator at each/the centre should comply with all the terms, conditions, 
and obligations of the CSA, or equivalent, for this study.  In the event of any inconsistency 
between this Clinical Study Protocol and the CSA, the terms of Clinical Study Protocol shall 
prevail with respect to the conduct of the study and the treatment of patients and in all other 
respects, not relating to study conduct or treatment of patients, the terms of the CSA shall 
prevail.
Agreements between Sponsor or Sponsor’s representatives, and the Principal Investigator 
should be in place before any study-related procedures can take place, or patients are 
enrolled.
9.2.3. Archiving Of Study Documents
The Investigator follows the principles outlined in the CSA.
To enable evaluations and/or inspections/audits from regulatory authorities or Pfizer, the 
investigator agrees to keep records, including the identity of all participating subjects 
(sufficient information to link records, eg, CRFs and hospital records), all original signed 
informed consent[/assent] documents, copies of all CRFs, safety reporting forms, source 
documents, and detailed records of treatment disposition, and adequate documentation of 
relevant correspondence (eg, letters, meeting minutes, and telephone call reports).  The 
records should be retained by the investigator according to the ICH guidelines, according to 
local regulations, or as specified in the clinical study agreement (CSA), whichever is longer.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 98
If the investigator becomes unable for any reason to continue to retain study records for the 
required period (eg, retirement, relocation), Pfizer should be prospectively notified.  The 
study records must be transferred to a designee acceptable to Pfizer, such as another 
investigator, another institution, or an independent third party arranged by Pfizer.  
Investigator records must be kept for a minimum of 15 years after completion or 
discontinuation of the study or for longer if required by applicable local regulations.  
The investigator must obtain Pfizer's written permission before disposing of any records, 
even if retention requirements have been met.
9.2.3.1. Data Handling And Record Keeping
A CRF is required and should be completed for each included subject.  The completed
original CRFs are the sole property of Pfizer and should not be made available in any form to 
third parties, except for authorized representatives of Pfizer or appropriate regulatory 
authorities, without written permission from Pfizer.
The investigator has ultimate responsibility for the collection and reporting of all clinical, 
safety, and laboratory data entered on the CRFs and any other data collection forms (source 
documents) and ensuring that they are accurate, authentic/original, attributable, complete, 
consistent, legible, timely (contemporaneous), enduring, and available when required.  The 
CRFs must be signed by the investigator or by an authorized staff member to attest that the 
data contained on the CRFs are true.  Any corrections to entries made in the CRFs or source 
documents must be dated, initialed, and explained (if necessary) and should not obscure the 
original entry. 
9.3. Study Timetable And End Of Study
The end of the study in all participating countries is defined as ‘the last visit of the last 
patient undergoing the study’ or date of study closure in the case of early study termination, 
whichever date is later.
The study is expected to start in Q3 2015 and to end by Q3 2018.
The study may be terminated at individual centres if the study procedures are not being 
performed according to Good Clinical Practice (GCP), or if recruitment is slow.  Sponsor
may also terminate the entire study prematurely if concerns for safety arise within this study 
or in any other study with CAZ-AVI.
9.4. Sponsor Discontinuation Criteria
Premature termination of this study may occur because of a regulatory authority decision, 
change in opinion of the IRB/EC, or investigational product safety problems, or at the 
discretion of the Sponsor.  In addition, the Sponsor retains the right to discontinue 
development of CAZ-AVI at any time.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 99
If a study is prematurely terminated, the Sponsor will promptly notify the investigator.  After 
notification, the investigator must contact all participating subjects and the hospital pharmacy 
(if applicable) within seven days.  As directed by the Sponsor, all study materials must be 
collected and all CRFs completed to the greatest extent possible.
9.5. Data Management 
The PRA Datalabs system will be used for data collection and query handling.  The 
Investigator will ensure that data are recorded on the CRFs as specified in the study protocol 
and in accordance with the instructions provided.
The Investigator ensures the accuracy, completeness, and timeliness of the data recorded and 
the provision of answers to data queries according to the CSA.  The Investigator will sign the 
completed CRFs.  A copy of the completed CRFs will be archived at the study site.
Data management will be performed by PRA, according to the Clinical Informatics Plan.  
Adverse events and medical/surgical history will be classified according to the terminology 
of the latest version of the MedDRA.  Medications will be classified according to the 
Sponsor Drug Dictionary.  All coding will be performed by the PRA coding group.  Data 
queries will be raised for inconsistent, impossible or missing data.  All entries to the study 
database will be available in an audit trail.
The data will be validated as defined in the Clinical Informatics Plan and Edit Specifications 
Document.  Quality control procedures will be applied to each stage of data handling to 
ensure that all data are reliable and have been processed correctly.  The Clinical Informatics 
Plan will also clarify the roles and responsibilities of the various functions and personnel 
involved in the data management process.
When all data have been coded, validated, signed and locked, clean file will be declared.  
Any treatment revealing data may thereafter be added and the final database will be locked.
Serious Adverse Event Reconciliation
Serious adverse event reconciliation reports are produced and reconciled with the patient 
safety database and/or the investigational site.  SAE reconciliation between safety data and 
clinical data will be performed by PRA.  The frequency depends on the expected volume of 
SAE reports and will be defined in the AE/SAE Reconciliation Plan.  
Management of external data
The data collected through third party sources will be obtained and reconciled against study 
data.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 100
10. ETHICAL AND REGULATORY REQUIREMENTS
10.1. Ethical Conduct Of The Study
The study will be conducted in accordance with the protocol, legal and regulatory 
requirements, and the general principles set forth in the International Ethical Guidelines for 
Biomedical Research Involving Human Subjects (Council for International Organizations of 
Medical Sciences 2002), ICH Guidelines for Good Clinical Practices, and the Declaration of 
Helsinki.
10.2. Patient Data Protection
The ICF/Assent Form will incorporate (or, in some cases, be accompanied by a separate 
document incorporating) wording that complies with relevant data protection and privacy 
legislation.
All parties will ensure protection of subject personal data and will not include subject names 
or other identifiable data in any reports, publications, or other disclosures, except where 
required by law. 
When study data are compiled for transfer to Pfizer and other authorized parties, subject 
names, addresses, and other identifiable data will be replaced by numerical codes based on a 
numbering system provided by Pfizer in order to de-identify study subjects.  The investigator 
site will maintain a confidential list of subjects who participated in the study, linking each 
subject’s numerical code to his or her actual identity.  In case of data transfer, Pfizer will 
maintain high standards of confidentiality and protection of subjects’ personal data consistent 
with applicable privacy laws.
10.3. Ethics And Regulatory Review
An Independent Ethics Committee (IEC)/Institutional Review Board (IRB) should approve 
the final study protocol, including the final version of the ICF, Assent Form, and any other 
written information and/or materials to be provided to the patients.  The Investigator will 
ensure the distribution of these documents to the applicable IEC/IRB, and to the study site 
staff. All correspondence with the IRB/EC should be retained in the investigator file.  Copies 
of IRB/EC approvals should be forwarded to Pfizer or its representative.
The opinion of the IEC/IRB should be given in writing.  The Investigator should submit the 
written approval to PRA before enrolment of any patient into the study. 
The IEC/IRB should approve all advertising used to recruit patients for the study.
PRA and Sponsor should approve any modifications to the ICF and Assent Form that are 
needed to meet local requirements.
If required by local regulations, the protocol should be re-approved by the IEC/IRB annually.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 101
Before enrolment of any patient into the study, the final study protocol, including the final 
version of the ICF and Assent Form, is approved by the national regulatory authority or a 
notification to the national regulatory authority is done, according to local regulations. The 
only circumstance in which an amendment may be initiated prior to IRB/EC approval is 
where the change is necessary to eliminate apparent immediate hazards to the subjects.  In 
that event, the investigator must notify the IRB/EC and Pfizer in writing immediately after 
the implementation.
The Sponsor or PRA will handle the distribution of any of these documents to the national 
regulatory authorities.
The Sponsor or PRA will provide Regulatory Authorities, IECs/IRBs and Principal 
Investigators with safety updates/reports according to local requirements.
Each Principal Investigator is responsible for providing the IECs/IRB with reports of any 
serious and unexpected adverse drug reactions from any other study conducted with the IP.  
PRA will provide this information to the Principal Investigator so that he/she can meet these 
reporting requirements.
10.4. Informed Consent
The informed consent documents and any subject recruitment materials must be in 
compliance with ICH GCP, local regulatory requirements, and legal requirements, including 
applicable privacy laws.  The Principal Investigator(s) at each centre will:

Ensure each patient's parent(s) or other legally acceptable representative(s) and 
patient when applicable (if age appropriate according to local regulations) is given 
full and adequate oral and written information about the nature, purpose, possible risk 
and benefit of the study;

Ensure each patient's parent(s) or other legally acceptable representative(s) and 
patient when applicable (if age appropriate according to local regulations) is notified 
that they are free to discontinue from the study at any time;

Ensure that each patient's parent(s) or other legally acceptable representative(s) and 
patient when applicable (if age appropriate according to local regulations) is given the 
opportunity to ask questions and allowed time to consider the information provided;

Ensure each patient’s parent(s) or other legally acceptable representative(s) provides 
signed and dated informed consent and patient (if age appropriate according to local 
regulations) provides signed and dated assent before conducting any procedure 
specifically for the study;

Ensure the original, signed ICF(s) and Assent Form (if age appropriate according to 
local regulations) is/are stored in the Investigator’s Study File;
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 102

Ensure a copy of the signed ICF(s) and Assent Form (if age appropriate according to 
local regulations) is given to the patient’s parent(s) or other legally acceptable 
representative(s);

Ensure that any reimbursement for study visits as any provisions for patients harmed 
as a consequence of study participation are described in the ICF(s) and Assent Form
(if age appropriate according to local regulations) that is approved by an IEC/IRB.
10.5. Changes To The Protocol And Informed Consent Form
Study procedures will not be changed without the mutual agreement of the International 
co-ordinating Investigator and Sponsor.
If there are any substantial changes to the study protocol, then these changes will be 
documented in a study protocol amendment and where required in a new version of the study 
protocol (Revised Clinical Study Protocol).
The amendment is to be approved by the relevant IEC/IRB and if applicable, also the 
national regulatory authority approval, before implementation.  Local requirements are to be 
followed for revised protocols.
Sponsor or its representative will distribute any subsequent amendments and new versions of 
the protocol to each Principal Investigator(s). For distribution to IEC/IRB see Section 10.3.
If a protocol amendment requires a change to a centre’s ICF and/or Assent Form, the Sponsor
or its representative and the centre’s IEC/IRB are to approve the revised ICF and/or Assent 
Form (if applicable) before the revised form(s) is/are used. 
If local regulations require, any administrative change will be communicated to or approved 
by each IEC/IRB.
10.6. Audits and Inspections
Pfizer or its agent will conduct periodic monitoring visits during study conduct to ensure that 
the protocol and Good Clinical Practices (GCPs) are being followed.  The monitors may 
review source documents to confirm that the data recorded on CRFs are accurate.  The 
investigator and institution will allow Pfizer monitors/auditors or its agents and appropriate 
regulatory authorities direct access to source documents to perform this verification.  This 
verification may also occur after study completion.
During study conduct and/or after study completion, authorised representatives of Pfizer, or 
companies working on behalf of Pfizer, a regulatory authority, or an IEC/IRB may perform 
audits or inspections at the centre, including source data verification.  The purpose of an 
audit or inspection is to systematically and independently examine all study-related activities 
and documents, to determine whether these activities were conducted, and data were 
recorded, analysed, and accurately reported according to the protocol, GCP, guidelines of the 
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 103
ICH, and any applicable regulatory requirements.  The Investigator(s) will notify Pfizer or its 
agent immediately if contacted by a regulatory agency about an inspection at the centre.  
Furthermore, the investigator will cooperate with Pfizer or its agents to prepare the 
investigator site for the inspection and will allow Pfizer or its agent, whenever feasible, to be 
present during the inspection.  The investigator site and investigator will promptly resolve 
any discrepancies that are identified between the study data and the subject's medical records.  
The investigator will promptly provide copies of the inspection findings to Pfizer or its agent.  
Before response submission to the regulatory authorities, the investigator will provide Pfizer 
or its agents with an opportunity to review and comment on responses to any such findings.
It is important that the investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process.
10.7. Reporting Of Safety Issues And Serious Breaches Of The Protocol Or ICH GCP
In the event of any prohibition or restriction imposed (ie, clinical hold) by an applicable
regulatory authority in any area of the world, or if the investigator is aware of any new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, Pfizer should be informed immediately.  
In addition, the investigator will inform Pfizer immediately of any urgent safety measures 
taken by the investigator to protect the study subjects against any immediate hazard, and of 
any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.
10.8. Publication Of Study Results
10.8.1. Communication of Results by the Sponsor
Pfizer fulfills its commitment to publicly disclose clinical trial results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Database (EudraCT), and/or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations. 
In all cases, study results are reported by Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the study or the country in 
which the study was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial US Basic Results on www.clinicaltrials.gov for Pfizer-sponsored 
interventional studies (conducted in patients) that evaluate the safety and/or efficacy of a 
Pfizer product, regardless of the geographical location in which the study is conducted.  US 
Basic Results are submitted for posting within 1 year of the primary completion date (PCD) 
for studies in adult populations or within 6 months of the PCD for studies in pediatric 
populations.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 104
PCD is defined as the date that the final subject was examined or received an intervention for 
the purposes of final collection of data for the primary outcome, whether the clinical study 
concluded according to the prespecified protocol or was terminated.
EudraCT
Pfizer posts European Union (EU) Basic Results on EudraCT for all Pfizer-sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 year of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
Pfizer posts Public Disclosure Synopses (clinical study report synopses in which any data 
that could be used to identify individual patients has been removed) on www.pfizer.com for 
Pfizer-sponsored interventional studies at the same time the US Basic Results document is 
posted to www.clinicaltrials.gov.
10.8.2. Publications by Investigators
Pfizer supports the exercise of academic freedom and has no objection to publication by the 
principal investigator (PI) of the results of the study based on information collected or 
generated by the PI, whether or not the results are favorable to the Pfizer product.  However, 
to ensure against inadvertent disclosure of confidential information or unprotected 
inventions, the investigator will provide Pfizer an opportunity to review any proposed 
publication or other type of disclosure of the results of the study (collectively, “publication”) 
before it is submitted or otherwise disclosed.
The investigator will provide any publication to Pfizer at least 30 days before it is submitted 
for publication or otherwise disclosed.  If any patent action is required to protect intellectual 
property rights, the investigator agrees to delay the disclosure for a period not to exceed an 
additional 60 days.
The investigator will, on request, remove any previously undisclosed confidential 
information before disclosure, except for any study- or Pfizer product-related information 
necessary to the appropriate scientific presentation or understanding of the study results.
If the study is part of a multicenter study, the investigator agrees that the first publication is 
to be a joint publication covering all investigator sites, and that any subsequent publications 
by the PI will reference that primary publication.  However, if a joint manuscript has not 
been submitted for publication within 12 months of completion or termination of the study at 
all participating sites, the investigator is free to publish separately, subject to the other 
requirements of this section.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 105
For all publications relating to the study, the institution will comply with recognized ethical 
standards concerning publications and authorship, including Section II - “Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, 
established by the International Committee of Medical Journal Editors.
Publication of study results is also provided for in the CSA between Pfizer and the 
institution.  In this section entitled Publications by Investigators, the defined terms shall have 
the meanings given to them in the CSA.
If there is any conflict between the CSA and any attachments to it, the terms of the CSA 
control.  If there is any conflict between this protocol and the CSA, this protocol will control 
as to any issue regarding treatment of study subjects, and the CSA will control as to all other 
issues.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 106
11. LIST OF REFERENCES
1.
European Commission 2008, European Commission.  Ethical considerations for clinical 
trials on medicinal products conducted with the paediatric population: 
Recommendations of the ad hoc group for the development of implementing guidelines 
for Directive 2001/20/EC relating to good clinical practice in the conduct of clinical 
trials on medicinal products for human use.  2008.  Available from: 
http://ec.europa.eu/health/files/eudralex/vol-10/ethical_considerations_en.pdf.  
2.
Howie 2011,Howie SR.  Blood sample volumes in child health research: review of safe 
limits.  Bull World Health Organ 2011;89:46-53.
3.
Schwartz et al 2009,Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, 
Warady BA, et al.  New equations to estimate GFR in children with CKD.  J Am Soc 
Nephrol 2009 Mar;20(3):629-37.
4.
Stachyra et al 2009,Stachyra T, Levasseur P, Péchereau MC, Girard AM, Claudon M, 
Miossec C, et al.  In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 
carbapenemase and Enterobacteriaceae expressing KPC carbapenemases.  J Antimicrob 
Chemother 2009;64(2):326-9.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 107
Appendix 1. Labelling And Shipment Of Biohazard Samples
International Airline Transportation Association (IATA) classifies biohazardous agents into 3 
categories (http://www.iata.org/whatwedo/cargo/dangerous_goods/infectious_substances
.htm). For transport purposes the classification of infectious substances according to risk 
groups was removed from the Dangerous Goods Regulations (DGR) in the 46th edition 
(2005).  Infectious substances are now classified either as Category A, Category B or 
Exempt.  There is no direct relationship between Risk Groups and categories A and B.
Category A Infectious Substances are infectious substances in a form that, when exposure 
to it occurs, is capable of causing permanent disability, life-threatening or fatal disease in 
otherwise healthy humans or animals.  Category A pathogens are eg, Ebola, Lassa fever 
virus:

are to be packed and shipped in accordance with IATA Instruction 602.
Category B Infectious Substances are infectious Substances that do not meet the criteria for 
inclusion in Category A.  Category B pathogens are eg, Hepatitis A, B, C, D, and E viruses, 
Human immunodeficiency virus (HIV) types 1 and 2.  They are assigned the following UN 
number and proper shipping name:

UN 3373 – Biological Substance, Category B

are to be packed in accordance with UN3373 and IATA 650
Exempt - all other materials with minimal risk of containing pathogens

Clinical trial samples will fall into Category B or exempt under IATA regulations

Clinical trial samples will routinely be packed and transported at ambient temperature 
in IATA 650 compliant packaging 
(http://www.iata.org/whatwedo/cargo/dangerous_goods/infectious_substances.ht
m)

Biological samples transported in dry ice require additional dangerous goods 
specification for the dry-ice content

IATA compliant courier and packaging materials should be used for packing and 
transportation and packing should be done by an IATA certified person, as applicable

Samples routinely transported by road or rail are subject to local regulations which 
require that they are also packed and transported in a safe and appropriate way to 
contain any risk of infection or contamination by using approved couriers and 
packaging / containment materials at all times.  The IATA 650 biological sample 
containment standards are encouraged wherever possible when road or rail transport 
is used.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 108
Appendix 2. Actions Required in Cases of Combined Increase of Aminotransferase and 
Total Bilirubin - Hy’s Law
TABLE OF CONTENTS
1.
INTRODUCTION
2.
DEFINITIONS
3.
IDENTIFICATION OF POTENTIAL HY’S LAW CASES
4.
FOLLOW-UP
4.1.
Potential Hy’s Law Criteria Not Met
4.2.
Potential Hy’s Law Criteria Met
5.
REVIEW AND ASSESSMENT OF POTENTIAL HY’S LAW CASE
1.
INTRODUCTION
During the course of the study the Investigator will remain vigilant for increases in liver 
biochemistry.  The investigator is responsible for determining whether a patient meets 
potential Hy’s Law (PHL) criteria at any point during the study.
The Investigator participates, together with Sponsor clinical project representatives, in review 
and assessment of cases meeting PHL criteria to agree whether Hy’s Law (HL) criteria are 
met.  HL criteria are met if there is no alternative explanation for the elevations in liver 
biochemistry other than Drug Induced Liver Injury (DILI) caused by the Investigational 
Medicinal Product (IMP). 
The Investigator is responsible for recording data pertaining to PHL/HL cases and for 
reporting Adverse Events (AE) and Serious Adverse Events (SAE) according to the outcome 
of the review and assessment in line with standard safety reporting processes.
2.
DEFINITIONS
Potential Hy’s Law (PHL)
Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≥ 3x Upper Limit of 
Normal (ULN) and Total Bilirubin (TBL) ≥ 2xULN irrespective of an increase in Alkaline 
Phosphatase (ALP), at any point during the study following the start of study medication.  
The elevations do not have to occur at the same time or within a specified time frame.
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 109
Hy’s Law (HL)
AST or ALT ≥ 3x ULN and TBL ≥ 2xULN, where no other reason, other than the IMP, can 
be found to explain the combination of increases, eg, elevated ALP indicating cholestasis, 
viral hepatitis, another drug.  The elevations do not have to occur at the same time or within a 
specified time frame.
For PHL and HL the elevation in transaminases must precede or be coincident with (ie, on 
the same day) the elevation in TBL, but there is no specified timeframe within which the 
elevations in transaminases and TBL must occur.
3.
IDENTIFICATION OF POTENTIAL HY’S LAW CASES
In order to identify cases of PHL it is important to perform a comprehensive review of 
laboratory data for any patient who meets any of the following identification criteria in 
isolation or in combination:

ALT ≥ 3xULN

AST ≥ 3xULN

TBL ≥ 2xULN
When the identification criteria are met from laboratory results the Investigator will without 
delay:

Determine whether the patient meets PHL criteria (see Section 2 of this Appendix for 
definition) by reviewing laboratory reports from all previous visits (including both 
central and local laboratory results)
The Investigator will without delay review each new laboratory report and if the 
identification criteria are met will:

Notify the Sponsor representative;

Determine whether the patient meets PHL criteria (see Section 2 of this Appendix for 
definition) by reviewing laboratory reports from all previous visits;

Promptly enter the laboratory data into the laboratory CRF.
4.
FOLLOW-UP
4.1.
Potential Hy’s Law Criteria Not Met
If the patient does not meet PHL criteria the Investigator will:
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 110

Perform follow-up on subsequent laboratory results according to the guidance 
provided in the Clinical Study Protocol.
4.2.
Potential Hy’s Law Criteria Met
If the patient does meet PHL criteria the Investigator will:

Notify the Sponsor representative who will then inform the central Study Team
The Medical Monitor contacts the Investigator, to provide guidance, discuss and agree an 
approach for the study patients’ follow-up and the continuous review of data.  Subsequent to 
this contact the Investigator will:

Monitor the patient until liver biochemistry parameters and appropriate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically 
indicated.  The patient should return to the investigator site and be evaluated as soon 
as possible, preferably within 48 hours from awareness of the abnormal results.  This 
evaluation should include laboratory tests, detailed history, and physical assessment.  

Investigate the etiology of the event and perform diagnostic investigations as 
discussed with the medical monitor.  In addition to repeating measurements of AST 
and ALT and TBili, laboratory tests should include albumin, creatine kinase (CK), 
direct and indirect bilirubin, gamma-glutamyl transferase (GGT), prothrombin time 
(PT)/international normalized ratio (INR), total bile acids, alkaline phosphatase and 
acetaminophen drug and/or protein adduct levels.  Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for 
further testing, as needed, for further contemporaneous analyses at the time of the 
recognized initial abnormalities to determine etiology.  A detailed history, including 
relevant information, such as review of ethanol, acetaminophen (either by itself or as 
a coformulated product in prescription or over-the-counter medications), recreational 
drug, supplement (herbal) use and consumption, family history, sexual history, travel 
history, history of contact with a jaundiced person, surgery, blood transfusion, history 
of liver or allergic disease, and potential occupational exposure to chemicals, should 
be collected.  Further testing for acute hepatitis A, B, C, D, and E infection and liver 
imaging (eg, biliary tract) may be warranted. 

Complete the three Liver CRF Modules as information becomes available 

All cases demonstrated on repeat testing as meeting the laboratory criteria of 
AST/ALT and TBili elevation defined above should be considered potential DILI 
(Hy’s law) cases if no other reason for the LFT abnormalities has yet been found.  
Such potential DILI (Hy’s law) cases are to be reported as SAEs, irrespective of 
availability of all the results of the investigations performed to determine 
etiology of the LFT abnormalities.  
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 111

A potential DILI (Hy’s law) case becomes a confirmed case only after all results of 
reasonable investigations have been received and have excluded an alternative 
etiology
5. REVIEW AND ASSESSMENT OF POTENTIAL HY’S LAW CASES
The instructions in this Section should be followed for all cases where PHL criteria are met.
No later than 3 weeks after the biochemistry abnormality was initially detected, the Study 
Medical Monitor contacts the Investigator in order to review available data and agree on 
whether there is an alternative explanation for meeting PHL criteria other than DILI caused 
by the IMP.  The Sponsor Medical Monitor and Global Safety Physician will also be 
involved in this review together with other subject matter experts as appropriate.  
According to the outcome of the review and assessment, the Investigator will follow the 
instructions below.
If there is an agreed alternative explanation for the ALT or AST and TBL elevations, a 
determination of whether the alternative explanation is an AE will be made and subsequently 
whether the AE meets the criteria for a SAE:

If the alternative explanation is not an AE, record the alternative explanation on the 
appropriate CRF

If the alternative explanation is an AE/SAE, record the AE /SAE in the CRF 
accordingly and follow the Pfizer standard processes
If it is agreed that there is no explanation that would explain the ALT or AST and TBL 
elevations other than the IMP:

Update the report of the prior reported SAE (report term now ‘Hy’s Law’) according 
to Pfizer standard processes. 

The ‘Medically Important’ serious criterion should be used if no other serious 
criteria apply

As there is no alternative explanation for the HL case, a causality assessment of 
‘related’ should be assigned.
16. REFERENCES
FDA Guidance for Industry (issued July 2009) ‘Drug-induced liver injury: Premarketing 
clinical evaluation’:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidance
s/UCM174090.pdf
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Page 112
Appendix 3. Tanner Staging of Development
TANNER STAGING OF DEVELOPMENT IN GIRLS
Once the onset of puberty has begun, the resulting sequence of somatic and physiologic 
changes gives rise to the sexual maturity rating, or Tanner stages.  Figure 2 and Figure 3
depict the somatic changes which are also described in Table 15.
Figure 2.
Sexual Maturity Ratings (2 To 5) Of Pubic Hair Changes In Adolescent 
Girls. (Courtesy Of 
, MD,
 
England)
PPD
PPD
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
PFIZER CONFIDENTIAL
Page 113
Figure 3.
Sexual Maturity Ratings (1 To 5) Of Breast Changes In Adolescent Girls. 
(Courtesy Of 
, MD,
 
 England)
PPD
PPD
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)


Drug Substance 
Study Code AZ / Pfizer C3591005
Edition Number 3
Date 17 July 2017
Table 15.
Classification Of Sexual Maturity States In Girls
REFERENCE
Kliegman et al, 2011
Kliegman RM, Bonita S, St. Geme J, Schor N, Behrma.n RE. Nelson Textbook of Pediatrics. 
19th ed. Philadelphia, PA. Elsevier 2011; Part XIII:649-51. 
090177e18ddb7be5\0.1\Draft\Versioned On:06-Mar-2018 10:39 (GMT)

SAP_001.pdf: 
Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
1
Statistical Analysis Plan
Study Code
D4280C00016
Edition Number
2.0
Date
13 December 2017
A single blind, randomised, multi-centre, active controlled, trial to evaluate 
safety, tolerability, pharmacokinetics and efficacy of ceftazidime and 
avibactam compared with cefepime in children from 3 months to less than 
18 years of age with complicated urinary tract infections (cUTIs)
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
2
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
3
TABLE OF CONTENTS
LIST OF TABLES.....................................................................................................................5
LIST OF ABBREVIATIONS....................................................................................................6
AMENDMENT HISTORY .......................................................................................................8
1. STUDY DETAILS.................................................................................................................9
1.1. Study objectives ........................................................................................................9
1.2. Study design ..............................................................................................................9
1.3. Number of subjects..................................................................................................10
2. ANALYSIS SETS ...............................................................................................................11
2.1. Definition of analysis sets .......................................................................................11
2.1.1. Safety analysis set.......................................................................................11
2.1.2. Safety evaluable analysis set ......................................................................11
2.1.3. PK analysis set............................................................................................12
2.1.4. Efficacy analysis sets..................................................................................12
2.1.4.1. ITT analysis set .........................................................................12
2.1.4.2. Microbiological intent-to-treat set.............................................12
2.1.4.3. Clinically evaluable analysis set................................................12
2.1.4.4. Microbiologically evaluable analysis set ..................................13
2.2. Violations and deviations........................................................................................14
3. PRIMARY AND SECONDARY VARIABLES.................................................................14
3.1. Definitions and handling of missing data................................................................14
3.1.1. Demographic and baseline characteristic variables....................................15
3.1.2. Definition of prior and concomitant medication ........................................16
3.1.3. Exposure and compliance variables............................................................17
3.2. Primary outcome (safety) variables.........................................................................18
3.2.1. Definition of AEs........................................................................................18
3.2.1.1. Adverse events ..........................................................................18
3.2.1.2. Serious AEs...............................................................................19
3.2.1.3. Cephalosporin class effects .......................................................19
3.2.1.4. AEs of Special Interest (AEoSI) ...............................................19
3.2.2. Laboratory parameters................................................................................19
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
4
3.2.3. Physical examinations ................................................................................20
3.2.4. ECGs...........................................................................................................21
3.2.5. Vital signs...................................................................................................21
3.3. Secondary outcome (efficacy) variables .................................................................21
3.3.1. Definition of clinical outcome....................................................................21
3.3.2. Definition of Microbiological response......................................................27
3.3.3. Definition of Combined Response..............................................................29
4. ANALYSIS METHODS .....................................................................................................30
4.1. General principles ...................................................................................................30
4.2. Analysis methods ....................................................................................................31
4.2.1. Baseline characteristic analysis ..................................................................31
4.2.1.1. Patient disposition .....................................................................31
4.2.1.2. Demographics and baseline characteristics...............................31
4.2.1.3. Extent of exposure and compliance ..........................................32
4.2.2. Safety analysis ............................................................................................32
4.2.2.1. Adverse events ..........................................................................33
4.2.2.2. Laboratory safety assessments ..................................................33
4.2.2.3. Physical examinations...............................................................34
4.2.2.4. ECG...........................................................................................35
4.2.2.5. Vital signs..................................................................................35
4.2.3. Analysis of secondary variables .................................................................35
4.2.3.1. Pharmacokinetic outcome variables..........................................35
4.2.3.2. Clinical outcome, microbiological response and emergent 
infections ...........................................................................................36
5. INTERIM ANALYSES.......................................................................................................38
5.1. Data Safety Monitoring Board (DSMB) .................................................................38
6. CHANGES OF ANALYSIS FROM PROTOCOL .............................................................39
7. REFERENCES ....................................................................................................................40
8. APPENDIX..........................................................................................................................41
8.1. Evaluability Review Process...................................................................................41
8.2. Potentially clinically significant criteria..................................................................46
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
5
LIST OF TABLES
Table 1: Laboratory Parameters...............................................................................................20
Table 2: Visit Windows for End of 72 hours, EOIV, EOT, TOC, and LFU ...........................22
Table 3: Clinical outcome assessments at End of 72 hours.....................................................22
Table 4: Clinical outcome assessments at EOIV.....................................................................24
Table 5: Clinical outcome assessments at EOT.......................................................................25
Table 6: Clinical outcome assessments at TOC.......................................................................26
Table 7: Clinical outcome assessments at LFU.......................................................................26
Table 8: Per-pathogen microbiological outcome categories....................................................27
Table 9: Per-patient microbiological response ........................................................................28
Table 10: Emergent infections.................................................................................................29
Table 11: Per-patient combined response................................................................................29
Table 12: Evaluability assessments for Safety Analysis Sets and PK Analysis Sets ..............41
Table 13: Evaluability assessments for the ITT and micro-ITT Analysis Sets .......................41
Table 14: Evaluability assessments for the CE Analysis Sets.................................................43
Table 15: Evaluability assessments for the ME Analysis Sets ................................................44
Table 16: Classification of Pathogens with regards to causality of cUTI................................45
Table 17: Criteria for potentially clinically significant clinical laboratory tests .....................46
Table 18: Criteria for potentially clinically significant electrocardiogram tests .....................47
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
6
LIST OF ABBREVIATIONS
Abbreviation or 
special term
Explanation
AE
adverse event 
AEoSI
adverse event of special interest
ALT
alanine aminotransferase
AST
aspartate aminotransferase
BDR
blinded data review
BMI
body mass index
CAZ-AVI
ceftazidime-avibactam
CE
clinically evaluable
CFB
change from baseline
CFU
colony forming unit
cIAI
complicated intra-abdominal infection
CLSI
Clinical and Laboratory Standards Institute
CrCl
creatinine clearance
CRP
C-reactive protein
CSP
clinical study protocol
CSR
clinical study report
cUTI
complicated urinary tract infection
CV
coefficient of variation
DOB
date of birth
DSMB
data safety monitoring board
ECG
electrocardiogram
EOIV
end of intravenous treatment
EOT
end of treatment
HR
heart rate
β-hCG 
ß-human chorionic gonadotropin
ITT
intent-to-treat
IV
intravenous
LFU
late follow-up 
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
7
Abbreviation or 
special term
Explanation
LLN
lower limit of the normal range 
ME
microbiologically evaluable
MedDRA
Medical Dictionary for Regulatory Activities
MIC
minimum inhibitory concentration
Micro-ITT
microbiological intent-to-treat
N
number of patients or counts
NQ
not quantifiable
NR
not recorded
PCS
potentially clinical significant
PK
pharmacokinetic
QTm
QT measured
QTcB
QT interval corrected using Bazett’s formula
QTcF
QT interval corrected using Fridericia’s formula
SAE
serious adverse event 
SD
standard deviation
SMQ
standardised MedDRA search query
SOC
system organ class
TOC
test of cure 
ULN
upper limit of the normal range
WBC
white blood cells
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
8
AMENDMENT HISTORY
Date
Brief description of change
18Aug2015
, version 1.0
7 Dec 2017
and 
, version 2.0
Version 2.0 represents the change in sponsor from AstraZeneca to 
Pfizer.
Version 2.0 also incorporated changes from blinded data review
and feedback from the report writing process for Study 
D4280C00015. Major changes include:

Added rationale for changes to planned analysis to section 6;

Added ITT and Micro-ITT analysis sets to the analysis in line 
with protocol amendment 2 (
); refined 
and clarified the definition of efficacy analysis sets; 

Amended permissible visit windows for clinical and 
microbiological response;

Added in description to include total treatment statistics for 
table summaries of baseline variables;

Clarified approach with respect to microbiological definitions, 
including definition of response, selection of pathogen, 
determination of susceptibility, and grouping of pathogens;

Added analysis of combined response;

Updated derivation of age for patients with missing date of 
birth;

Added description of oral medications table summary;

Amended adverse events of special interest (AEoSI) to 
summarize by topic;

Added clarification and appendix for ECMA process;

Amended approach for summarising laboratory abnormality 
according to local lab criteria.
PPD
PPD
PPD
CCI
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
9
1. STUDY DETAILS
1.1. Study objectives
Primary objective (Safety)

Evaluate the safety and tolerability of ceftazidime-avibactam (CAZ-AVI) given at the 
selected dose regimen versus cefepime in paediatric patients aged ≥3 months to 
<18 years with complicated urinary tract infection (cUTI).
Secondary objectives 

Evaluate the descriptive efficacy of CAZ-AVI versus cefepime comparator in 
paediatric patients aged ≥3 months to <18 years with cUTI;

Evaluate the pharmacokinetics (PK) of CAZ-AVI in paediatric patients aged 
≥3 months to <18 years with cUTI.
Exploratory objectives
Not applicable.
1.2. Study design
This study is a single-blind, randomised, multi-centre, active controlled trial. Patients aged from 
3 months to less than 18 years with cUTI will be randomised to 1 of 2 groups (3:1 ratio): 
CAZ-AVI or cefepime. 
Randomization will be stratified as follows: 

Cohort 1: patients aged from 12 years to <18 years;

Cohort 2: patients aged from 6 years to <12 years;

Cohort 3: patients aged from 2 years to <6 years;

Cohort 4: patients aged from 3 months to <2 years.
The doses of CAZ-AVI are based on age and weight with adjustment according to renal 
function as detailed in Table 5 of the protocol.
Patients randomised to receive cefepime should receive the dose, schedule and infusion
duration as recommended in the local prescribing information or as prescribed by the
investigator. The maximum dose of cefepime in any single infusion should not exceed
2000 mg.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
10
Patients will receive IV treatment for a minimum of 72 hours (3 full days, ie, 9 doses for CAZ-
AVI treated patients, or 6 doses for cefepime treated patients) before having the option to switch 
to an oral therapy, at the Investigator’s discretion. The total period of treatment (ie, IV drug and 
oral switch treatment) is to be between 7 and 14 days. Patients may remain in the IV study 
treatment for the full 7 to 14 days.
Patients will be assessed for safety and efficacy throughout the study, and blood samples will be 
taken for PK assessment. The duration of each patient’s participation in the study will be a 
minimum of 27 days to a maximum of 50 days after start of study treatment (including 7 to 14 
days of active treatment), at which time there will be a Late Follow-up (LFU) assessment visit. 
The LFU is to be performed 20 to 36 days after the last dose of any treatment.
1.3. Number of subjects
Patients will continue to be recruited into this study until 80 patients complete at least 72 hours 
(3 full days, ie, 9 doses for CAZ-AVI treated patients, or 6 doses for cefepime treated patients) of 
study treatment (deemed to be evaluable patients). Patients will be randomised 3:1 to the CAZ-
AVI or cefepime study treatment groups. At least 60 and 20 evaluable patients respectively are 
required in the CAZ-AVI and cefepime groups.
The proposed sample size is based on the probability of observing a ‘rare’ safety event. The 
‘rare’ term used in this section is not based on the regulatory definition but is instead 
intended to reflect less common events. Safety data from this study and from Study 
D4280C00015 for complicated intra-abdominal infections (cIAIs) will be combined for analysis.
As a total of at least 120 patients will be treated with CAZ-AVI in both studies combined, when 
assuming an underlying incidence rate of 3% for a specific ‘rare’ event, this will ensure that the 
probability of observing such an event in at least 1 patient treated with CAZ-AVI exceeds 95%.
In addition, each of the patient cohorts is required to have a minimum number of evaluable
patients as follows:

Cohort 1: At least 6:2 evaluable patients aged from 12 years to <18 years

Cohort 2: At least 6:2 evaluable patients aged from 6 years to <12 years

Cohort 3: At least 9:3 evaluable patients aged from 2 years to <6 years

Cohort 4: At least 18:6 evaluable patients aged from 3 months to <2 years comprising 
Cohorts 4a and 4b as follows: 

Cohort 4a: At least 9:3 evaluable patients aged from 1 year to <2 years.

Cohort 4b: At least 6:2 evaluable patients aged from 3 months to <1 year, with a 
minimum of 3 patients with at least 1 PK sample aged from 3 months to 
<6 months treated with CAZ-AVI.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
11
Considering patients over all 4 cohorts combined, at least 10% of evaluable patients with 
urological abnormalities in the urinary tract should be included. 
Patients who are randomized and registered as having ended IV treatment with less than 9 
doses of CAZ-AVI or 6 doses of cefepime do not meet the criteria for evaluable patients and 
will be eligible for enrolment replacement. The process of replacement will ensure that the 
next patient randomized in the same stratum will be automatically assigned the same 
treatment group as the non-evaluable patient who needs to be replaced. The purpose of this is
to minimise over-recruitment to reach the required number of evaluable patients in each 
treatment arm. Replacement subjects can themselves be replaced (up to a maximum of 5 
replacements per allocated randomization code).
2. ANALYSIS SETS
2.1. Definition of analysis sets
The analysis of data will be based on different analysis sets according to the purpose of 
analysis, ie, for safety and efficacy. Assessment regarding eligibility for all analysis sets will 
be finalized prior to database lock Eligibility for all analysis sets will be determined 
programmatically, whenever possible. For cases in which criteria for analysis sets cannot be 
determined programmatically (e.g. protocol deviations and the use of prohibited concomitant 
medications that affect the assessment of efficacy), a manual review of data will be 
undertaken by an evaluability review committee, including at a minimum: medical personnel, 
a microbiologist, and a statistician. Preparation of data will be performed by unblinded study 
team members (protocol deviation data is potentially unblinding), and information will be 
presented in a blinded manner for decision making by the evaluability review committee. A
more detailed outline of the criteria which will be determined by this review is included 
within Section 8.1.
2.1.1. Safety analysis set
The Safety analysis set will include all randomised patients who received any amount of IV 
study therapy (ie, CAZ-AVI or cefepime). For the Safety analysis set, patients will be 
included in all outputs according to the study treatment they actually received.
2.1.2. Safety evaluable analysis set
The safety evaluable analysis set will be a subset of the patients in the Safety analysis set that 
received at least 9 doses of study treatment for patients on the CAZ-AVI arm, or 6 doses for 
patients on the cefepime arm. Each subject’s dosing profile will be reviewed by unblinded 
medical personnel to confirm evaluability. Any cases that are not clear will be identified and 
presented in a blinded manner at a formal evaluability and clinical/microbiological 
assessment (ECMA) meeting to determine whether the subject is acceptable for inclusion in 
the safety evaluable analysis set.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
12
2.1.3. PK analysis set
The PK analysis set will be a subset of the patients in the Safety analysis set who have at 
least 1 ceftazidime and/or avibactam plasma measurement available. 
2.1.4. Efficacy analysis sets
The efficacy analysis of data in this study will be based on 4 subsets of patients (intent-to-
treat (ITT), microbiological intent-to-treat (micro-ITT), CE and ME analysis sets) as defined 
below. The CE and ME analysis sets will be defined separately for each of the visits at which 
efficacy is assessed.
Patients who receive both study therapies will be excluded from the CE and ME analysis 
sets. Patients in the ITT, micro-ITT, CE and ME analysis sets will be summarized according 
to the randomized treatment assignment.
2.1.4.1. ITT analysis set
The ITT analysis set will include all patients who have been assigned a randomised 
treatment.
2.1.4.2. Microbiological intent-to-treat set
The micro-ITT analysis set will include all randomised patients who have at least 
1 Gram-negative typical pathogen (in the urine) at baseline known to cause cUTI and no 
Gram-positive pathogen (in the urine) at baseline.
2.1.4.3. Clinically evaluable analysis set
The CE analysis set is defined separately at the end of 72 hours of study treatment, and at 
each of the EOIV, EOT, TOC and LFU visits. It includes all patients meeting the following 
criteria: 
a.
Patients in the micro-ITT analysis set who have received IV study therapy and have a 
confirmed diagnosis of cUTI;
b. Have received at least 48 hours of IV study drug, unless discontinued due to a 
treatment-limiting AE;
c.
At the specific visit had a clinical response of cure, improvement or failure (or have 
been assessed as a clinical failure before the planned assessment visit);

or for LFU, have been evaluated with a clinical response of sustained cure or 
relapse.
d. Had no important protocol deviations that would affect assessment of efficacy;
e.
Did not take any concomitant antibiotics that would affect assessment of efficacy. 
This does not include antibiotic therapy taken for the treatment of cUTI by patients 
who are considered clinical failures.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
13
2.1.4.4. Microbiologically evaluable analysis set
The ME analysis set will be defined separately at each of the EOIV, EOT, TOC and LFU 
visits.  It includes all patients meeting the following criteria:
a.
Patients in the micro-ITT analysis set who have received IV study therapy and have a 
confirmed diagnosis of cUTI;
b. Have received at least 48 hours of IV study drug, unless discontinued due to a 
treatment-limiting AE;
c.
At the specific visit had a (per-patient) microbiological response which was not 
indeterminate; 
d. Had no important protocol deviations that would affect assessment of  the 
microbiological responses;
e.
Did not take any concomitant antibiotics that would affect assessment of the 
microbiological responses;
f.
Have at least 1 Gram-negative typical UTI bacterial pathogen which has been isolated 
from an adequate microbiological specimen (in the urine) at Baseline that is 
susceptible to both study agents (CAZ-AVI and cefepime)
2.1.4.4.1. Susceptibility to study drug for ME Analysis Set
Susceptibility to ceftazidime-avibactam for baseline pathogen species of Enterobacteriaceae 
and P. aeruginosa will be determined programmatically. A patient will be counted as having 
had at least 1 etiologic pathogen in the initial/pre-study culture that is susceptible to both 
study drugs if;
For cases when a central microbiology reference laboratory result is present, a pathogen that 
satisfies the following interpretive criteria of susceptibility:

Displays an MIC of ceftazidime-avibactam ≤ 8 mg/L for Enterobacteriaceae and/or 
P. aeruginosa (2017 FDA label, ceftazidime-avibactam highlights of prescribing 
information), categorizing it as susceptible to the combination

and displays an MIC of cefepime that categorizes it as susceptible by CLSI 
interpretive criteria, namely ≤ 8 mg/L for Enterobacteriaceae and for P. aeruginosa
(CLSI 2012), 
For cases when the local lab result is used, a pathogen that satisfies the following interpretive 
criteria of susceptibility:

displays a disk diffusion diameter for ceftazidime-avibactam (30 g ceftazidime and 
20 g of avibactam) greater than or equal to the susceptible breakpoint, ie, ≥ 21 mm 
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
14
for Enterobacteriaceae and P. aeruginosa (2017 FDA label, ceftazidime-avibactam 
highlights of prescribing information);

and disk diffusion diameters categorizing the isolate as susceptible to cefepime
judged on the CLSI interpretive criteria of ≥ 18 mm for Enterobacteriaceae and for 
P. aeruginosa (CLSI 2012).
Pathogen species not included in the definition above cannot be confirmed to be susceptible 
and therefore would not meet the criteria to be included in ME analysis sets.
2.2. Violations and deviations
Protocol deviations are defined as any variations from the protocol, including enrolment of a 
patient who did not meet all inclusion and exclusion criteria and/or failed to perform the 
assessments and procedures within the required time frame. Protocol deviations will be 
summarized in two ways: a) a summary table will display counts of patients with important 
protocol deviations and b) the analysis sets table will display the counts of patients excluded 
from CE and ME analysis sets due to important protocol deviations that would affect the 
assessment of efficacy. All protocol deviations and their classification (i.e. whether or not it 
was important and whether or not it led to the exclusion from the CE and ME analysis sets) 
will be listed.
The review and assignment of deviations that affect patient-level analysis set statuses will be 
finalized as part of the final data review before database lock.
3. PRIMARY AND SECONDARY VARIABLES
3.1. Definitions and handling of missing data
Baseline
For all variables, the last assessment made prior to the first dose of study drug will be defined 
as the baseline. 
For microbiological samples, if they come from a sterile source and are taken within 1 day of 
baseline and before any antibiotics are administered, it will also be considered for the 
derivation of baseline.
Change from Baseline (CFB)
Change from baseline will be calculated as the post-treatment value minus the baseline value. 
Missing Data
No missing values will be imputed except age for some patients owing to the descriptive 
nature of the study.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
15
3.1.1. Demographic and baseline characteristic variables 
Demographic and baseline characteristics include the following:

Age (in years for all patients, and in months for patients <2 years of age);

Sex (Male, Female);

Ethnicity (Hispanic or Latino, Not Hispanic or Latino);

Race category (White, Black/African American, Asian, Native Hawaiian/Pacific 
Islander, American Indian/Alaska Native, Other);

Height (cm);

Weight (kg);

Body mass index (BMI) (kg/m2);

Medical and Surgical History;

Renal status category (<30 mL/min/1.73m2, ≥30 to <50 mL/min/1.73m2, ≥50 to <80 
mL/min/1.73m2, ≥80 mL/min/1.73m2).

Diagnosis:

cUTI without pyelonephritis.

Acute pyelonephritis:

Acute pyelonephritis with no complicating factors;

Acute pyelonephritis with at least 1 complicating factor.

Complicating factors (protocol section 3.1, criterion 7b);

Presence or absence of urological Abnormalities, recorded at Screening via the IVRS 
system.
Some countries will record date of birth (DOB) only partially, either year or month and year. 
For those patients DOB will be imputed, and age will be derived based on the imputed DOB.
The following algorithm will be used for the imputation of DOB and derivation of age:
1. Use cohort to find the maximum and minimum possible age. 
2. If age is recorded on the CRF, use this value to further narrow down the maximum 
and minimum possible age.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
16
3. Use the date of informed consent alongside the maximum and minimum possible age 
to find the earliest and latest possible DOB.
4. Use any portions of the DOB which have been recorded to narrow down the earliest 
and latest possible DOB from step 3.
5. Find the midpoint of the earliest and latest possible DOB from step 4.
6. Use imputed DOB from step 5 to derive age at informed consent.
The following examples, all from Cohort 3 (2 to < 6 years), illustrate this algorithm:
Example
CRF_age
DOB 
(CRF) 
day/mo/yr
Informed
Consent 
Date
Range of Possible DOBs
Midpoint of 
range of 
possible 
DOBs
Derived 
age
1
Blank
xx/xx/2008
31-Aug-
2014
1-Sep-2008
31-Dec-2008
31-Oct-2008
5y 9mo
2
3
xx/xx/2011
31-Aug-
2014
1-Jan-2011
31-Aug-2011
2-May-2011
3y 3 mo
3
Blank
xx/xx/2011
31-Aug-
2014
1-Jan-2011
31-Dec-2011
2-Jul-2011
3y 1 mo
4
Blank
xx/xx/2011
31-May-
2014
1-Jan-2011
31-Dec-2011
2-Jul-2011
2y 10 
mo
5
Blank
xx/03/2011
10-Mar-
2014
1-Mar-2011
31-Mar-2011
16-Mar-2011
2y 11 
mo
A footnote will be added to the demography summary table to specify that imputation has 
been performed for age calculation and the number of patients within each cohort for which
the imputation has been performed.
The demography listing will present DOB both as recorded in the CRF (eg, with missing 
month / date as applicable) and age as derived at the date of informed consent, and a footnote 
will also be put in place to describe that age imputation has been performed there.
3.1.2. Definition of prior and concomitant medication 
A prior medication is defined as:
a.
A medication that was taken any time in the 2 weeks prior to study entry up to the 
date of randomisation, regardless of whether this was stopped prior to the date of 
randomization or not;
A concomitant medication is defined as:
a.
Any medication taken at any time between the date of randomisation and up to the 
LFU visit.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
17
Consequently, a medication could be counted as both prior and concomitant. Any medication 
prescribed at the LFU visit will not be deemed concomitant.
If any medications reported are not able to be determined as prior medications or 
concomitant medications due to missing or partial start dates and/or stop dates, the following 
imputation rules will be implemented: 

If the year is present but the month and day are missing, then 01JAN will be imputed 
for the start date and 31DEC for the stop date;

If the year and month are present but the day is missing, then 01 will be imputed for 
the start date and the last day of the month for the stop date.
If the start date is missing, it is prior if the stop date is prior to the date of randomization. 
Otherwise, it is both prior and concomitant. If the stop date is missing, it is concomitant if 
start date is later than the date of randomization. If start date is prior to the date of 
randomization, it will be both prior and concomitant. If both stop/start years are missing or 
both stop/start dates otherwise cannot be imputed, then the date will be treated as missing and 
the medication will be treated as both prior and concomitant medications.
In case it appears that some of the medications are clearly ‘prior’ but classified as 
‘concomitant’ and the imputation goes across the first dose day, such medications will be 
reviewed before the data base lock (BDRM) to make the final decision whether they should 
be classed as prior or concomitant.
An antibiotic is called “systemic” when it is classified as J01 (antibacterial for systemic use)
code based on ATC classification.
3.1.3. Exposure and compliance variables
Exposure (in days) to the study therapy for each of CAZ-AVI and cefepime will be 
calculated as the difference between the last study therapy date and time and the first study 
therapy date and time converted to days plus 1 day. Total number of infusions will be 
calculated by summing all the number of infusions together. Average daily infusions will be 
calculated dividing total number of infusions by days of exposure. Treatment compliance 
over the entire treatment period will be defined as the number of infusions over all doses 
received, divided by the number of infusions over all doses expected during the treatment 
period, and then multiplied by 100. Any partial infusion will be considered as a complete 
infusion for the purpose of compliance, and the relevant details will be listed.
Exposure (in days) will also be calculated for patients who switch to oral therapy, using start 
and stop dates of oral therapy in the same way as described for study therapy above. In 
addition, the combined exposure (in days) of IV study treatment and oral therapy (if 
applicable) will be calculated.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
18
3.2. Primary outcome (safety) variables
The primary outcome variables are for safety and tolerability as assessed by:

Adverse events (AEs) and Serious adverse events (SAEs).

Cephalosporin class effects and additional AEs (including, but not limited to seizures, 
C. difficile-associated diarrhoea, allergic reactions, hepatic abnormalities, haemolytic 
anaemia and changes in renal function).

Vital signs (pulse, blood pressure, respiratory rate, temperature).

Physical examination.

Laboratory parameters, including CrCl.

Electrocardiogram (ECG).
3.2.1. Definition of AEs
3.2.1.1. Adverse events
An AE is the development of an undesirable medical condition or the deterioration of a pre-
existing medical condition, whether or not considered casually related to the product. An 
undesirable medical condition can be symptoms (eg, nausea, chest pain), signs (eg, 
tachycardia, enlarged liver) or the abnormal results of an investigation (eg, laboratory 
findings, ECG). In clinical studies, an AE can include an undesirable medical condition 
occurring at any time, including run-in or washout periods, even if no study treatment has 
been administered. All AEs will be classified using the Medical Dictionary for Regulatory 
Activities (MedDRA) Version 20.0 or higher.
The term AE is used to include both serious and non-serious AEs. Non-serious AEs and 
SAEs will be collected for each patient from the time when informed consent or assent 
(whichever is earliest) is obtained at Screening through to the LFU visit. Any AEs that are 
unresolved at the patient’s last AE assessment will be followed up by the investigator until 
the event is resolved or stabilized. 
Each AE will be graded for severity. Each AE will be assessed for relationship to the study 
therapy as well. Where there is partial date information which does not clearly define 
whether an AE occurs post first infusion of IV therapy, the same imputation rules will be 
utilised as for the definition of prior or concomitant medications in Section 3.1.3, where 
assignment to post first infusion will be assumed where dates are in any way compatible for 
this to be true.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
19
3.2.1.2. Serious AEs
An SAE is an AE occurring during any study phase (ie, run-in, treatment, washout, follow-
up), that fulfils 1 or more of the following criteria:

Results in death;

Is immediately life-threatening;

Requires in-patient hospitalization or prolongation of existing hospitalization;

Results in persistent or significant disability/incapacity or substantial disruption of the
ability to conduct normal life functions;

Is a congenital abnormality or birth defect;

Is an important medical event that may jeopardize the patient or may require medical 
intervention to prevent one of the outcomes listed above.
3.2.1.3. Cephalosporin class effects
Cephalosporin class effects (first time episode of hypersensitivity to class of cephalosporin 
drugs) and additional AEs will also be closely monitored (including, but not limited to 
seizures, C. difficile-associated diarrhoea, allergic reactions, hepatic abnormalities, 
haemolytic anaemia and changes in renal function).
3.2.1.4. AEs of Special Interest (AEoSI)
AEoSI will include the following safety topic groups for AEs:

Liver disorder;

Diarrhoea;

Hypersensitivity/anaphylaxis;

Haematological disorder;

Renal disorder.
3.2.2. Laboratory parameters
Blood and urine samples for determination of clinical chemistry, haematology, and urinalysis 
will be taken at the times indicated in Table 1 of the clinical study protocol (CSP).
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
20
Table 1 presents the laboratory parameters that will be measured:
Table 1: Laboratory Parameters
Clinical Chemistry
Haematology
Urinalysis
Magnesium 
Bicarbonate
Sodium 
Potassium 
Phosphorus 
Chloride 
Calcium 
Alkaline phosphatase 
Gamma glutamyltransferase 
Alanine Aminotransferase (ALT )
Aspartate Aminotransferase (AST)
Creatine kinase 
Lactate dehydrogenase 
Total bilirubin 
Indirect bilirubin
Glucose, non-fasting
Creatinine
Blood urea nitrogen
C-reactive protein (CRP) (optional) 
Haematocrit
Haemoglobin
Erythrocyte count
Mean cell volume
Leukocyte count (WBC)
Neutrophils
Lymphocytes
Monocytes
Eosinophils
Basophils
Platelets
Coombs test (direct)
Pregnancy testing
Serum Beta-Human 
chorionic 
gonadotropin ( β-hCG)
Urinalysis (routine and
microscopy) will be
performed according to the
study centre’s standard
procedures
Creatinine clearance will be measured throughout the study until LFU using the child’s 
measured height (length) and serum creatinine within the updated “bedside” Schwartz 
formula (Schwartz et al, 2009):
CrCl (mL/min/1.73m2)=0.413×height (length) (cm)/serum creatinine (mg/dL)
3.2.3. Physical examinations
A complete physical examination will be performed and will include an assessment of the 
following: general appearance, skin, head and neck (including ears, eyes, nose and throat), 
lymph nodes, thyroid, respiratory, cardiovascular, abdomen, musculoskeletal (including 
spine and extremities) and neurological systems, including height and weight. BMI (kg/m2) 
will be calculated as the ratio of weight in kg/(height in cm/100)2. BMI will only be 
calculated at Baseline (Day -1/Day 1). BMI will not be calculated for children <2 years of 
age (Cohorts 4a and 4b) as BMI is not considered a screening tool for healthy weight in 
children <2 years of age. 
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
21
3.2.4. ECGs
Each ECG will be interpreted as appropriate for the patient’s age. ECG variables include 
ECG heart rate, QRS duration, QT interval, RR interval, PR interval, QTc (QTcB and QTcF). 
Where QTm=QT measured, RR = RR interval, and HR = Heart rate; QTcB (QT interval 
corrected by Bazett’s formula) is calculated using the following formula:
QTc = QTm / √(RR) 
Where RR = 60 / HR
QTcF (QT interval corrected by Fridericia’s formula) is calculated dividing QT measured by 
the cube root of RR:
QTc = QTm / 3√(RR)
3.2.5. Vital signs
Vital signs include heart rate (beats per minute), body temperature (°C), respiratory rate 
(breaths per minute), systolic blood pressure (mmHg), and diastolic blood pressure (mmHg).
3.3. Secondary outcome (efficacy) variables

Plasma concentrations and PK parameters of CAZ and AVI;

Clinical response at End of 72 hours’ treatment, EOIV, EOT, and TOC;

Microbiological response at EOIV, EOT, TOC, and LFU;

Clinical relapse at LFU;

Emergent infections;

Combined response at EOIV and TOC.
3.3.1. Definition of clinical outcome
Clinical response outcomes at End of 72 hours and EOIV are clinical cure, clinical 
improvement, clinical failure and indeterminate, and at EOT and TOC outcomes are clinical 
cure, clinical failure and indeterminate. Clinical response outcomes at LFU are sustained 
clinical cure, relapse and indeterminate. The derived analyses windows in Table 2 will be 
used to identify permissible values for the analysis for the CE and ME analysis sets:
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
22
Table 2: Visit Windows for End of 72 hours, EOIV, EOT, TOC, and LFU
Visit
Protocol-defined Window
Derived Analyses Window
End of 72 hours
After 72 hours of treatment, and up to 8 
hours later
From completion of 9th study 
dose up of CAZ-AVI or 6th dose 
of cefepime to 80 hours after 
start of study drug
End of IV therapy 
(EOIV)
Within 24 hours of completion of the last 
infusion of study drug
On day of last infusion of study 
drug (or +1 day), and no later 
than same day as start of oral 
therapy.
End of Treatment 
(EOT)
Within 48 hours of completion of the last 
dose of oral switch therapy for patients 
who switch, or within 24 hours of the last 
infusion of study drug for those who do not 
receive oral switch therapy
On day of last dose of oral 
therapy (or +2 days) for oral 
switch patients; on day of last 
infusion of study drug (or +1 
day) for patients who do not 
switch
Test of cure (TOC)
8 to 15 days after the last dose of any study 
drug
7 to 19 days after the last dose 
of study drug
Late follow-up 
(LFU)
20 to 36 days after the last dose of any 
study drug
20 to 43 days after the last dose 
of study drug
The following tables present the definitions for each visit.
3.3.1.1.1. Clinical outcome at end of 72 hours
The clinical outcome categories at the End of 72 hours are defined in Table 3. Favourable 
clinical outcomes are clinical improvement and clinical cure. 
Table 3: Clinical outcome assessments at End of 72 hours
Outcome 
Definition
Clinical Cure
Resolution of all acute signs and symptoms of 
cUTI or improvement to such an extent that no 
further antimicrobial therapy is required
Clinical Improvement
Patients who are improving but not enough to 
switch to oral therapy and are still on IV study 
drug at End of 72 hours and meet the following 
criterion:
-Absence of new signs and symptoms, 
and improvement in at least 1 symptom 
or sign (ie, fever, pain, tenderness, 
elevated WBCs, elevated CRP) from 
Baseline, and with no worsening of any 
symptom or sign
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
23
Table 3: Clinical outcome assessments at End of 72 hours
Outcome 
Definition
Clinical Failure
Patients who meet any of the following criteria:
-Discontinuation of study drug due to 
insufficient therapeutic effect, including 
persistence, incomplete clinical 
resolution, or worsening in signs and 
symptoms of cUTI that requires 
alternative non-study antimicrobial 
therapy
-Discontinuation of study drug due to an 
AE and requirement for alternative 
non-study antimicrobial therapy for cUTI
-Death in which cUTI is contributory
-Patients who are improving but not 
enough to switch to oral therapy and are 
still on IV study drug at End of 72 hours 
and who fail to meet the following 
criterion:
Absence of new signs and symptoms, 
and improvement in at least 1 symptom 
or sign (ie, fever, pain, tenderness, 
elevated WBCs, elevated CRP) from 
Baseline, and with no worsening of any 
symptom or sign
Indeterminatea
Study data are not available for evaluation of 
efficacy for any reason, including:
-Death in which cUTI is clearly 
non-contributory
-Extenuating circumstances precluding 
classification as a cure or failure (eg, 
patient lost to follow-up)
a Any prophylactic systemic antibiotic medication use after first dose until the End of 72 hours assessment will
  result in a clinical outcome of Indeterminate.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
24
3.3.1.1.2. Clinical outcome at EOIV
The clinical outcome categories at EOIV are defined in Table 4. Favourable clinical 
outcomes are clinical improvement and clinical cure. A clinical failure at EOIV will be 
carried forward to the EOT and TOC visits.
Table 4: Clinical outcome assessments at EOIV
Outcome 
Definition
Clinical Cure
Resolution of all acute signs and symptoms of 
cUTI or improvement to such an extent that no 
further antimicrobial therapy is required
Clinical Improvement
Patients who switch to oral therapy and meet all 
of the following criteria at EOIV:
-Afebrile (temperature ≤38.0°C) for at 
least 24 hours
-Absence of new and improvement in at 
least 1 symptom or sign (ie, fever, pain, 
tenderness, elevated WBCs, elevated 
CRP) from Baseline and worsening of 
none
Clinical Failurea
Patients who meet any of the following criteria:
-Discontinuation of study drug due to 
insufficient therapeutic effect, including 
persistence, incomplete clinical 
resolution, or worsening in signs and 
symptoms of cUTI that requires 
alternative non-study antimicrobial 
therapy
-Discontinuation of study drug due to an 
AE and requirement for alternative 
non-study antimicrobial therapy for cUTI
-Death in which cUTI is contributory
Indeterminateb
Study data are not available for evaluation of 
efficacy for any reason, including:
-Death in which cUTI is clearly 
non-contributory
-Extenuating circumstances precluding 
classification as a cure or failure (eg, 
patient lost to follow-up)
a A clinical failure at EOIV will be carried forward to EOT and TOC.
b Any prophylactic systemic antibiotic medication use after first dose until the EOIV assessment will 
  result in a clinical outcome of Indeterminate.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
25
3.3.1.1.3. Clinical outcome at EOT
The clinical outcome categories at EOT are defined in Table 5. A favourable clinical outcome 
is clinical cure. A clinical failure at EOT will be carried forward to the TOC visit.
Table 5: Clinical outcome assessments at EOT
Outcome 
Definition
Clinical Cure
Resolution of all acute signs and symptoms of
cUTI or improvement to such an extent that no 
further antimicrobial therapy is required
Clinical Failurea
Patients who meet any of the following criteria:
-Discontinuation of study drug due to 
insufficient therapeutic effect, including 
persistence, incomplete clinical 
resolution, or worsening in signs and 
symptoms of cUTI that requires 
alternative non-study antimicrobial 
therapy
-Discontinuation of study drug due to an 
AE and requirement for alternative 
non-study antimicrobial therapy for cUTI
-Death in which cUTI is contributory
Indeterminateb
Study data are not available for evaluation of 
efficacy for any reason, including:
-Death in which cUTI is clearly 
non-contributory
-Extenuating circumstances precluding 
classification as a cure or failure (eg, 
patient lost to follow-up)
a A clinical failure at EOT will be carried forward to TOC.
b Any prophylactic systemic antibiotic medication use after first dose until the EOT assessment will 
  result in a clinical outcome of Indeterminate.
3.3.1.1.4. Clinical outcome at TOC
The clinical outcome categories at TOC are defined in Table 6. A favourable clinical 
outcome is clinical cure.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
26
Table 6: Clinical outcome assessments at TOC
Outcome 
Definition
Clinical Cure
Resolution of all acute signs and symptoms of 
cUTI or improvement to such an extent that no 
further antimicrobial therapy is required
Clinical Failure
Patients who meet either of the following criteria:
-Incomplete resolution or worsening of 
cUTI signs or symptoms or development 
of new signs or symptoms requiring 
alternative non-study antimicrobial 
therapy
-Death in which cUTI is contributory
Indeterminate
Study data are not available for evaluation of 
efficacy for any reason, including:
-Death in which cUTI is clearly 
non-contributory
-Extenuating circumstances precluding 
classification as a cure or failure (eg, 
patient lost to follow-up)
Any prophylactic systemic antibiotic medication use after the EOT assessment will not impact clinical outcome at TOC.
3.3.1.1.5. Clinical outcome at LFU
Each patient who was considered clinically cured at TOC will be reassessed at LFU for 
evidence of clinical relapse of cUTI symptoms. The clinical outcome categories at LFU are 
defined in Table 7. A favourable clinical outcome at LFU is sustained clinical cure.
Table 7: Clinical outcome assessments at LFU
Outcome
Definition
Sustained Clinical Cure
Continued favourable response, defined as resolution of all acute signs 
and symptoms of cUTI and no further antimicrobial therapy is required
Clinical Relapse
Patients who meet either of the following criteria:
-Reappearance or worsening of signs and symptoms of cUTI that 
requires further antimicrobial therapy and/or surgery
-Death after TOC in which cUTI is contributory
Indeterminate
Study data are not available for evaluation of efficacy for any reason, 
including:
-Death in which cUTI is clearly non-contributory
-Extenuating circumstances precluding classification as 
sustained clinical cure or clinical relapse (eg, patient lost to 
follow-up)
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
27
Note: Clinical outcome at LFU will only be assessed in patients who were considered clinically cured at TOC.
Any prophylactic systemic antibiotic medication use after the EOT assessment will not 
impact clinical outcome at LFU.
For the CE and ME analysis sets, the proportion of patients with a clinical relapse is defined 
using the following formula: 
Number of patients with clinical relapse
(Number of patients with sustained clinical cure or with clinical relapse)
3.3.2. Definition of Microbiological response 
Baseline pathogens will be determined based on central laboratory data where available. In 
the absence of any baseline central laboratory data, then local laboratory data will be used to 
identify baseline pathogens. 
3.3.2.1.1. Per-pathogen microbiological response
The per-pathogen microbiological outcome categories are defined in Table 8 using the same 
windows as defined for clinical outcome within Table 2. Favourable microbiological 
outcomes are eradication. 
Table 8: Per-pathogen microbiological outcome categories
Outcome
Definition
Eradication
Source specimen demonstrated absence of the original baseline 
pathogen
Persistence
Source specimen demonstrates continued presence of the original 
baseline pathogen
Persistence with 
increasing MICa
Source specimen demonstrates continued presence of the original 
baseline pathogen with a minimum inhibitory concentration (MIC) 
value ≥4-fold larger than that observed for the baseline pathogen
Indeterminate
Source specimen was not available to culture
a Persistence with increasing MIC is a subset of the Persistence outcome
For patients who have a microbiological outcome of persistence at a particular visit, this 
outcome will be carried forward to subsequent visits.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
28
3.3.2.1.2. Per-patient microbiological response
In the cases that the overall microbiological responses are different in samples taken from 
urine and blood, the per-patient microbiological response will be assessed based on the 
results from the urine culture.
Per-patient microbiological response is defined in Table 9. In order for a patient to have a 
favourable per-patient microbiological response, the outcome for each pathogen must be 
favourable (eradicated). If the outcome for any pathogen is unfavourable (persistence), the 
patient will be considered to have an unfavourable per-patient microbiological response 
(regardless of the outcome of all other pathogens). In order for a patient to have an 
indeterminate per-patient microbiological response, the outcome for each pathogen must be 
indeterminate.
Table 9: Per-patient microbiological response
Pathogen 1
Pathogen 2
Per-Patient Outcome
Eradicated
Favourable
Persistent
Unfavourable
Indeterminate
Indeterminate
Eradicated
Eradicated
Favourable
Persistent
Unfavourable
Indeterminate
Unfavourable
Persistent
Any result
Unfavourable
Indeterminate
Eradicated
Unfavourable
Persistent
Unfavourable
Indeterminate
Indeterminate
Note: For patients who have a microbiological outcome of persistence at a particular visit, this outcome will be carried 
forward to subsequent visits. In the cases that the overall microbiological responses are different in samples taken from urine 
and blood, the per-patient microbiological response will be assessed based on the results from the urine culture.
3.3.2.1.3. Pathogen group
Each pathogen will be assigned into one of the following groups to be used in summaries and 
listings, using a pre-defined list of groupings:

Enterobacteriaceae;

Gram-negative other than Enterobacteriaceae;

Gram-positive;

Anaerobes.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
29
3.3.2.1.4. Emergent infections
Pathogens first appearing after Baseline (“emergent infections”) until the LFU are 
categorized in Table 10, using microbiological laboratory results.  
Table 10: Emergent infections
Emergent Infections
Definition
Superinfection
A urine culture identified pathogen other than a baseline pathogen 
during the course of active treatment with study therapy along with 
worsening signs and symptoms of infection requiring alternative 
antimicrobial therapy.
New infection
A urine culture identified pathogen other than a baseline pathogen at any 
time after study treatment has finished along with worsening signs and 
symptoms of infection requiring alternative antimicrobial therapy. 
3.3.3. Definition of Combined Response 
At the EOIV and TOC assessments, the clinical and per-patient microbiological responses 
will be used to create a combined response. If either clinical or microbiological response is 
unfavourable, then the combined response will be unfavourable. Otherwise, in the absence of 
unfavourable responses, then if either clinical or microbiological response is indeterminate or 
missing, then the response will be indeterminate. Finally if both clinical and microbiological 
responses are favourable, then the outcome will be favourable. This is summarised in cross-
tabulation form in Table 11.
Table 11: Per-patient combined response
Clinical Outcome
Microbiological Outcome
Favourable
Indeterminate
Unfavourable
Favourable
Favourable
Indeterminate
Unfavourable
Indeterminate
Indeterminate
Indeterminate
Unfavourable
Unfavourable
Unfavourable
Unfavourable
Unfavourable
Note: Indeterminate responses include missing assessments and assessments which were not performed.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
30
4. ANALYSIS METHODS
4.1. General principles
Descriptive summaries will be provided where appropriate for each of the primary and 
secondary variables. In general, summaries will be presented by cohort, treatment group and 
overall for treatment group across all cohorts. For disposition, demographics, medications, 
and data collected exclusively at baseline, the total within each cohort will be presented as 
well. For the following summary tables summaries for cohort 4 will be broken down into
cohorts 4a and 4b:

Plasma concentrations;

Study drug administration and accountability;

Overall summary of adverse events in any category;

Overall summary of adverse events by system organ class (SOC) and preferred term;

Summary of quantitative laboratory variable results and change from baseline results 
by visit;

Summary of ECG variable results and change from baseline results by visit;

Summary of physical examination results by visit.
Unless otherwise specified, demographics and baseline characteristics will be summarized 
for safety analysis set.
Continuous and quantitative variable summaries will include the number of patients (N), 
mean, standard deviation (SD), median, and ranges (minimum and maximum). Plasma 
concentrations will be summarized by the number of patients (N), mean, coefficient variation 
(CV), median, and ranges (minimum and maximum). Categorical and qualitative variable 
summaries will include the frequency and percentages of patients who are in the particular 
category. In general the denominator for the percent calculation will be based upon the total 
number of patients in the study population for each treatment group and cohort, unless 
otherwise specified. 
For the reporting of descriptive statistics, the mean and median values will be presented to 1 
or more decimal precision as the source data, SD values will be presented to 2 or more 
decimal precision, minimum and maximum values will be presented to the same precision as 
the source data, and percent will be presented with 1 decimal precision. In the event the SD 
or mean is at least 4 decimal places, the SD will be displayed to same number of decimal 
places as mean.
To determine upper limit of the normal range (ULN) and lower limit of the normal 
range (LLN) values, site-level ranges will be converted for laboratory data in this study. 
These ranges will then be used to define the potentially clinically significant (PCS) criteria in 
Table 17. 
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
31
All analysis will be performed using SAS®, release 9.4 or higher.
A separate document will be produced containing the templates for table, listing, and figure.
4.2. Analysis methods
4.2.1. Baseline characteristic analysis
Baseline characteristics will be summarized for safety analysis set only. 
4.2.1.1. Patient disposition
The number of patients who are randomized but never treated, who completed the study up to 
the TOC visit, and up to the LFU visit, and the number of patients withdrawing from the 
study therapy and study, including reason for withdrawal, will be summarized by cohort, 
treatment, overall within each cohort, and overall for each treatment for the ITT analysis set. 
All data relevant to randomization and reasons for randomized but never treated as well as 
inclusion and exclusion criteria will be listed. 
The number of patients in each of the analysis sets and the reasons for exclusion from 
analysis sets will be listed and summarized for the ITT analysis set.
A summary of important protocol deviations will be presented to display the number of 
patients with an important protocol deviation overall, and further broken down by deviation 
category for the safety analysis set.
A summary of the number of patients in each country and each centre will be produced for 
the ITT analysis set.
4.2.1.2. Demographics and baseline characteristics
Demographic and baseline characteristics included in Section 3.1.1 will be summarized by 
cohort, treatment group, overall within each cohort, and overall for each treatment. Age will 
be summarized in years as a continuous variable with 2 decimal places, taking into 
consideration all available data in years, months and days. For cohort 4 age will be 
summarized in months in addition to years. For all other cohorts (1-3) age will be 
summarized in years only.
Medical history data and current medical conditions (a medical history subset formed of 
conditions which are ongoing at screening) will be summarized by system organ class and 
preferred term for each cohort, treatment group overall within each cohort, and overall for 
each treatment. The surgical history data will also be summarized system organ class and 
preferred term for each cohort, treatment group, overall within each cohort, and overall for 
each treatment. Both the medical history and the surgical history will be coded with 
MedDRA Version 20.0. 
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
32
All prior and concomitant medications will be coded using the AZDD Drug dictionary 
medication code (version: 17.1 or later) and systemic antibiotic medications will be 
summarized by ATC classification and preferred term (as well as cohort, treatment group, 
overall within each cohort, and overall for each treatment). Prior and concomitant 
medications that are not antibiotics will also be summarized by ATC classification and 
preferred term (as well as cohort, treatment group, overall within each cohort, and overall for 
each treatment).
The diagnosis of acute pyelonephritis will be identified from medical history records ongoing 
at screening, whereby any entries of the text “pyelonephritis” without mention of the text 
“chronic”, will be determined to reflect a diagnosis of acute pyelonephritis. Patients without 
such a record will be determined to not have acute pyelonephritis.
4.2.1.3. Extent of exposure and compliance
Exposure
Exposure (in days) to CAZ-AVI and to cefepime will be summarized by cohort, treatment 
group, cohort and overall for each treatment. Average daily infusions and total number of IV 
infusions will also be summarized descriptively by cohort and overall for each cohort.
For patients who switch to oral therapy at the conclusion of their randomized treatment, a 
summary will be provided for the exposure (in days) to oral therapy by type of oral therapy, 
cohort, treatment group, and overall for each treatment to which they were originally 
randomized. A table in the same format will also be presented for the combined exposure 
duration of IV and oral therapies.
Exposure of study and oral therapy will be presented in the study medication listings. 
Treatment compliance
Treatment compliance will be summarized by cohort, treatment group and overall for each 
treatment. Compliance will be summarized descriptively (n, mean, standard deviation, 
median, minimum, maximum) and also with counts and percentages for the categories 
(<80%, 80%-120% and >120%).
4.2.2. Safety analysis
The primary variables are for safety and tolerability. No inferential statistical tests will be 
performed for any safety variables. Unless otherwise specified, the Safety analysis set will be 
used for summaries and listings. In addition the Safety evaluable analysis set will be used to 
assess key safety data such as adverse events, laboratory, vital signs and ECG data.
Safety assessments will be based on AE reports and the results of vital sign measurements, 
physical examinations, ECGs and clinical laboratory tests. 
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
33
4.2.2.1. Adverse events
The incidence of AEs will be summarized and reviewed for potential significance and 
clinical importance. AEs occurring from the start of the first infusion of IV study therapy will 
be summarized by preferred term and SOC. AEs occurring before the start of study treatment 
will only be listed and not included in tables. 
Adverse events will be grouped in tables by SOC and preferred term for each cohort, 
treatment group and overall for each treatment. All recorded AEs will be listed.
Summaries and listings of AEs leading to death, SAEs and AEs leading to discontinuation of 
study treatment will also be presented. Summaries will also be presented by blinded 
observer's causality assessment and by investigator reported AE intensity.
AEoSI will be pre-defined using specific AE preferred terms from the MedDRA vocabulary 
for the following safety topic groups:

Liver disorder;

Diarrhoea;

Hypersensitivity/anaphylaxis;

Haematological disorder;

Renal disorder.
The number and percentage of patients with at least 1 AE within each AEoSI topic group will 
be presented by study cohort, treatment and overall together with a further presentation of the 
AE incidence rates for each PT within each AEoSI topic group.
Cephalosporin class effects and additional AEs (including, but not limited to seizures, C. 
difficile-associated diarrhoea, allergic reactions, hepatic abnormalities, haemolytic anaemia 
and changes in renal function) will be detailed in clinical study report (CSR) by reviewing 
the AEoSI.
4.2.2.2. Laboratory safety assessments
Local laboratory data for chemistry and haematology parameters will be summarized and 
plotted (box plots and/or scatter graphs) by cohort, treatment group, overall for each 
treatment, and visit for the observed values and for the corresponding change from baseline 
(CFB) values using descriptive statistics.  If a patient has multiple results for a particular test 
at a particular visit, the first non-missing value will be used for the summary. Système 
International units will be reported for all analyses, but listings will reflect the original unit 
that was provided by the local laboratory with the test result. If a particular combination of 
treatment and cohort for a given parameter has fewer than five patients with data, then that 
combination will not be included in the boxplot.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
34
The urinalysis parameters glucose, ketones, protein, nitrite, urobilinogen, and leukocyte 
esterase will be summarised using a shift table showing the number of patients with each 
combination of baseline value compared to maximum post-baseline value observed during 
treatment.
In addition, the following summaries at each applicable visit will also be provided:

The number and percentage of patients with normal values, low values, and high 
values according to local laboratory reference ranges;

Shift tables (from baseline) showing the number of patients with low, normal, or high 
values according to local laboratory reference ranges;

The numbers and percentage of patients with abnormal or out of range values based 
on PCS criteria (Table 12) at any time during the study up to EOT visit, and 
separately at any time up to LFU visit.
The criteria for PCS results for laboratory tests are described in Table 13. For relationship to 
normal reference range, shift table summaries, and PCS summaries, if a patient has multiple 
values for a particular test at a particular visit the first non-missing value will used. Shift 
plots (ie, Scatter plot) of baseline and EOT continuous values will also be provided by 
cohort, treatment group and overall for each treatment. 
The number and percentage of patients who meet potential Hy’s law criteria: AST or ALT ≥3 
× ULN and total bilirubin ≥2 × ULN at any point during the study will be summarized by 
cohort, treatment group and overall. The number of patients with ALP<=2 x ULN (alone and 
in addition to meeting potential Hy’s law criteria) will also be summarised.   The number of 
patients with maximum on-treatment ALT, AST and ALP will be cross-tabulated with the 
maximum on-treatment total bilirubin classified into the groups: <3 x ULN, ≥3 -<5 x ULN, 
≥5 - <10 x ULN and ≥10 x ULN for ALT and AST, <=2 x ULN for ALP, and <2 x ULN and 
>= 2 x ULN for total bilirubin. A listing of PCS values for liver function tests will be 
presented.
Listings of all laboratory values for each patient will be presented, and abnormal or 
out-of-range PCS values will be flagged alongside these results. 
The number and percentage of patients with CrCl in the following ranges: 
<30mL/min/1.73m2, ≥30 to <50 mL/min/1.73m2, ≥50mL/min/1.73m2 to <80mL/min/1.73m2, 
and ≥80mL/min/1.73m2 will be tabulated at each of the Baseline, Day 7, EOIV, TOC and 
LFU visits for each cohort, treatment group, and overall.
4.2.2.3. Physical examinations
The numbers and percentage of patients with normal or abnormal assessment for each body 
system will be summarized by cohort, treatment group and overall for each treatment, 
including change from baseline.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
35
All physical examination data will be listed.
4.2.2.4. ECG
Descriptive statistics for ECG at each applicable visit and for the corresponding change from 
baseline values at each applicable post-baseline visit will be summarized and plotted (box-
plot) by cohort, treatment group and overall for each treatment. Shift plots from baseline to 
TOC will also be provided by cohort, treatment group and overall for each treatment. 
The number and percentage of patients within overall ECG interpretation category (normal, 
abnormal) for baseline and post-baseline by cohort, treatment group and overall for each 
treatment and visit will be summarized. The number of patients with normal, abnormal ECG 
interpretation shift results from baseline to the TOC visit will be provided.
Categorical summaries of absolute QT, QTcB, and QTcF values (≥450 msec, ≥480 msec, 
≥500 msec) and CFB values in QT, QTcB, and QTcF values (≥30 msec, ≥60 msec) will be 
presented by treatment group, cohort and visit. The number and percentage of patients with 
post-baseline value of ≥500 msec and CFB value of ≥60 msec will also be presented by 
treatment group, cohort and visit.
Electrocardiogram results and the overall interpretations of these results will be listed
respectively.
Listings of all ECG values for each patient will be presented with abnormal or out-of-range 
PCS ECG values flagged. These are defined in Table 13.
4.2.2.5. Vital signs
Vital signs will be summarized and plotted (box plots) for the observed values and for the 
corresponding CFB values at each applicable visit by cohort, treatment group and overall for 
each treatment.
Vital signs will be listed.
4.2.3. Analysis of secondary variables
4.2.3.1. Pharmacokinetic outcome variables
A listing of ceftazidime and avibactam concentrations at the nominal sampling windows by 
patient and cohort will be provided. For Cohorts 1 to 4, the plasma concentration will be 
summarized by nominal sampling time window using appropriate descriptive statistics (eg, 
number, mean, SD, minimum, median, maximum, geometric mean, and coefficient of 
variation).
Plasma concentrations that are not quantifiable (NQ) or if there are missing values (e.g. no 
result [NR]) will be handled as follows:

Where there is NR, these will be set to missing.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
36

At a time point where there is less than or equal to 50% of the values are NQ, all NQ 
values will be set to the LLOQ, and all descriptive statistics will be calculated.

At a time point where more than half of the values are NQ, the mean, SD, geometric 
mean and CV% will be set to Not Calculated (NC).  The maximum value will be 
reported from the individual data, and the minimum and median will be set to NQ.

If all values are NQ at a time point, no descriptive statistics will be calculated for that 
time point.  Not calculated (NC) will be written in the field for standard deviation and 
CV% and NQ will be written in fields for mean, geometric mean, minimum, median 
and maximum.

The number of NQ values (n below LLOQ) will be reported for each time point.

Data from subjects excluded from the PK analysis set will be included in the data 
listings, but not in the descriptive statistics.
Four figures showing median plasma concentrations of ceftazidime and of avibactam against 
time by cohort will be presented on a linear and log scale.
PK modelling is not in the scope of this document.
4.2.3.2. Clinical outcome, microbiological response and emergent infections
4.2.3.2.1. Clinical response outcome
Within each analysis set, the proportion of patients with a favourable outcome at End of 72 
hours’ treatment and EOIV is defined using the following formula: 
Number of patients with clinical cure or improvement
(Number of patients in the analysis set)
Within each analysis set, the proportion of patients with a favourable outcome at EOT and 
TOC is defined using the following formula: 
Number of patients with clinical cure
(Number of patients in the analysis set)
Within each analysis set, the proportion of patients with a favourable outcome at LFU is 
defined using the following formula:
Number of patients with sustained clinical cure
(Number of patients in the analysis set)
Where clinical response is summarized for the ITT and micro-ITT analysis sets, the nominal 
visit (i.e. as recorded on the CRF) throughout, whereas for summaries for the CE and ME 
analysis sets, visit windows will be used as defined in Table 2.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
37
Clinical response outcomes will be summarized by cohort, treatment group and overall for 
each treatment in the ITT, micro-ITT, CE and ME analysis sets at End of 72 hours’ treatment
(CE at 72 hours only), EOIV, EOT, TOC, and LFU. 
The number and percentage of patients with each clinical response outcome at each time
point will be summarized by cohort, treatment group and overall for each treatment. For each 
time point the number, percentage and proportion of patients with clinically favourable 
outcome will also be summarized. A two-sided 95% CI for the percentage of subjects with a 
favourable outcome will be presented within each cohort and treatment group, and treatment 
group overall (computed using Jeffreys method). The rate of favourable clinical response at 
TOC will also be presented for each baseline pathogen in the ME at TOC and micro-ITT 
analysis sets.
The analysis for clinical response outcome described above will be repeated and split by 
patients with/without diagnosis of acute pyelonephritis at screening in the CE, ME, micro-
ITT and ITT analysis sets. Additionally the analysis will be repeated again for the CE 
analysis set only at the end of 72 hour visit window, where the eligibility for this window is 
amended from that in Table 2 to be from 72 hours until 80 hours after first dose of study IV 
treatment.
4.2.3.2.2. Microbiological Response 
Where microbiological response is summarized for the micro-ITT analysis set, the nominal 
visit (i.e. as recorded on the CRF) will be used throughout, whereas for summaries for the 
ME analysis set, visit windows will be used as defined in Table 2.
4.2.3.2.3. Per-patient microbiological response
The number and percentage of patients with a favourable microbiological response outcome 
at each end point will be summarized by cohort, treatment group and overall for each 
treatment in the micro-ITT and ME analysis set at the EOIV, EOT, TOC and LFU visits.
4.2.3.2.4. Per-pathogen microbiological response
The number and percentage of patients with per-pathogen microbiological favourable 
response will be summarized within pathogen group by cohort, treatment group, and overall 
for each treatment for the micro-ITT and the ME analysis sets at the EOIV, EOT, TOC and 
LFU visits. This summary will be repeated to display the favourable response in the same 
manner, with additional subsetting by baseline CAZ-AVI MIC and by baseline cefepime
MIC.
4.2.3.2.5. Emergent Infections
The proportion of patients with any emergent infection, and further subsetted into super 
infections and/or new infections, will be summarized by cohort, treatment group and overall 
for each treatment for the micro-ITT and ME at TOC analysis sets.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
38
4.2.3.2.6. Baseline pathogen, susceptibility and MIC
The number and percentage of patients with each pathogen at baseline will be presented 
within pathogen group by cohort, treatment, overall for each treatment group for the micro-
ITT and ME at TOC analysis sets.
The number and percentage of patients with baseline aerobic Gram-negative pathogens 
classed as susceptible, non-susceptible, intermediate, and resistant to each of CAZ-AVI, 
ceftazidime and cefepime will be summarized for the micro-ITT analysis set alongside the 
number of patients with a pathogen, the number of isolates, and the number of isolates tested.
Culture results and susceptibility testing results will be based upon the CLSI assessments and 
listed by cohort and treatment group for each treatment and patient. The results of the in vitro 
susceptibility tests of each baseline aerobic, Gram-negative pathogen (‘Susceptible’ and 
‘Non-susceptible’) will be summarized by cohort, treatment group and overall for each 
treatment for the micro-ITT analysis set.
MIC frequencies for each infecting species within pathogen group will be reported 
separately. Descriptive statistics for MICs will be reported for each infecting species and
MIC range. Additionally, for infecting species for which the number is 10 or more, the MIC 
to inhibit the growth of 50% (MIC50), and for which the number is 10 or more the MIC to 
inhibit the growth of 90% of organisms (MIC90) will be reported.
4.2.3.2.7. Combined Response
Combined clinical and microbiological response will be summarised in micro-ITT and in the 
ME by Visit Analysis Sets at EOIV and TOC visits.  The number and percentage of patients 
for combined response outcome at each end point will be summarized by response 
categories, cohort, treatment group, and overall for each treatment.
5. INTERIM ANALYSES
As this study is descriptive in nature, no interim or final inferential analyses will be 
performed for either efficacy or safety. 
5.1. Data Safety Monitoring Board (DSMB)
A data safety monitoring board (DSMB) is deemed necessary since the trial has a long period 
of enrolment, is multi-centre and multi-national.
The DSMB is charged with reviewing and evaluating the study safety (AEs, SAEs, and PCS
laboratory results) at periodic intervals. The DSMB members will be familiarised with AEs 
and SAEs likely to occur in this patient population, based on experience in adults and 
adolescents, as well as with this class of drugs (cephalosporins). The DSMB will conduct 
pre-planned and possibly ad hoc reviews of accumulating data.
Based on the findings of these reviews, the DSMB may make recommendations to the 
sponsor regarding the study, including, but not limited to: continue the study without 
modification, modify the protocol or informed consent/assent document(s), or temporarily 
stop enrolment in all or some of the study centres. The sponsor will be responsible for 
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
39
discussing and, if considered appropriate, implementing the DSMB recommendations. 
Further details can be found in the DSMB charter.
6. CHANGES OF ANALYSIS FROM PROTOCOL
Although protocol section 8.5.2.3 states that “Baseline pathogens will be determined based 
on central laboratory data”, section 5.2.1 of the protocol gives the option for the sample to be 
analyzed by the central or local lab. Therefore, in case central lab results are not available for 
the determination of baseline pathogens, local lab results will be used if available (SAP 
section 3.3.1 under subsection “Microbiological response assessments”).
The definition of superinfection and new infections in Table 9 has been amended from Table 
13 of the CSP as the dichotomous response of “Growth” or “No Growth” is recorded on the 
database, in place of CFU results.
An additional criterion was added for the CE and ME analysis sets (Sections 2.1.4.3 and 
2.1.4.4) whereby a patient should not have received concomitant antibiotics that would affect 
the assessment of efficacy. This extra constraint was implemented as a result of discussions 
held during formal ECMA review meetings.
Categories of CrCl used for analysis purposes were given in protocol section 8.5.1.2 as 
mL/min, however since the Schwartz formula used to derive CrCl was based on 
mL/min/1.73m2, this was the unit used for CrCl categories.
The protocol indicated that clinical response was to be summarized by visit for the ITT, 
micro-ITT, CE and ME at all visits. However, since microbiological response at 72 hours 
was not assessed, it was not possible to define an ME analysis set for the 72 hour visit. With 
that, a summary of clinical response at 72 hours for the ME at 72 analysis set was not 
presented.
The summary table for combined response in the ITT Analysis Set was mentioned in the 
protocol but has been replaced by a summary table for combined response in the ME by Visit 
Analysis Set.
Changes were made to the text used for the definition of the CE and ME analysis set with the 
following goals:
1. To simplify the language and add clarity to the criteria being applied to the logic of 
programming, and 
2. To clarify that only patients who received a minimum amount of IV study drug for 
the assessment of efficacy are eligible for the CE and ME analysis sets.
3. To separate the criteria for eligibility to the CE and ME analysis sets from the clinical 
efficacy response assessment.
4. To further specify that the CE and ME analysis sets are a subset of the micro-ITT 
analysis set.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
40
7. REFERENCES
Schwartz et al, 2009
1.
Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New 
equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009 
Mar;20(3):629-37.
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
41
8. APPENDIX
8.1. Evaluability Review Process
Assessment of patient’s evaluability for each analysis set will be determined by the criteria 
described in Section 2.1.  Where possible, assignments will be made using programming 
algorithms.  In some cases manual review of data may be necessary in order to determine 
assignment (see Table 12, Table 13, Table 14 and Table 15).  
Data will be reviewed, and cases identified for presentation and discussion at the blinded 
evaluability and clinical/microbiological assessment (ECMA) meeting.  Potentially 
unblinding data (e.g. protocol deviations, concomitant medication and study drug dosing) 
will only be reviewed by team members who are unblinded, and case summaries will be 
presented for discussion at the blinded ECMA meeting for determination of evaluability.
The output of the each ECMA meeting will be a spreadsheet of analysis set assignments of 
the cases that were discussed and decided to be excluded from any analysis set. This 
spreadsheet will be provided to the programming group and incorporated into the database.  
Result of assessment and rationale for any manual updates to analysis set assignments will be 
documented in the form of ECMA minutes.  
Evaluability of each patient to each analysis set will be finalized prior to database lock.
Table 12: Evaluability assessments for Safety Analysis Sets and PK Analysis Sets
Analysis set
Description
Analysis set criterion
Assessment performed
Safety Analysis 
Set (SAS)
randomised patients who received 
any amount of IV study therapy 
(ie, CAZ-AVI or cefepime).
Any amount of IV study 
therapy
Programmed
Safety 
Evaluable 
Analysis Set 
(SES)
subset of the patients in the SAS 
that received at least 9 doses of 
study treatment for patients on the 
CAZ-AVI arm, or 6 doses for 
patients on the cefepime arm.
in SAS
Programmed 
at least 9 doses of CAZ-
AVI or 6 doses of 
cefepime
Manual confirmation by 
unblinded team, with 
blinded discussion of 
selected cases during 
ECMA meeting, if 
required
PK Analysis 
Set
subset of the patients in the SAS 
who have at least 1 ceftazidime 
and/or avibactam plasma 
measurement available
in SAS
Programmed
at least 1 ceftazidime 
and/or avibactam plasma 
measurement
Table 13: Evaluability assessments for the ITT and micro-ITT Analysis Sets
Analysis set
Description
Analysis set criterion
Assessment performed
ITT Analysis Set
patients who have been 
assigned a randomised
treatment.
randomized
Programmed
Micro-ITT Analysis Set
randomised patients who 
have at least 1 Gram-
randomised 
Programmed
at least 1 Gram-negative 
Programmed and 
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
42
negative typical 
pathogen (in the urine) at 
baseline known to cause 
cUTI and no Gram-
positive pathogen (in the 
urine) at baseline
typical pathogen in urine 
at baseline known to 
cause cUTI
AND
No Gram-positive 
pathogen in the urine at 
baseline
manual:
A list of all baseline 
pathogens in this study 
will be manually 
classified by 
microbiologist as always, 
or never known to cause 
cUTI (see Table 16).
Patients who have at 
least one Gram-negative 
baseline pathogen in the 
urine classified as 
“always” are potentially 
eligible for the micro-
ITT, provided that they 
do not have baseline 
Gram-positive pathogens 
in the urine. 
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
43
Table 14: Evaluability assessments for the CE Analysis Sets
Description
Analysis set criterion
Assessment performed
Patients who receive both study 
therapies will be excluded from 
CE and ME analysis sets
Subject did not receive both study 
therapies
Programmed
The CE analysis set is defined separately at the end of 72 hours of study treatment, and at each of the EOIV, 
EOT, TOC and LFU visits. It includes all patients meeting the following criteria:
a) patients in the micro-ITT 
analysis set who have received IV 
study therapy and had a confirmed 
diagnosis of cUTI
a) in micro-ITT, received IV study 
therapy, and have a confirmed 
diagnosis of cUTI
Programmed
b) received at least 48 h of IV 
study drug, unless discontinued 
due to a treatment-limiting AE
b) ≥ 48h IV treatment
OR
b) < 48h IV treatment and 
discontinued due to a treatment-
limiting AE
A manual review of IV study drug 
will be performed by unblinded 
personnel. These flags will be 
incorporated into the database, and 
the remaining criteria of clinical 
response will be assessed 
c) At the specific visit had a 
clinical response of cure, 
improvement or failure (or have 
been assessed as a clinical failure 
before the planned assessment 
visit)
or for LFU have been evaluated 
with a clinical response of 
sustained cure or relapse
For EOIV, EOT and  TOC 
c) clinical response of cure, 
improvement,  or failure at 
relevant visit (or clinical failure 
carried forward from previous 
visit)
For LFU
c) clinical response of sustained 
cure or relapse
Programmed
d) Had no important protocol 
deviations that would affect 
assessment of efficacy
d) No important protocol 
deviations affecting efficacy
5.
Manual review of 
protocol deviations by 
unblinded personnel to 
select cases for discussion 
at ECMA meeting, during 
which a blinded 
assessment will be made 
of the evaluability of 
these cases.
e) Have not received concomitant 
antibiotics that would impact 
assessment of efficacy. This does 
not include antibiotics therapy 
taken for the treatment of cUTI by 
patients who are considered 
clinical failure.
e) No concomitant antibiotics 
affecting efficacy
Manual review of reasons for 
concomitant antibiotic medications 
to select cases for discussion at 
ECMA meeting, during which a 
blinded assessment will be made 
of evaluability for these cases. 
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
44
Table 15: Evaluability assessments for the ME Analysis Sets
Description
Analysis set criterion
Assessment performed
Patients who receive both study 
therapies will be excluded from 
CE and ME analysis sets
As per CE
As per CE
The ME analysis set is defined separately at each of the EOIV, EOT, TOC and LFU visits. It includes all 
patients meeting the following criteria:
a) patients in the micro-ITT who 
have received IV study therapy 
and had a confirmed diagnosis of 
cUTI
As per CE
As per CE
b) Have received at least 48 hours 
of IV study drug, unless 
discontinued due to a treatment-
limiting AE
As per CE
As per CE
c) At the specific visit had a (per-
patient) microbiological response 
which was not indeterminate;
c) Micro response not 
indeterminate 
Programmed
d) Had no important protocol
deviations that would affect 
assessment of efficacy
As per CE
e) Have not received concomitant 
antibiotics that would impact 
assessment of the microbiological 
responses
e) No concomitant antibiotics 
affecting microbiological response 
Manual review of reasons for 
concomitant antibiotic medications 
to select cases for discussion at 
ECMA meeting, during which a 
blinded assessment will be made 
of evaluability for these cases.
f) Have at least 1 gram-negative 
typical UTI bacterial pathogen 
which has been isolated from an 
adequate microbiological 
specimen (in the urine) at Baseline 
that is susceptible to both study 
agents (CAZ-AVI and cefepime)
f) ≥1 typical cUTI bacterial 
pathogen isolated from an 
adequate microbiological 
specimen (in the urine) at baseline
As per micro-ITT
f) susceptible to both study agents 
(CAZ-AVI and cefepime)
Programmed, see section 2.1.4.4 
for definition of susceptibility
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
45
Table 16: Classification of Pathogens with regards to causality of cUTI
AZ Micro 
Code
AZ Micro Name
Classification
Enterobacteriaceae
Flag
C86091
ACINETOBACTER CALCOACETICUS-
BAUMANNII COMPLEX
Gram Negative - Never
AZ0022
CANDIDA ALBICANS
Never
C86265
CITROBACTER FREUNDII
Gram Negative - Always
E
C86266
CITROBACTER FREUNDII COMPLEX
Gram Negative - Always
E
C62584
COAGULASE NEGATIVE 
STAPHYLOCOCCUS
Gram Positive - Never
C86329
CRONOBACTER SAKAZAKII
Gram Negative - Always
E
C86360
ENTEROBACTER CLOACAE
Gram Negative - Always
E
C76311
ENTEROCOCCUS
Gram Positive - Never
C86368
ENTEROCOCCUS FAECALIS
Gram Positive - Never
C86369
ENTEROCOCCUS FAECIUM
Gram Positive - Never
C14206
ESCHERICHIA COLI
Gram Negative - Always
E
C86424
GRAM-POSITIVE COCCUS
Gram Positive - Never
C86455
KLEBSIELLA OXYTOCA
Gram Negative - Always
E
C86457
KLEBSIELLA PNEUMONIAE
Gram Negative - Always
E
C86019
PROTEUS MIRABILIS
Gram Negative - Always
E
C62583
STAPHYLOCOCCUS
Gram Positive - Never
C50921
STAPHYLOCOCCUS AUREUS
Gram Positive - Never
C86757
STAPHYLOCOCCUS EPIDERMIDIS
Gram Positive - Never
C86761
STAPHYLOCOCCUS 
HAEMOLYTICUS
Gram Positive - Never
C86770
STAPHYLOCOCCUS 
SAPROPHYTICUS
Gram Positive - Never
C86780
STREPTOCOCCUS AGALACTIAE
Gram Positive - Never
C86797
STREPTOCOCCUS MITIS GROUP
Gram Positive - Never
AZ0506
STREPTOCOCCUS VIRIDANS
Gram Positive - Never
C86811
STREPTOCOCCUS VIRIDANS GROUP
Gram Positive - Never
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
46
8.2. Potentially clinically significant criteria
Table 17: Criteria for potentially clinically significant clinical laboratory tests
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen;
  LLN, lower limit of normal; N/A, not applicable; RBC, red blood cell (erythrocytes); ULN, upper limit of 
  normal; WBC, white blood cell (leukocytes).
Note that for PCS low flags, both the lower limit and percentage decrease criteria must be met and for PCS high 
flags, both the upper limit and percentage increase criteria must be met.
Category
Parameter
Lower limit
Upper limit
Percent
decrease from
baseline
Percent
increase from
baseline
Haematology
Haemoglobin 
Haematocrit 
RBC 
WBC 
Neutrophils
Lymphocytes 
Eosinophils
Platelets 
<0.6 x LLN
<0.6 x LLN
<0.8 x LLN
<0.5 x LLN
<0.5 x LLN
<0.2 x LLN
N/A 
<0.4 x LLN
>1.3 x ULN
>1.3 x ULN
>1.3 x ULN
>2.0 x ULN
>2.2 x ULN
>2.2 x ULN
>4.0 x ULN
>2.0 x ULN
>25%
>25%
>20%
>60%
>70%
>70%
N/A
>40%
>30%
>30%
>30%
>100%
>100%
>100%
>400%
>100%
Chemistry
ALT 
Albumin 
Alkaline phosphatase
AST 
Bicarbonate 
BUN 
Calcium 
Chloride 
Creatinine 
Direct bilirubin 
Glucose, non-fasting 
Potassium 
Sodium 
Total bilirubin 
N/A
<0.6 x LLN
<0.5 x LLN
N/A
<0.7 x LLN
N/A
<0.7 x LLN
<0.8 x LLN
N/A
N/A
<0.6 x LLN
<0.8 x LLN
<0.85 x LLN
N/A
>3.0 x ULN
N/A
>3.0 x ULN
>3.0 x ULN
>1.3 x ULN
>3.0 x ULN
>1.3 x ULN
>1.2 x ULN
>2.0 × ULN
>2.5 x ULN
>4.0 x ULN
>1.2 x ULN
>1.1 x ULN
>2.5 x ULN
N/A
>60%
>80%
N/A
>50%
N/A
>30%
>20%
N/A
N/A
>40%
>15%
>10%
N/A
>300%
N/A
>300%
>300%
>30%
>300%
>30%
>20%
>100%
>150%
>200%
>20%
>10%
>300%
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)


Statistical Analysis Plan 
Study Code D4280C00016
Edition Number 2.0 
Date 13 December 2017
47
Table 18: Criteria for potentially clinically significant electrocardiogram tests
Parameter
Age Range
Lower limit
Upper limit
Heart Rate
< 12 years
>=12 years
< 50 bpm and decrease >=15 bpm 
from baseline
< 50 bpm and decrease >=15 bpm 
from baseline
> 120 bpm and increase >= 15 bpm from 
baseline
> 110 bpm and increase >= 15 bpm from 
baseline
PR Interval
< 12 years
>=12 years
<= 90 ms
<= 100 ms
>= 170 ms
>= 180 ms
QRS Duration
<12 years
>=12 years
<= 55 ms
<= 70 ms
>= 90 ms
>= 100 ms
QT
<= 200 ms
>= 500 msec and increase of >=60 msec 
from baseline
QTcB
>= 450 msec
>= 500 msec
Increase of >= 30 msec from baseline
Increase of >= 60 msec from baseline
>= 450 msec and increase of >= 30 msec 
from baseline
>= 500 msec and increase of >= 60 msec 
from baseline
QTcF
>= 450 msec
>= 500 msec
Increase of >= 30 msec from baseline
Increase of >= 60 msec from baseline
>= 450 msec and increase of >= 30 msec 
from baseline
>= 500 msec and increase of >= 60 msec 
from baseline
090177e18ddac419\0.1\Draft\Versioned On:06-Mar-2018 05:10 (GMT)